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Summary
Using animal models of diabetes, hepatic guanine 
nucleotide regulatory protein (G protein) function has been 
investigated. Diabetes mellitus can be classified into two major 
catagories; type I (I.D.D.M.) an insulin - dependent form of the 
disease and type II (N.I.D.D.M.) a non- insulin dependent form 
of the disease often associated with obesity.
Guanine nucleotide regulatory proteins (G proteins) are 
membrane associated components which are involved in the 
transduction of chemical signals across cell plasma membranes. 
The G protein Gi, inhibits adenylate cyclase activity and the G 
protein Gs, stimulates adenylate cyclase activity. Adenylate 
cyclase is an. integral membrane protein which catalyzes the 
formation of cAMP from ATP. cAMP is an important cellular signal 
for the control of metabolism.
In both type I and type II diabetic rats, activity of 
the inhibitory G protein, Gi, is absent in hepatocytes . It is 
proposed that in type I diabetic animals, hepatic Gi expression 
is abolished. In type II diabetic rats, hepatic Gi is modified, 
but present in a non-functional state.
Insulin has the ability to inhibit glucagon-stimulated 
adenylate cyclase activity. This action of insulin is reduced in 
liver plasma membranes prepared from type II diabetic rats and is 
absent in liver plasma membranes prepared from type I diabetic 
rats. Insulin administration to type I diabetic animals resulted 
in the return Gi function and insulin's ability to inhibit
1
adenylate cyelase activity. It is therefore proposed that the 
loss of Gi function and insulin mediated inhibition of adenylate 
cyclase activity is a result of insulin deficiency in this 
type I diabetic condition.
The mechanism by which insulin mediates inhibition of 
adenylate cyclase activity was investigated. It is proposed that 
insulin activates a G protein which is distinct from Gi, and 
inhibits glucagon-stimulated adenylate cyclase activity by the 
release of subunits from a distinct G protein subunit (ov.B'V) 
complex. These B subunits inhibit the stimulatory G protein , 
Gs, from interacting with and thereby stimulating the activity of 
the adenylate cyclase catalytic unit.
In addition, the effect of the hvpoglvcaemic drug^_ 
metformin, was assessed. This drug has been used in human 
diabetic therapy and is reported to have post - receptor effects. 
This drug was found to restore insulin’s ability to inhibit 
hepatic adenylate cyclase activity in type I diabetic animals and 
enhance this insulin action in type II diabetic animals.
Finally, insulin has the ability to stimulate a high 
affinity GTPase activity associated with a G protein which is 
distinct from the G proteins Gi, Gs and a putative G protein Gp. 
This insulin activated G protein may be the G protein through 
which insulin is able to regulate the activity of adenylate 
cyclase . The activity of this G protein may be altered in 
diabetic states.
2
It is proposed that alterations in G protein function 
may reflect post-receptor defects in the diabetic state. 
Transraembrane signal transduction may resultantly be suppressed 
and therefore the ability of hormones to control metabolism would 
be reduced.
3
1. INTRODUCTION
1.1 Insulin & Diabetes Mellitus
1.1.1 The Hormone j_ Insulin
Insulin is a polypeptide hormone with a molecular 
weight of about 6 K Da. Structurally it consists of two peptide 
chains denoted A and B which are linked together by two 
interchain disulphide bridges. Between animal species, insulin 
displays highly conserved sequence homology ( see figure 1 ).
The amino acid sequence of the A and B chains was determined by 
Sanger and colleagues in the early nineteen fifties ( Sanger & 
Tuppy 1951;Sanger & Thompson 1953 ).
The hormone is synthesized in and secreted from the 
beta cells of the islets of Langerhans in the pancreas. Studies 
on the biosynthesis of insulin have revealed the presence of two 
precursor forms of the hormone; proinsulin and preproinsulin 
(Steiner et al 197^; Steiner 1977).
Preproinsulin, the precursor of proinsulin, is believed 
to contain an additional N - terminal peptide sequence of about 
20 amino acids which acts as a "signal” to allow binding to and 
insertion through endoplasmic reticulum membranes. Subsequent 
intralumenal molecular processing occurs rapidly ( within 
minutes) to produce the insulin precursor molecule 
proinsulin.
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Studies using electron microscopy and pulse-chase 
radiolabelling of proinsulin have indicated the site of synthesis 
of this insulin precursor molecule to be associated with 
ribosomes which themselves are associated with rough endoplasmic 
reticulum fractions. Proinsulin molecules are released from the 
endoplasmic reticulum in membrane bound vesicles termed 
"micro vesicles" and within 10-30 min after their synthesis (see 
figure 2) they are transferred to the Golgi apparatus. The 
transfer of of proinsulin from the endoplasmic reticulum to the 
Golgi has been shown to be an energy dependent process and a 
necessary requirement for further proinsulin processing (Jamieson 
& Pallade 1968).
Proinsulin is a single polypeptide chain of between 81-
86 amino acid residues with three distinct peptide regions; the B
chain, a " C peptide " and the A chain (see figure 3). The C
peptide acts as a connecting segment between the A and B chains.
Formation of interchain disulphide bonds and proteolytic
cleavage then occurs to yield a free C peptide and the
disulphide bridge linked A and B chain insulin molecule. This
proinsulin processing is believed to take place in the Golgi
apparatus of the beta cell and has an estimated t value of
0.5
about 1h.
7
Figure 2 Proinsulin Processing In The Pancreatic Beta Cell
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Figure 3 Amino Acid Sequence of Human Proinsulin
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Figure Illustrates the A, B and C chain composition of 
human proinsulin.Arrows indicate where proteolytic 
cleavage occurs. Also, inter and intra chain disulphide 
bonds are indicated.
Insulin molecules crystallize as hexamers which are stabilized
by two zinc atoms coordinated with the B10 Histidine residues and
form particulate species termed secretory granules. There is also
evidence that proinsulin and insulin molecules in the presence of
zinc can form mixed dimeric and hexameric crystalline structures
within the Golgi ( Steiner 1973)* The significance of this is not
known, but insulinomas are known to secrete high levels of
proinsulin molecules into the blood stream.
Secretory granules in the Golgi fuse with the plasma
membrane of the beta cell. Their contents are expelled in
response to appropriate stimuli such as high plasma glucose
2+
concentration, Ca and in the case of diabetic therapy,
hypoglycaemic drugs classified in the group
"sulphonylureas" (Feinglos & Lebovitz 1978).
1.1.2 Diabetes Mellitus
The "normaln human fasting plasma insulin concentration 
- 1
is 5-24 u Units ml which is approximately 4-6nM (Tager et_ al
1979).
The condition of diabetes mellitus is symptomised by fasting
- 1
venous plasma glucose levels of greater or equal to 200mg dl 
(which is approximately 11mM (Tager et all979) ). Hyperglycaemia 
and glycosuria are also often present. .Clinical diagnosis of 
the disease is often by administration of an oral glucose
10
tolerance test (OGTT) which basically involves the ingestion of 
a given amount of glucose and venous plasma glucose 
concentration determinations are made at time points between 0 
and 2h.
Diabetes is a heterogeneous disease and because of this 
a defined system of classification is used ( National Diabetic 
Data Group 1979). Basically the disease can be considered as 
being of three distinct subclasses
1) The insulin dependent, ketosis prone type which has often been 
termed "Juvenile” or "Insulin Dependent Diabetes Mellitus" 
(IDDM). This subclass is also known as Type I diabetes.
2) Non - insulin - dependent - diabetes Mellitus (NIDDM) , a 
non ketosis prone type of diabetes which may be further 
subclassified with respect to the presence or absence
of obesity. Often hyperinsulinaemia is present. This type of
diabetes is also known as Type II diabetes.
3) Secondary diabetes mellitus, a form of diabetes associated 
with other conditions such as pancreatic disease or genetic 
syndromes.
High glucose intolerance accentuates the existance of insulin
resistance because one of the primary actions of insulin is the 
stimulation of hexose transport into muscle, erythrocytes and 
adipose tissue. Over the last ten years or so, insulin stimulated 
glucose transport has been examined very closely in order to 
gain an insight into the possible molecular mechanism wherby
11
insulin exerts its effects upon this system.
Glucose Transport and Insulin Resistance
Glucose enters the cell by facilitated diffusion; 
under normal physiological conditions basal D-glucose is at a 
fairly constant concentration of 5mM in blood plasma (Lehninger 
1977) . Thus, there is normally a glucose concentration 
gradient which acts as the driving force for a net influx of the 
sugar. However, as glucose is a polar compound and thus cannot 
passively diffuse into cells across the lipid bilayer, its 
translocation requires a specific carrier system located within 
the plasma membrane.
The hexose carrier is believed to be an intrinsic 
plasma membrane glycoprotein with a monomeric molecular weight of 
55 K Da (Czech 1980; Shroer 1986). Experiments performed with 
less rigorous purification techniques suggest the possibility of 
oligomeric transporter complexes existing with a molecular weight 
of approximately 200 K Da ( Baldwin & Lienhard 1981). As the 
molecular motion in the membrane appears to be important for the 
expression of the transporter's activity; it cannot operate as a 
rigid fixed channel or "pore"(Czech 1980).
Cytochalasin B is a reversible competitive inhibitor of 
the glucose transporter. This compound and immunoblotting 
techniques have been used to provide measurements of the amount 
of transporter in cell membranes. In addition, non -metabolizable
12
glucose analogues such as 2-deoxyglucose and 3,0-methylglucose or 
14
radiolabelled (U -C) glucose have been used to quantitate 
specific cellular uptake . In addition, kinetic parameters of 
the system in adipocytes and erythrocytes have been made. 
Whitesell & Gliemann (1979) demonstrated in rat adipocytes that 
insulin increases the Vmax value for glucose transport with no 
apparant change in the Km value. This observation therefore led 
to the suggestion that insulin increased the number of glucose 
carriers rather than changing the carrier’s affinity to bind 
glucose molecules.
This observation was proven to be correct when Cushman 
& Wardzala ( 1979 ) used cytochalasin B to estimate 
the number of glucose carrier molecules both in the
plasma membrane and intracellular locations. They found that 
insulin induced the "recruitment” of carrier molecules from 
a microsomal cell fraction to the plasma membrane and thereby 
increased the maximum capacity of the transport process.
This insulin mediated stimulation of glucose carrier
recruitment was rapidly initiated and was not a result of de 
novo synthesis of new carrier molecules.
Karnieli . at al_ (1981) demonstrated that this 
recruitment process was reversible. Using anti-insulin antibody, 
after incubation of rat adipocytes with insulin, they 
observed the movement of carrier molecules from the plasma 
membrane to a microsomal fraction. They confirmed the
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results found in these cytochalasin binding studies by using 
3,0-methylglucose transport measurements and found the Vmax value 
for the transport of this compound simultaneously decreased to 
its original value as the carrier molecules were removed from the 
plasma membrane. Thus the molecular mechanism by which insulin 
enhances glucose influx in rat adipocytes has been elucidated. 
However, the human erythrocyte glucose transport system does 
not appear to respond to insulin in the same way as the 
rat adipocyte.
Work performed by Dustin & colleagues (1984) has 
demonstrated that human erythrocytes possess a rapid 
stereospecific D-hexose transport system. Incubation of cells 
with insulin resulted in a decreased Km value for glucose influx 
to the cell, but no Vmax change was observed. However, if the 
cells were subjected to two incubation periods with insulin not 
only did the Km value for the process decrease,but also 60 % of 
the insulin receptors were lost; a process known as 
downregulation. It was therefore suggested that the mechanism 
by which insulin stimulates glucose transport in erythrocytes 
may be different from that in adipocytes. The significance of 
this is unknown .Also, there is no evidence that insulin has the 
ability to stimulate glucose transport in liver. However, 
this tissue is a major target for insulin action and metabolic 
control.
Also, the mechanism by which insulin has the ability to
14
stimulate the recruitment of glucose carriers from the microsomal 
fraction is still unknown. However, an important set of 
experiments performed by Kahnet al (1978); Pillion etal (1978a) 
and Pillion et al(1978b) using monovalent Fab and anti Fab 
antibodies demonstrated the possibility that lateral aggregation 
of the insulin receptor may be an obligatory requisite for 
carrier "activation" (see figure 4 ). Insulin receptor 
phosphorylation has also been linked with carrier "activation", 
but this will be discussed in section 1.2.4 which is entitled 
"Tyrosine Kinase Activity".
Diabetes and insulin resistance are clinically 
diagnosed on the basis of insulin’s ability to activate glucose 
uptake from blood plasma. Understandably much work has been 
performed to investigate the relationship between insulin 
binding to its receptor (see section 1.2.2) and the ability 
of this action to stimulate glucose transport.Due to glucose 
transport being studied so extensively in adipose tissue and the 
relative ease of removing adipose tissue from diabetic patients 
during surgery, this is the tissue which has been most studied 
to determine a receptor-resistance relationship.
Experimentation suggests that certain obese patients 
(Ciciraldi et^  a^ 1981) and NIDDM patients (Kolterman eit al 1981) 
may display both receptor and post - receptor defects. 
However, adipocytes isolated from IDDM patients (Jarvinen et^  al_
1984) and aged subjects displaying glucose intolerance 
(Pagano et al 1982)
15
-Figure 4 Requirement of Multivalency For Activation of
Hexose Transport By Anti-Membrane Protein Antibodies In 
Intact Fat Cells
ANTI-MEMBRANE ANTI-MEMBRANE ANTI-MEMBRANE Fab
) Fab (— ) plus
ANTI-Fab
 f 1 _ r
ACTIVATION NO RESPONSE ACTIVATION
Outline of results obtained from antibody Fab fragment 
experiments described in text. In brief, multivalent 
antibody or antibody Fab fragments are required for activation 
of the hexose transport system in fat cells.
Figure is-reproduced from Czech 1980.
indicated only a reduced number of insulin receptors on the cell
surface, but no apparent post - receptor defect.
It has been demonstrated that occupancy of all the
insulin receptors on the cell surface is not necessary for a
maximal insulin response; a concept known as "receptor reserve".
For example, Pedersen & Gliemann (1981) suggested that adult
human adipocytes show maximum stimulation of hexose transport by
insulin (1nM) during 25 % occupancy of receptors. Gammeltoft
(1984) suggested that rat adipocytes require only 4 %
receptor occupancy for maximal stimulation of hexose transport.
Thus , it appears that insulin responsiveness for a given
insulin concentration would be affected only if receptor
number was significantly reduced . Therefore in order to
distinguish between receptor defects and post -receptor defects
the K and Vmax values for the glucose transport process 
0.5
must be considered. In general,•distinction between receptor and
post- receptor defects have been made on the assumption that if
the defect occurs at a receptor level then the K for the
0.5
transport process would increase, but the maximal response (Vmax)
would remain unchanged.If however, the defect was at the\receptor 
level | then both the Kq ^ and Vmax values would be expected to 
change . . ' •
In order to try to study receptor and post- receptor 
defects which could explain the human diseased state/s of 
diabetes mellitus, animal models of the disease have been used.
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These models are generally mice or rats which display 
characteristics of Type I or Type II diabetic states.
1.1.4 Animal Models Of Diabetes 
Type I - (IDDM)
Human insulin dependent diabetes mellitus (IDDM) is 
clinically characterized by the abrupt onset of symptoms such as 
hyperinsulinaemia, ketosis, hyperglycaemia and glycosuria. In 
order to sustain life, daily injection of insulin is required 
(Natioanal Diabetes Data Group 1979). This subclass of diabetes 
mellitus was classically diagnosed in juveniles and is often 
therefore known as '* juvenile onset diabetes”. This 
classification however is not strictly true because diagnosis of 
this disease has been made within a wide range of age groups.
Factors associated... with the onset of this form of 
diabetes include abnormal immune responses (islet cell antibodies 
are often present at diagnosis ) genetic inheritance (genes on 
chromosome 6 have been suggested) and viral infection. 
Chemically induced destruction of the B cells of the pancreas has 
been demonstrated to mimick the symptoms of type I / insulin 
dependent diabetes mellitus. Two chemicals in particular; 
streptozotocin ( 2-deoxy-2- (3-methyl - 3 - nitrosoureido ) - D - 
glucopyranose ) and alloxan ( 2,4,5,6-tetra oxo hexa hydro 
pyrimidine) have been used in rats and mice to chemically induce
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an animal model for this form of diabetes. Both streptozotocin 
and alloxan can induce severe B cell necrosis (Wilson et al 1984) 
however, the mechanisms by which these drugs cause B cell damage 
is not entirely clear.
Streptozotocin
Streptozotocin has an LD value of 137.7 mg/Kg when
50
administered to rats by intravenous injection ( Merck Index 
nineth edition 1976) It has a molecular weight of 265.2 (the 
structure of this compound is illustrated in Appendix II, figure 
A2 ). This drug has been suggested ( Uchigata et al 1982) to 
cause DNA strand breakage by the generation of carbonium 
ions (CH .) during decomposition of methylnitrourea from the
3
drug itself. However, Wilson et_ al (1984) suggest that the 
generation of carbonium ions does not cause DNA strand 
breakage, but may alkylate DNA bases which leads to the 
activation of poly (ADP-ribose) synthetase to repair these 
modified sites. Cellular NAD is used as the enzyme’s substrate 
and thereby subsequently results in NAD depletion and cell death 
occurs.
Robbins et al (1980) have suggested that the drug 
generates oxygen free radicals, but Wilson et al (1984) contest 
this proposal because they found no evidence that superoxide 
dismutase, a superoxide scavenger, gave any protection against 
streptozotocin’s cytotoxic effects.
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Rossini et al (1978) demonstrated that a combination of
the non-metabolizable glucose analogue 3-0 - methylglucose and 
antilymphatic serum can protect mice from low doses of 
streptozotocin. They proposed that the glucose analogue prevented 
hyperglycaemia and the antilymphocyte serum prevented the 
lymphocytic infiltration of pancreatic islets. The mechanism by 
which the glucose analogue prevented hyperglycaemia was not 
speculated upon. Perhaps the mechanism of protection was related 
to the similarity between the two structures with glucose.
Alloxan has an LD value of 200 mg/Kg when administered
50
intravenously in mice (merck Index, Nineth Edition (1976) ). The 
structure of the compound is illustrated in Appedix II, figure 
A1. Like streptozotocin, this drug has also been suggested
(Uchigata > cause DNA strand breakage as a result of
oxygen free radical generation . Others have questioned whether 
these free radicals generated by alloxan have the ability to 
break DNA strands (Wilson et al 1984; Sandler & Swene 1983).
alloxan inactivates glucokinase in pancreatic islet B cells and 
thereby prevents glucose metabolism in these cells. They suggest 
that glucokinase acts as the" glucose sensor"; that is, 
inactivation of this enzyme results in the abolition of glucose 
stimulated release of insulin from B cells. High levels of
Alloxan
Interestingly, Meglasson et al (1986) propose that
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glucose can " protect" glucokinase from inactivation by alloxan.
This group did not comment on the mechanism by which alloxan
causes B cell necrosis.
Finally, another group, Colca et al (1983) have
2+
proposed that alloxan inhibits a Ca - calmodulin protein kinase 
in pancreatic islets and this inhibition leads to a loss of 
glucose stimulated insulin secretion. Again, this action can be 
prevented by the presence of glucose. Once again the mechanism by 
which alloxan causes this intracellular effect is unknown. Also 
do glucokinase and this enzyme share the same mechanism by which 
they control the secretion of insulin in response to glucose ? 
The answers appear to be unknown as is the precise mechanism by 
which alloxan conveys cytotoxicity specifically to islet B cells.
Type II - Non Insulin Dependent Diabetes Mellitus
This subclass of diabetes is fairly difficult to detect 
in its early stages because frequently minimal or no symptoms 
such as fasting hyperglycaemia may exist. ( National Diabetes
Data Group 1979). This type of diabetes has been termed "maturity
onset diabetes", but this method of classification is not 
strictly correct because NIDDM may develope at any age, but it is
true to say that most patients do develope this type of diabetes
after the age of forty. It is this form of the disease which 
occurs most frequently in western society.
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Also, 60 - 90 % of all NIDDM patients in western
society are obese and treatment in some cases is restricted to 
diet alone. In other cases, controlled diet and sulphonylurea 
(see appendix II, figure A3) or biguanide (see appendix II , 
figure A5) therapy is administered. Clinical diagnosis of NIDDM, 
in the absence of observable symptoms , is generally made by
the administration of an oral glucose tolerance test. Insulin
resistance is characteristic and this has been associated with a 
defect at the post receptor level ( Kolterman et^  al_ 1981 ).
Hyperinsulinaemia and normoglycaemia is often also present. 
Secondary effects of NIDDM are more apparent.
The animal models used for this type of diabetes 
include obese Zucker rats and db/db mice. Only the Zucker rat 
will be discussed here because this is the model for NIDDM that 
I have used in my work. The Zucker rat adequately illustrates 
the common characteristics of a type II diabetic model.
The Zucker Rat
The "fatty" Zucker rat appeared as a spontaneous 
genetically obese condition in the Laboratory of Comparative 
Pathology, Stow, Massachusetts, U.S.A. in 1961 ( Zucker & Zucker 
1961). As the obese progeny were observed at a 25 % incidence per 
litter, the condition was believed to be due to a single 
recessive gene and the "fatty" condition is therefore a 
homozygous recessive expression. Obesity is observable within
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three weeks of birth (see figure 5 ) and food intake is
significantly increased in these animals. The blood plasma of 
"fatties” is of milky appearance. Indeed, the serum fatty acid
level is ten times the level observed in lean Zucker rats and
cholesterol is four times higher in serum from fat animals when
compared to leans ( Zucker & Zucker 1961). Low density 
lipoproteins (LDL) and high density lipoproteins (HDL) are 
increased two fold in serum from "fatty" rats ( Bray 1977). Even 
when food intake is restricted, the "fatty" rats are still obese 
when compared to controls. However, there is no evidence of 
arterial thickening.
Hyperinsulinaemia is present in "fatties" before 
obesity is observed and plasma insulin concentration appears to
be dependent on the age of the rat. However, when fat Zuckers are 
compared to lean controls with respect to their relative ages ; 
plasma insulin levels are calculated to be about four times 
higher in the obese rats than the leans ( York et_ al_ 1972; Curry 
& Stern 1985) and B cell hypertrophy is also recorded ( Stolz & 
Martin 1982). Glucagon levels in the pancreas appear to be 
normal, but circulating glucagon concentration is decreased
in obese animals (Eaton et al 1976).
Interestingly, Clark et^  al_ (1983) have identified the 
presence of diabetes ; as assessed by a glucose tolerance test 
and the lowering of body fat and triglyceride, when compared to 
obese normoglycaemic rats. This condition appeared in obese
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Figure shows a lean Zucker rat (447g) and its obese litter 
mate ( 1035g). Both are 10 months of age.
Figure is reproduced from Zucker & Zucker 1961
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Zucker rats after six months of age and surprisingly occurred in 
more males than females.
Stolz & Martin (1982) tried chemically inducing 
diabetes in obese and lean Zucker rats in order to determine 
whether there was any relationship between plasma insulin 
levels, food intake and weight gain. They carefully controlled 
the plasma insulin levels in each set of animals by daily 
injection of exogenous insulin and they came up with some 
rather surprising results. The food intake and weight gain in 
the obese animals were reduced to that of the lean animals, 
but hepatic lipogenesis was still elevated and therefore 
independent of insulin concentration and food intake. This 
appears to be in agreement to some extent with the observation 
that obesity in these animals can be distinguished prior to 
the condition of hyperinsulinaemia being present (Curry & Stern
1985).
Finally, Guerre-Millo and colleagues (1985) have 
suggested that in adipocytes isolated from obese and lean Zucker 
rats, insulin mediated glucose transport is enhanced in the obese 
animals . Cytochalasin B binding studies suggest that this may be 
due to a significantly increased number of glucose carrier 
molecules in an intracellular microsomal ’’pool". This could 
obviously be considered as a hypersensitiveresponse to insulin.
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1.2 The Insulin Receptor
1.2.1 Structure
a) Protein Subunit Composition
The insulin receptor is an integral membrane
glycoprotein generally accepted to be composed of two distinct
polypepytide subunit species denoted oL and p (Czech etal 1981).
The proposed functional receptor, depicted in figure 6 , is
comprised of an (0(p) subunit complex which is stabilized by
2
disulphide bridges. Theo(. and p subunit molecular weights have 
been estimated to be about 120 K Da and 90 K Da 
respectively.(Pilch & Czech 1980).
Purification of the insulin receptor was originally 
achieved by solubilisation using non-ionic detergent, followed by 
chromatography using immobilized lectin columns and finally 
affinity chromatography utilizing immobilized insulin 
columns (Fujita & Yamaguchi 1984; Finn et_ al 1984). However, 
monoclonal antibodies raised against the insulin receptor now 
facilitates purification of the holomeric protein (Soos et^  al_ 
1986 ; O'Brien et_ al 1986).
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The use of photoaffinity labelled I-insulin and the 
cross linking agent disuccinimidyl suberate (Pilch & Czech 1980) 
has greatly facilitated determination of its subunit composition. 
This has allowed identification of the binding site for insulin
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Figure 6 Proposed Insulin Receptor Structure
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Schematic diagram of the insulin receptor subunit structure 
illustrating the position of disuphide bridges and apparent 
molecular weights of each subunit. Intact complex molecular 
weight estimation was obtained under non-reducing conditions 
Figure is reproduced from Czech et al 1981.
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to be the oL subunit. The OC subunits are transmembrane 
species, exposed at the external surface of the plasma
membrane and the p subunits are exposed at both the
extracellular and cytosolic surface of the membrane (Hedo &
Simpson 1984).
Initially , determination of subunit stoichiometry was 
facilitated by the use of two experimental techniques; that 
is,the reduction of interchain disulphide bonds and specific in 
vitro proteolysis of the insulin receptor.
Interchain disulphide bond studies were performed by 
Jacobs et_ al_ (1979) & Massague et_ al_ (1980). Using various 
concentrations of the reducing agent dithiothreitol , they 
identified two catagories of disulphide bridges which were 
classified with respect to their differing sensitivity to 
reductants. The disulphide bridges most sensitive to reductant 
were found to link together the (<X p) receptor fragments. One 
receptor complex was found to yield two (0C]3) fragments under 
mildly reducing conditions.
The other class of disulphide bridges were found to 
link together theocand B subunits. However, these disulphide 
bridges were only reduced in the presence of detergents which 
allowed solubilization of the insulin receptor complex. Hence, 
receptor complex formation must have prevented the exposure of 
these disulphide bridges and thereby protected them from 
reduction by dithiothreitol.
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Studies using in vitro proteolysis of the receptor and 
subsequent receptor fragment resolution on S.D.S. gels (Massague 
et al 1981) has led to the identification of receptor 
fragments (which have to some extent been isolated from 
partially purified membranes. This observation has led to 
suggestions that in vivo partial proteolysis of the receptor 
may occur. This may explain why other workers such as Baron & 
Sonksen (1983 ) have proposed three different molecular 
subunit types; the (X , J3 and an additional cT subunit. This cT 
subunit was suggested to have a molecular mass of 65 K Da and is 
not a glycoprotein. Therefore, presumably this subunit would not 
face the outside of the cell. This polypeptide could conceivably 
be an artifact due to spontaneous proteolysis ( for example of 
the J3 subunit which is sensitive to proteolysis) or if it does 
exist, it may be a protein which is associated with the insulin 
receptor in the plasma membrane.
Crosslinking (Baron & Sonksen 1983) and 
immunoprecipitation (Kasuga et_ al 1982a; Kasuga et_ 'al 1982b) 
studies suggest that there may be protein subunits non-covalently 
associated with the insulin receptor which would be removed 
during the solubilisation and purification procedure. In 
addition, Harmon et_ al (1980) have presented evidence for a 
protein species which may have the ability to reduce hormone 
binding upon association with the receptor.
Finally, Graves et al (1985) have proposed a calmodulin 
binding domain either on the B subunit of the insulin receptor or
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on a protein such as the ATPase which copurifies with the
2+
receptor. They suggest that upon Ca - calmodulin interaction
with the receptor, the affinity for insulin binding increases.
Probably one of the most exciting and most informative 
developements in structural elucidation has been the cloning of 
the insulin receptor from human placenta. This has been achieved 
by two independent groups (Ebina jat al_ 1985; Ulrich et a!1985). 
It appears that the OC and p subunits of the insulin receptor are 
derived from one polypeptide precursor molecule which is encoded 
for by a single mRNA and is therefore presumed to be the 
expression of a single gene which Ebina and colleagues have 
located on chromosome 19 (see figure 7).
Both groups indicate the presence of a 27 amino acid
sequence at the N-terminal of the precursor which is
characteristic of a hydrophobic "signal sequence" found in 
post-translationally modified proteins. TheO(subunit sequence
follows this and consists of between 720 - 735 amino acid
residues. Ebina predicts the molecular weight of the cL subunit 
to be 84.2 K Da and identifies 15 possible glycosylation sites 
which could increase the molecular weight to the apparent 120-130 
K Da level. The oL subunit contains a cysteine rich domain with 
a very high proportion of hydrophilic residues. Ebina calls this 
a " cross-linking " region and this shows high homology to a
cysteine rich region in the EGF receptor. The N - terminal of the
subunit also contains two short hydrophobic domains which
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Figure 7 The Cloned Insulin Receptor Structure
fl-Subunit , -Subunit
A=putatiye signal peptide 
B=crosslinking region 
C= transmembrane region 
D= cytoplasmic phosphokinase domain 
E=C terminal region
A
I
B C D E
Figure is reproduced from Ebina et al 1985
apparently are not large enough to span the membrane, but would 
conceivably form a hydrophobic interaction with the membrane or 
alternatively could form a hydrophobic ” core " within itself.
The C - terminal of the (X subunit shows no structural 
homology with the EGF receptor, but is speculated to contain the 
insulin binding site. There is also a potential glycosylation 
site in this region which may or may not play a role in insulin 
binding or recognition. Following the sequence coding for the 
oC subunit is a domain which contains several proteolytic 
processing sites which would allow generation of the <X. and p 
subunits from the precursor.
hjckopbcbiC
The p subunit sequence contains a domain of 23^ A amino 
acids followed by 3 positively charged amino acids . This is 
suggested to be a n trans membrane domain n which would allow 
insertion of the polypeptide into the membrane . The polar 
amino acids would act as a 11 stop signal " to allow anchorage of 
the protein in the membrane. An ATP binding site has been 
identified on the p subunit sequence which shows slight homology 
with the EGF receptor and the V- ros gene product ( an oncogene 
product known to exhibit tyrosyl kinase activity (Hunter 1986)).
The C-terminal region contains highly hydrophilic amino 
acids and is suggested to be the cytoplasmically exposed region 
which could be susceptible to intracellular proteolytic cleavage. 
Finally, Ebina and colleagues also indicate,the presence of a so 
called B ; segment which is present in the precursor p subunit
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sequence. Upon analysis of solubilised and antibody purified 
insulin receptors, a 45 K Da polypeptide band was obtained. This 
has been identified as the segment found in the precursor j3 
subunit sequence. The importance (if any) of this polypeptide 
is not known. However, it is possible that it could be related to 
the 65 K Da d peptide subunit proposed by Baron & Sonksen 
(1983) or indeed it could explain the high molecular weight form 
of the insulin receptor observed by Helmerhorst et_ al (1986).
Ebina’s group ( Ebina et_al 1985 b) using the cloned
insulin receptor cDNA , demonstrated that by construction of
an expression plasmid they could express the human insulin
receptor in both xenopus oocytes and Chinese hamster ovary cells
(CHO). They also demonstrated that in the CHO cells the human
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insulin receptor not only bound I - insulin with high affinity 
and specificity, but could also stimulate autophosphorylation of 
the insulin receptor and 2-deoxyglucose uptake; actions 
characteristic of the functional insulin receptor.
b) Post translational Processing of The Insulin Receptor 
Subunits
In the early seventies Cuatracasas (1973a & 1973b)
demonstrated that the insulin receptor binds to lectins, in 
particular wheat germ agglutinin and concanavalin A . This led 
to the suggestion that the insulin receptor is highly
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glycosylated. This observation was iater confirmed by Jarett and
Smith (1974). More direct evidence for the presence of
carbohydrate moieties on the insulin receptor came from Hedo et_
al (1981) when they demonstrated that both the <*■ and the p
subunits of the insulin receptor in IM-9-lymphocytes can 
3 3 3
incorporate H carbohydrates such as H-fucose and H-mannose.
Further study of the insulin receptor biosynthetic 
pathway has been aided by the use of the inhibitor tunicamycin. 
This compound has the ability to inhibit the attachment of core 
oligosaccharide to asparaginyl residues of nascent 
glycoproteins. Ronnet\f & Lane (1981) and Reed et_ al( 1981) 
demonstrated that glycosylation is essential for the post- 
translational formation of a functional insulin receptor in 3T3- 
L1 adipocytes . In the presence of this compound the number of 
cell surface insulin receptors were depleted and 
non - glycosylated receptor proteins accumulated intraeellularly. 
Therefore, they proposed that glycosylation may be important in 
receptor movement to the cell surface.
More recently however, elaborate pulse - chase 
3
experiments using H- mannose (Hedo & Simpson 1985) and 
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(S) -methionine (Ronnett et_ al_ 1984) have been performed. 
Both groups agree that very early (within minutes) in the 
receptor biosynthetic pathway, a 190 K Da ,fpro-receptorn protein 
appears.
However, Ronnett et_ al_ believe that prior to the 
appearance of this 190 K Da protein, there is a lower molecular
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weight protein of about 180 K Da . This species, unlike the 190 
K Da species, is not glycosylated. It is of course conceivable 
that this lower molecular weight species would be undetectable to 
Hedo & Simpson because they are pulse - chasing carbohydrate 
units, not protein units of the precursor molecule.
Both groups demonstrated glycosylation in an 
intracellular fraction (believed to be the endoplasmic
reticulum) was followed by terminal glycosylation. This process 
was referred to by Ronnettfs group as n sialic acid capping ".
Proteolytic cleavage of the o', and {3 subunits occurs in the
Golgi prior to receptor insertion into the plasma membrane.
However, the major discrepancy between the two groups
is the question of whether or not a precursor molecule with a
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molecular weight of 205 - 210 K Da can bind I - insulin .
Ronnettfs group suggest that only the processed insulin
receptor inserted into the plasma membrane has the ability
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to bind I - insulin.This point of contention has still to 
be resolved, but if the cloning studies of Ebina et_ al_ (1985a)
are accurate then the insulin binding site is at the
C - terminal end of the oi polypeptide sequence. This therefore 
would not be accessible for interaction with insulin until
cleavage of the oi and p segments had occured . This process
(both groups claim) occurs immediately prior to insertion of the 
receptor into the plasma membrane.
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Now that the structure of the insulin receptor and its
biosynthesis are known in more detail, it is hoped that these
processes can be studied in human diseased states such as 
diabetes mellitus. To date, most receptor experimentation carried 
out on insulin resistant diabetic patients has been aimed at 
looking for changes in insulin binding affinity and receptor
number, rather than changes in receptor structure. However, f3|an
et al (1976) using samples from type II diabetics and Chang 
et^  al (1975) using animal models of type II diabetes have 
suggested receptor structural changes.
Interestingly, Chandramouli et_ al (1977) have looked at lectin 
binding to liver plasma membranes in streptozotocin - induced 
diabetic rats . They concluded that this insulin deficient state 
led to significant generalized ' changes in cell surface 
glycoproteins. Perhaps such changes could occur on the insulin 
receptor . Certainly , lectins such as concanavalin A and 
wheat germ agglutinin have been suggested to compete with 
insulin to bind to the insulin receptor (Cuatracasas & Tell
1973) . These lectins were found to mimick insulin’s ability
to enhance glucose transport.
1.2.2 The Binding of Insulin To Its Receptor
Most insulin binding studies have been performed using
125
the radiolabelled ligand I - insulin . In the case of cell
125
surface receptor number estimations, I - insulin has been used
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in conjunction with disuccinimidyl suberate to covalently 
cross - link and specifically label the receptors. Criticism 
concerning the specificity of insulin binding studies has been 
made ( Cuatracasas 197*1 ) . However , the radio-ligand
technique has been very informative about kinetic parameters 
of binding, dissociation and movement of receptors . Two 
models of insulin receptor binding have been proposed
1) There are at least two distinct kinds of insulin receptors on 
the extracellular surface of the plasma membrane, each with a 
different affinity for insulin binding. These two receptor 
populations do not interact with each other in order to affect 
each other's binding activity.
2) There is only one form of insulin receptor on the 
extracellular surface of the plasma membrane, but receptors act 
in a negatively cooperative manner towards one another with 
respect to binding insulin such that, upon insulin binding to 
one receptor, the affinity of other receptors to bind insulin is 
reduced.
These models were proposed as a result of Scatchard binding 
analysis indicating curvilinear or biphasic characteristics. The 
evidence to support the two site model includes the following
a) Kahn et_ al_ (197*0 submitted data which they proposed was 
indicative of the presence of two "sites” whose Km values were
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dependent upon the incubation temperature.
b) Czech et_al(198l) proteolytically cleaved the B subunit of 
the insulin receptor and were able to generate three insulin 
receptor forms . They suggest this could occur vivo as a 
result of lysosomal protease processing.
c) Corin & Donner (1982) proposed two affinity states of the 
hormonal - receptor complex ie. the formation of a "high 
affinity" complex occurs upon insulin binding to its receptor.
The evidence to support the negative cooperativity 
model is as multitudinous as that for the two site model. One 
particularly strong piece of evidence in favour of this model is
that presented byDe Meytset al (1976). This group demonstrated
that the plant lectin concanavalin A was able to inhibit the
site-site interactions between insulin receptors without binding 
to the insulin receptor binding site. This resulted in the 
linearization of the Scatchard plot.
When these binding studies are considered in context 
with the insulin receptor structural determinations, it is
conceivable that either model may well be correct . For example, 
the proteolytic processing of the B subunit is evidently possible 
when the receptor cloning studies are considered. Indeed, Ebina 
et al identified a Bf peptide which they suggest is cleaved from 
the B subunit sequence during pro-receptor processing. If 
however, the glycosylation studies are considered; the presence 
of a relatively small amount of glycosylation of the B
*•8
subunit ( the subunit which is not generally accepted to be the 
insulin binding site) may serve the function of facilitating 
inter-receptor interactions. After all, insulin receptors do 
appear to aggregate prior to internalisation ; a process known 
as receptor mediated endocytosis (RME) . Also, the suggestion 
that plant lectins such as concanavalin A may compete with 
insulin for binding to the insulin receptor could be a result of 
their binding to carbohydrate moities. This could therefore 
reduce access to the insulin binding site. The observations by 
De Meytset al are to some extent in agreement with observations by 
Cuatracasacs & Tell (1973). The ability of lectins to mimick 
insulin's stimulation of glucose transport in target cells could 
also be a result of receptor interactions and the endocytotic 
process.
In conclusion then, the precise model of insulin
receptor binding is still a controversial issue. More 
recently , studies to investigate insulin binding in diabetic
states, to determine whether insulin resistance could be 
attributed to insulin receptor abnormalities have been
undertaken. Much literature is available in this area ,but only 
a few examples will be outlined here :
Livingston et_ al_ (1984) studied the binding of insulin 
in human adipocytes isolated from obese, insulin resistant and 
lean control subjects . They found no significant difference
in binding affinity or capacity between these two classes of
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subjects. It was therefore assumed that any defects were probably 
at the post-receptor level and not associated with insulin 
binding. Conversely, Salhanick et_ al_ (1985) and others such as 
Czech et_ al_ (1980) and Sampson et_ al^  (1982) have reported 
enhanced insulin binding in hepatocytes isolated from 
streptozocin - induced diabetic rats . This has been attributed 
to an "up regulation" or recruitment of receptors from 
intracellular locations. This would tend to suggest that the 
receptor levels themselves are controlled by the circulating 
plasma insulin concentration . Obviously in the case of this 
model of type I diabetes, the mechanism of insulin resistance
does not appear to be reduced insulin binding capability.
Yki-Jarvinen et_ al_ (1984) looked at insulin binding in
human adipocytes from control and type I diabetic subjects. They 
found a slight decrease in the total receptor number, but no
change in receptor affinity. In addition, various hypoglycaemic
agents therapeutically used in type II diabetes have been 
examined for possible effects on insulin binding. The literature 
published in this area is vast, but in general, the use of 
biguanides such as metformin (Vigneri et al_ 1982 ; Lord et al_ 
1983 and Holle et_ al 1981 ) and phenformin (Iwamoto ejt al_ 1981)
appear to increase the number of insulin receptors in a wide 
range of human cell lines. Increases in receptor number does 
not appear to involve de_ novo synthesis of receptors. 
Instead, receptors are recruited from an intracellular "pool".
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Sulphonylureas have been reported in_ vitro (Maloff & 
Lockwood 1983; Vigneri et al 1982) to have no influence on 
insulin binding to its receptor. However, in vivo (Olefsky et al 
1976; Feinglos & Leibovitz 1978 and Beck-Nielsen et al
1979) sulphonylureas appear to enhance insulin binding.
This phenomenon has been attributed sulphonylureas in vivo 
increasing plasma insulin levels and therefore indirectly 
affecting insulin receptor number.
One very important point to mention is the comment on
insulin binding studies which was made by Rizza et al (1981).
That was, that many of the cell types used in such studies are 
not identified as insulin target cells. Therefore the value of 
such studies should be questioned.
1.2.3 Movement of Insulin Receptors From The Plasma Membrane
The process by which receptors are removed from the 
extracellular surface of the plasma membrane to intercellular 
localisations is known as "receptor mediated endocytosis " 
(RME). This process was first investigated by Goldfine et_ 
al (19 78) and Schlessinger et al_ (1978).Using radiolabelled or 
fluorescently labelled insulin, they demonstrated that occupied 
insulin receptors were internalized into hepatocytes. 
Similarly, utilization of photo-affinity labelled insulin has 
allowed the study of receptor lateral movement in the plasma 
membrane. It is proposed that occupied receptors must aggregate
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or "cluster" prior to internalization in "pits" or plasma
membrane indentations. These "pits" are coated on their
cytoplasmic surface with a protein called clath rin (Pastan
& Willingham 1983). Receptor aggregation has been reported to be
important in insulin action (Kahn et_ al 1978) . Exposure of rat
adipocytes to anti-insulin receptor antibodies resulted in
125
the inhibition of I- insulin binding. It was
demonstrated that although both monovalent and bivalent Fab 
fragments affected radiolabelled insulin binding ,only bivalent 
Fab fragments triggered insulin - like effects in these cells. 
This therefore led to the proposal of receptor - hormone
complex aggregation being an obligatory requirement for some 
of insulin’s actions.
Compounds such as methylamine and ammonia have been 
shown to inhibit the clustering of a number of receptors 
(Maxfield et al 1979) . This inhibition of clustering has been 
demonstrated to block the internalization process. Indeed, 
activation of glucose transport has also been suggested to 
involve receptor movement in the plasma membrane ( Simpson & Hedo
1984) . This process of receptor movement and internalization is 
proposed to occur in a series of distinctive stages (see figure 
8 ).
The ligand - receptor complexes cluster into clath rin 
coated pits and become invaginated into vesicular structures 
inside the cell known as "endosomes". These endosomes may or may 
not be coated with clathorin ( Pastan & Willingham 1983 )
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Figure 8 Schematic Diagram of The Process of Endocytosis
Ligand
□
Plasma Membrane
Receptor
Coated Pit
\ / °
\  Receptosome
• \ s<n
Exocytosis \  8 5 ;
Golgi 
Coated Pits
Lysosome
Golgi
ER
Nucleus
E.R. = endoplasmic reticulum. "Receptosomes" are endosomes 
containing the receptor - ligand complex.
Figure is reproduced from Pastan & Willingham 1983.
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However, they do appear to have an internal acid pH which is 
proposed to trigger the dissociation of the ligand - receptor 
complex (Helenius et_ al_ 1983). There is strong evidence 
that the internalized receptors are recycled back to the plasma 
membrane , a process which appears to be independent of protein 
synthesis (Marshall et_ al_ 1981). This recycling process can be 
blocked by chloroquine and subsequently results in a net loss 
of cell surface receptors ( a process known as 
"downregulation" of receptors ). More recently, Huecksteadt 
et al (1986) used an iodinated , photoreactive analogue of 
insulin to covalently label the insulin receptor exposed on the 
extracellular surface of rat adipocytes.They demonstrated that 
insulin receptors may be recycled without the obligatory 
dissociation of the ligand-receptor complex. Thus, the process 
which "sorts” the ligand and the receptor moieties 
( Baervziger & Fiete 1986) may only distinguish with respect to 
the receptor and not the ligand.
It has also been demonstrated (Marshall et a!198l) that 
in order for the internalisation process to occur, there is an 
obligatory requirement for occupancy of the receptor. Assuming 
that the insulin - receptor complex is internalised, 
dissociated and the receptor subsequently recycled, what then 
happens to the hormone ?
Insulin has been demonstrated to -be proteolytically 
cleaved early after its internalization ( Assoian & Tager 1981 ). 
However, this process was blocked using lysosomotropic agents
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( Ward 1984 ). Interestingly, Blazar e^b al ( 1984 ) used 
chloroquine in. vivo to inhibit insulin degradation in a diabetic 
patient who showed severe insulin resistance. This treatment 
was said to be very effective .
Now, "following" the internalization of insulin into 
hepatocytes, Ward (1984) found that the internalized hormone 
rapidly accumulated in the microsomal and / or Golgi fractions
of the cells. However, the hormone did not accumulate in the
lysosomes. The importance of this is not known at the 
moment, but much work is being continued in this area . It is of 
course possible that the internalization of insulin could be 
required for insulins’ long-term effects such as specific protein 
synthesis induction. Perhaps an unidentified intracellular 
receptor for the hormone may exist . Or perhaps the 
internalization of the hormone acts only as a means to remove
the hormone from the receptor and allow recycling of an
unoccupied receptor back to the plasma membrane and thereby 
conserving the energetic expense of synthesizing a new receptor.
Of course as a result of this receptor movement it is 
possible that other membrane components are simultaneously 
translocated . There is evidence that insulin triggers the 
movement of IGF II receptors (Oppenheimer et^  al 1983) and 
transferrin receptors (Davis et_ al_ 1986) to the plasma 
membrane from intracellular (possibly microsomal) locations. The 
mechanism by which this occurs is unknown, but it does seem 
likely that this process of insulin stimulated RME would
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influence such membrane movements.
Another process which seems to occur spontaneously upon 
insulin binding to its receptor is the autophosphorylation of the 
insulin receptor’s p subnit. Over the past few years this area of 
insulin ’’action” has received a large amount of attention. 
A relatively brief outline of this process and its possible role 
in the normal and diabetic states will be presented.
1.2.4 Autophosphorylation Of The Insulin Receptor And Its 
possible Role In insulin Action
Kasuga el: al (1982) were the first to demonstrate that insulin
had the ability to stimulate phosphorylation of the p subunit of
its own receptor. This was later confirmed by others and work
performed by Shia & Pilch (1983) established the site of this
insulin phosphorylation to be tyrosine specific. This
autophosphorylation occured rapidly in the presence of
o
insulin with a K of 30 sec at 22 C (White et^  al 1984 ) and a 
0.5
K of 5 min at 4 C ( Zick et al_ 1983). The maximum and steady 
0.5
state levels of phosphorylation is achieved at between 10 and 20 
min in the presence of insulin and is dependent upon the 
incubation temperature used. In the absence of insulin,
46
phosphorylation does occur, but only slowly (Gamraeltoft & Van
2+ 2+
Obberghem 1986). Mn and Mg have been shown (Pike et_ al^  1984)
to augment the insulin stimulated phosphorylation of the insulin
2+ 2+ 24-
receptor, but the divalent cations Ca , Zn and Cr were found
2+
to be ineffective, although Co does have a slight effect
( Avruch et_ al_ 1982; Zick el: al_ 1983). The phosphate donor for
the phosphorylation reaction is ATP (Kasuga et al 1982) and the
Km value for ATP in the presence of insulin is in the order of
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30 - 50 uM (Gammeltoft & Van Obberghen 1986). ADP inhibits P ATP 
incorporation into the J3 subunit.
Insulin stimulation of this autophosphorylation process 
results in enhanced tyrosine kinase activity ( Vmax increases , 
but Km remains unchanged ). This autophosphorylation also 
results in phosphorylation of exogenous substrates in_ vitro such 
as caesin, actin, (Kasuga et_ al_ 1983) angiotensin II, histone 2B 
( Klein et_ aL 1985)and synthetic peptides (Casnellie et_ al 1982; 
Zick et_ al_ 1985) on tyrosine residues.
Comparisons have been made between tyrosine kinase 
activity associated with the insulin receptor and the EGF
receptor, particularly with respect to their specificities for
exogenous substrates ( Pike ejb al 1984; Klein et al_
1985 ; Stadtmauer & Rosen 1983). It is believed that both
receptor kinases phosphorylate similar exogenous substrates in 
vitro. However, it must be remembered.that the conditions 
employed for in_ vitro studies are hardly physiological and when
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the cellular localisation of some of these " exogenous 
substrates" are considered (such as histone 2B) there is no 
evidence as yet, to suggest that the insulin receptor and 
therefore the kinase has any direct contact with such substrates.
Rather interestingly however, is the observation that 
tyrosine kinase activity has been associated with a range of 
oncogene products (Hunter 1980) , the EGF receptor,the PDGF 
receptor (Ek et_ al_ 1982) and the IGF I receptor (JaCtobs et_ al 
1983b). As a result of these observations, it may be feasible to 
suggest that the function of this tyrosyl kinase activity may 
well be associated with growth and cellular proliferation.
There are however differences in the sites of 
phosphorylation of the insulin receptor when in vitro and in vivo 
studies are compared. White and colleagues (1985) demonstrated 
that isolated receptor in_ vitro studies showed only 
phosphotyrosine containing p subunit , but iri vivo receptor 
studies indicated that phosphoserine and phosphothreonine 
residues were also present in receptor p subunits stimulated 
with insulin in vivo before isolation. Using partially purified 
insulin receptor preparations, others ( Zick et_ al 1983; Yu & 
Czech 1984) have suggested the presence of a serine kinase which 
is non-covalently associated with the receptor . This is 
proposed to be removed during the receptor purification procedure 
( see fig 9).
Since the insulin receptor has been demonstrated to
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Figure 9 Schematic Representation of The Insulin Receptor
Tyrosine Kinase And Associated Serine Kinase
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Unidentified 
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Figure reproduced from Gammeltoft & Van Obberghen 1986.
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exhibit kinase activity , it has been the aim of many workers to 
ascribe a function to this action . Probably the most dramatic 
experiments in this field of research have been done by Ellis et 
al (1986). Site directed mutagenesis has been used to
demonstrate a correlation between insulin’s ability to
autophosphorylate its receptor and insulin’s ability to stimulate
glucose transport. This group altered or removed tyrosine 
residues in the suggested autophosphorylation region of the £ 
subunit and then expressed these mutant receptors in Chinese 
hamster ovary cells (CHO) . They demonstrated that tyrosine 
kinase activity in these cells was subsequently reduced or 
abolished . Simultaneously, insulin stimulated 2-deoxyglucose
transport was also demonstrated to be reduced or abolished 
whilst the insulin binding affinity remained unchanged. They 
therefore suggested that the autophosphorylation of the 
insulin receptor could regulate glucose transport in_ vivo. 
Similarly, Morgan & Roth (1987) used a monoclonal antibody which 
inhibits the insulin receptor kinase activity . This antibody was 
demonstrated to inhibit simultaneously the uptake of 
2-deoxyglucose , phosphorylation of the S6 ribosomal protein and 
decrease glycogen synthesis in CHO cells, a human hepatoma cell 
line and rat adipocytes.
However, Zick et_ al_ (1984) demonstrated that polyclonal 
antisera directed against the insulin receptor inhibited insulin 
binding, stimulated lipogenesis in isolated rat! adipocytes, but
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did not stimulate the phosphorylation of the insulin receptor. 
Similarly, Simpson & Hedo (1984) reported that polyclonal
antisera directed against the insulin receptor did not stimulate 
receptor phosphorylation ,but did stimulate glucose transport in 
intact isolated rat adipocytes. These polyclonal antisera 
experiments seem to suggest that activation of these rapid "short 
term" effects of insulin are a result of binding to the insulin 
receptor binding site rather than directly interacting with the 
tyrosine kinase activity ( as in the case of the monoclonal 
antibody) . However, the important point to be made from these 
antisera experiments is that stimulation of receptor
phosphorylation does not appear to be an obligatory prerequisite 
for these insulin actions.
It is of course possible that the receptor
phosphorylation in the ill vivo studies could stimulate this 
postulated serine, threonine kinase believed to be associated 
with the insulin receptor in the plasma membrane. This kinase 
could play a role in the regulation of these short term 
insulin actions. It is also conceivable that these site directed 
receptor mutants could affect non-covalent associations with 
peptides or other molecules at the cytoplasmic surface of the 
plasma membrane. Interference with insulin stimulated activities 
could thus occur.
The phorbol ester TPA ( 12-o-tetradecanoyl phorbol-13- 
acetate, see figure A7) has been demonstrated to activate protein 
C in a variety of tissues ( Niedel et al 1983; Castagna et al
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1982). This phorbol ester and protein kinase C have been shown 
to serine and threonine phosphorylate the insulin receptor 
(Jacobs et_ al_ 1983|>jBollag et^  al 1986) .This resulted in the 
reduction of the insulin tyrosine kinase activity and 
decreased insulin stimulated glycogen synthase activity. 
This therefore suggested a link between tyrosine kinase 
activity and an early affect of insulin.
However, Van de Werve et_ al_ (1985) demonstrated that 
tumour promoting phorbol esters stimulated lipogenesis in rat 
adipocytes without altering insulin binding , but reduced 
insulin stimulated lipogenesis. Thus, phorbol esters themselves 
may have insulin like actions . In addition, insulin and TPA 
have been shown to phosphorylate an apparently common 40 K Da 
protein in adipocyte plasma membranes( Graves & McDonald 1985 ). 
The identity of this protein is unknown, but the phosphorylation 
of this protein does suggest another common feature between 
protein kinase C and insulin action. Of course the question 
of whether or not this membrane associated protein has kinase 
activity itself will be of great interest to answer . If this 
were found to be the case this would open up further potential 
research into the postulated serine kinase associated with the 
insulin receptor and its link with insulin action.
It is also of interest to note that activation of 
protein kinase C by diacylglycerol is believed to produce other 
insulin like effects such as activation of glucose and amino acid
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transport ( Farese et_ al_ 1986 ). Intriguingly, decreased 
autophosphorylation of the insulin receptor in the diabetic type 
I model has been suggested to occur (Kadowaki et_ al_ 1984). 
However, Amatruda et_ al (1985) reported normal receptor kinase 
activity in this model of diabetes. Therefore, this may or
may not be a mechanism by which insulin resistance could occur.
Also, catecholamine treatment has been suggested to 
decrease tyrosine kinase activity of the insulin receptor. 
This treatment induces an M insulin resistant " state ( Haring
et_ al 1986). Pessin et_ al_ (1983) have also demonstrated that 
p- adrenergic agonists ( catecholamines) inhibit both insulin
and EGF binding to their respective receptors. This action
appears to involve a cAMP - dependent process . As both receptor
populations exhibit tyrosine autophosphorylation , it is a 
possibility that cAMP could be stimulating a protein kinase to 
phosphorylate the receptors themselves.This could inhibit ligand 
binding and subsequent activation of signal transduction in these 
systems. Such an action has not been proven , but it is a
feasible speculation to make and does suggest "cross-talk"
between hormones / receptor agonists with opposing metabolic 
actions.
1.3 Insulin Action
Insulin exerts many diverse biochemical effects within 
a wide variety of target tissues. The hormone displays both long
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term and short term effects. Long term effects include changes in 
protein synthesis and breakdown . To date, this area of 
insulin action and mechanisms involved are poorly understood. 
Short term effects however, have been well characterisd and 
generally are a result of changes in the activity of existing 
enzymes and membrane transporters.
Principa. lly, insulin controls carbohydrate and fat 
metabolism in liver, skeletal muscle and adipose tissue (Czech 
1977; Denton et ajL 1981). The hormone's control of anabolic 
processes such as j glycogen & lipid synthesis in general are
attributed to enhanced glucose transport and changes in covalent 
modification of key regulatory enzymes. Table I illustrates some 
of these short term effects and the mechanisms suggested via 
which these effects are mediated. As can be seen from the table, 
insulin has the ability to alter the activity of a range of 
enzymes in a variety of intracellular localisations . This 
observation has been intriguing to workers who have searched (and 
are still searching) for a classical” second messenger". Such a 
second messenger must have access to enzymes both in 
membrane - bound organelles and the cytosol.
Many second messenger proposals have been made and 
include ; elevated cGMP levels ( Illiano et_ al_ 1973; Vydelingum 
et_ al_ 1975), cellular calcium flux (Clausen et_ a^ L 1974; Kissebah 
et al 1975) and a peptide mediator released from the plasma 
membrane ( Larner 1984). However, none of these proposals have 
been able to account for all of insulin’s observed effects.
Ta
bl
e 
I 
Sh
or
t-
Te
rm
 
Ef
fe
ct
s 
of
 
In
su
li
n
-po
0
<H
<H
W
Co
•H
-p
cd
i— i 
>> 
Go
xa
0
o
xa
T3
0
0cd
0
Go
c•H
0
e
>>N
c<D
00
X
cd
>•H
-po
cd
o
xx
<H
o
G  O •H 
-P 
0 i—I 
>5
G
o
xaw
o
xao
x
3
<
0
G•H
0
O
G
>>
-P
0
0o
G0
x
c
0
Go
-pa
0o
0
G
-p•H
>
•H
-po
0
0
0
0
G
•H
x
GO
•rH
-p 
0 i—I 
>5
GO
xara
o
xa
0
c
•H
G
0ra
TD
0
0
0
0
Go
c
G CQ CQ
•H 0 0
0 o O
X 3 3
o T3 'O
G 0 0a G G
03 G C
0 O O
CQ •rH •H
0 -p -p
0 0 0
G rH rH
O >5 >>
G G G
•H O O
X X
X a >> a >5
-p CO X 0 -P
•H O •H o •pH
£ X > X >a •H a •H
CQ -P x
0 CQ O T3 o
X •rH 0 0 0 0
0 0 CQ 0
rH 0 0 0 0 0
0 X 0 E 0 E
G -p G >> G >j
G G o N o N
O >5 0 G 0 G
O ra Q 0 Q 0
0 0
0 o
0 G
i— 1 >5
>> X
X
G o G
•H X O
0 G X
-p 0 a
o a 0
G O
a, < 0
o G
o
G
0 i— 1 •H 0
E >5 rH 0
>5 X 3 0
N 0 0 G
G o G •H
W < H
G
•H
0
-po
Ga
0
EO
0O
X
♦H
G
COCO
0
CQ
0
G
•rH
x
0
0
0
rH
>5
GO
xa
CQ
o
x
a,
0
CQ 
0 i—i 
>5
GO
xa
CQ
o
xa
Go
•H
-p
0o
o
XI
0
o
E
CQ
0
rH
ao
x
>5o
0
G
0
G
X!
E
0
E
0
E
CQ
0
rH
a
CQ 
0 
X 
0 I—Ia
EOo
G
0GOOO
>5
rH
GO
CQ
0
X
0
rHa
EOo
G
0
GOOO
>5
rH
GO
55
Li
ve
r,
Fa
t 
mi
to
ch
on
dr
ia
 
py
ru
va
te
 
de
hy
dr
og
en
as
e 
De
cr
ea
se
d 
ph
os
ph
or
yl
at
io
n 
of
en
zy
me
en
ha
nc
es
 
ac
ti
vi
ty
Recently, it has been suggested that insulin might 
exert actions by stimulating other 11 second messenger n 
production or mediation systems. Some of these suggestions will 
now be briefly considered.
1.3.1 Phosphoinositol (_ P.I) Turnover
A wide variety of hormones ( Berridge 1984) and
neurotransmitters (Nahorski et_ al 1986) have been implicated in
2+
intracellular Ca mobilization by the second mesenger
transmembrane signalling system known as P.I. turnover. In
brief, receptor activation leads to an increase in intracellular
diacylglycerol and inositol 1,4,5 trisphosphate. Diacylglycerol
ioositcl
is known to activate protein kinase C anda 1,4,5 trisphosphate is
2+ '
believed to release Ca from the endoplasmic reticulum
(Nishizuka 1984; Berridge & Irvine 1984; Downes& Michell 1985).
2+
As a result of protein kinase C activation and intracellular Ca 
elevation, a number of responses such as smooth muscle 
contraction and secretory process are mediated. This P.I. "cycle" 
is very simplistically illustrated in fig 10 . This area of 
transmembrane signalling has become particularly active over the 
last few years and rapid advancement in the elucidation of 
phosphorylated inositol species and protein kinase C activation 
and localisation has been made.
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However, insulin’s possible involvement in the P.I.
cycle has been investigated since the nineteen sixties and
seventies and its role (if any) remains controversial. Work has
been published which supports the view that insulin can enhance
the phosphorylation of phospholipids such as phosphatydlcholine,
phosphatidylinositol , phosphatidylethanolamine and phosphatidic
acid ( Stein & Hales 197^; DeTorrontegue & Berthet 1966; Creba et
32
al 1983). The problem with this work however, is that Pi
labelled ATP was used as the phosphate donor . This is a poor
method for examining such effects because the hormone increases
32
the specific activity of ( P) ATP (Hepp et_ al^  1968; Stein &
Hales 197^ ). When this insulin induced increase in the
specific activity of the ATP is considered, significant
phosphate incorporation into specific phospholipids cannot
necessarily be assumed.
More recently, Pennington & Martin (1985) have 
3
demonstrated , using H- labelled inositol, that insulin may 
stimulate the de_ novo synthesis of phosphatidyl inositol and 
phosphatidyl *1,5 diphosphate. This of course must be a better 
way of quantifying insulin’s specific effects upon P.I. 
metabolism, but one criticism which should perhaps be made is 
that the accumulation of phosphatidyl inositol was measured for 
30 min . This incubation period is rather long when one 
considers the rapid actions of insulin , such as glucose 
transport, which occurs within a few minutes. Phorbol esters are
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known to stimulate protein kinase C and have been suggested to 
also have the ability to stimulate glucose transport ( Farese et_ 
al 1986). This could therefore conceivably be a possible effect 
of P.I. breakdown when diacylglycerol is released and stimulates 
protein kinase C activity. However, Creba elb al_ (1983), Thomas & 
Williamson (1983) and Pennington & Martin (1985) have all 
reported that insulin does not have the ability to stimulate P.I. 
breakdown and thereby insulin would be assumed not to have the 
ability to stimulate the release of diacylglycerol for the 
activation of protein kinase C . It would therefore appear that 
the P.I cycle does not operate as a second messenger system for 
insulin in the same way as it does for hormones such as 
vasopressin or for neurotransraitters in the central nervous 
system. Although, it is possible that long term protein 
synthesis effects associated with insulin action could in some 
way involve phophorylation of phospholipids.
Indeed, some workers have j suggested that there may be a 
relationship between the insulin receptor kinase activity and 
phosophatidylinositol phosphorylation (Machicao & Wieland 1984; 
Sale et_ al_ 1986). This phosphatidylinositol kinase actvity has 
been associated with both the partially purified insulin receptor 
and the homogeneously purified insulin receptor . Under these 
experimental conditions the serine kinase associated with the 
insulin receptor would be removed . This would therefore 
strongly suggest that the insulin receptor kinase or another
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kinase activity strongly associated with the insulin receptor is 
responsible for this phosphorylastion event.
There is evidence for oncogene products of the rous 
sarcoma and avian sarcoma viruses being tyrosine kinases . These 
proteins may also phosphorylate phosphotidylinositides (Sugimoto 
et al_ 1984; Macara et_ al 1984) .In addition the suggestion 
of a relationship between the ras 21 oncogene product and 
P.I. breakdown occuring has been made (Wakelam et_ aj^  1986). 
Therefore should a more positive link between insulin and P.I. 
metabolism be established a breakthrough in understanding 
insulin’s long term effects may be achieved.
Interestingly, Urumow & Wieland (1986) have 
demonstrated guanine nucleotide control of phosphotidylinositol 
4,phosphate phosphorylation in human placental membranes.This 
event lead to activation of phospholipase C and subsequent 
P.I. turnover . This is similar to the suggestion that insulin 
also has the ability to interact with proteins whose activity is 
controlled by guanine nucleotides .
1.3.2 A_ Non-peptide Mediator Release
An American group ( Saltiel & Cuatrecasas 1986 ; Saltiel 
et_ al 1986) have recently partially purified two novel mediators 
(see also Houslay & Wakelam 1981 for a review). They propose that 
unlike Larner's "peptide mediator" , these mediators are complex 
compounds containing glucosamine and inositol. Upon insulin 
stimulating an enzyme analagous to phospholipase C, this compound
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is hydrolysed to a glucosamine containing inositol phosphate and 
diacylglycerol. They demonstrated that the enzyme catalyzing 
this action was distinct from phospholipase C which controls P.I. 
turnover.
The diacylglycerol produced has been suggested to 
contain myristoyl chains and would therefore be distinct from 
diacylglycerol produced from phosphatidyl inositol phosphates. 
This group also suggested that a specific species of protein 
kinase C could be activated by this distinctive diacylglycerol. 
Therefore it has been proposed that this diacylglycerol species 
could mediate insulin’s so called ’’long term effects” such as 
the specific induction of protein synthesis and cellular growth.
1.3.3 The involvement of Guanine Nucleotide Regulatory Proteins 
in Insulin Action
General Introduction To Guanine Nucleotide Regulatory Proteins
In the late 1970’s and early 1980Ts, guanine nucleotide 
regulatory proteins (G Proteins) began to be recognised as 
important components in hormone transmembrane signalling 
processes. Rapidly the G proteins Gi and Gs were postulated and 
a role in adenylate cyclase regulation ascribed to them ( Stadel 
et al 1980 ). They were isolated, purified and their subunit
structures determined ( Northup et_ al_ 1983a ; Northup et al_
1983b; Codina et al 1984). Another G protein termed transducin
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was proposed to be involved in the regulation of cGMP 
phosphodiesterase activity in rod outer segments . This too, was 
isolated and purified and its structure determined (Fung 1983).
Hence, these G proteins (termed as such because their 
activity is regulated by guanine nucleotides ) were identified as 
a "family" of proteins.Each has its own distinctive, but similar 
structural composition and each exhibits a crucial role in signal 
transduction between surface receptor and transmembrane effector 
systems ( Houslay 1984 ).
Structurally, these proteins were initially believed to 
be of heterodimeric subunit composition. The subunits were 
denoted oC and p and the holomeric complex had an ( OC p) 1:1 
stoichiometry. Thec(subunits of these G proteins was distinctive 
from and non-identical to each other. The guanine nucleotide 
binding site was identified as being located on the oc subunits. 
The p subunit was identified as a 35 KDa molecular weight species 
which appeared to be identical in each member of the G protein 
family ( Codina et_ al_ 1984; Manning & Gilman 1983 ).
The p subunit has recently been cloned ( Sugimoto et_ al_ 1985 ) 
and both polyclonal and monoclonal antibodies have been raised 
against this polypeptide ( Rosenthall et_ al_ 1986; Lingham et al 
1986).
Codina et_ al_ (1984) isolated a third subunit species 
with a low molecular weight of between <10-15 K Da. This 
subunit, which was termed the •'Y subunit , was found to be
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present in Gs, Gi and transducin protein complexes. The 'V
subunit is believed to associate so tightly with the B subunit
that initial purification procedures used had not been able to 
resolve the two subunit species. Recently , the Of subunit in 
transducin has been shown to be structurally distinct from the Of 
subunits of Gs and Gi. However, the Of subunits of Gs and Gi
appear to be identical ( Manning & Gilman 1983; Hildebrandt et al
1985).
Also, in the early nineteen eighties ,a G protein was 
proposed to be involved in the mediation of two rapid insulin 
stimulated processes (Heyworth et al 1983 ;Heywortli& Houslay 1*985 | 
These processes were the activation of specific membrane 
associated cAMP phosphodiesterase activity and the inhibition of 
glucagon stimulated adenylate cyclase activity in isolated 
hepatocytes and liver plasma membranes. This G protein was termed 
n G ins "
Since these early G protein postulations and 
purifications , further G proteins have been identified and 
purified from brain and placenta ( Sternweis & Robishaw 1984,
Evans et_ a_l 1986). In particular, a G protein termed Go whose 
of. subunit appears to be structurally similar to Gi, has been 
isolated and purified . The precise function of this G protein , 
which has been found in relative abundance in brain tissue, has 
yet to be determined. A G protein termed Gp has been purified 
from brain and placenta . This G protein has been suggested to be
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involved in phospholipase C activation and therefore may be a 
modulator between receptors and an effector in the P.I. cycle 
signal pathway ( Berridge 1986 ).
Other intracellular G proteins not associated with the 
plasma membrane have also been identified. These are believed to 
be invovled in processses such as cytoskeletal function and 
protein synthesis. Bacterial toxins have greatly aided the 
identification of G proteins both in terms of purification and 
functional studies. These studies will be discussed in more
detail with respect to structural characteristics of Gs, Gi and 
Gins. My work has been primarily involved with one effector, 
that is , adenylate cyclase and its regulation by the G proteins 
Gs , Gi and the putative Gins. As a result of this, only these G 
proteins will be dealt with in greater detail. Also, the putative 
Gins will only be reviewed up to the time when my work began.
Structural _& Functional Characteristics of Gs
Gs, is the guanine nucleotide regulatory protein which 
has the ability to stimulate the activity of the enzyme
adenylate cyclase . It has been purified from a wide variety 
of tissues including brain and skeletal muscle. Itsot subunit has 
a molecular weight of 45 K Da . An additional higher molecular
weight form of 52 K Da was initially als9 found in rabbit
skeletal muscle preparations. Recently,cDNA studies have
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demonstrated the presence of two distinct forms of Gs in a
wide variety of tissues ( Robishaw et al 1986 ; Harris et_ al_
1985). The 0^  subunit of this protein is ADP- ribosylated by
cholera toxin in the presence of a membrane bound protein factor
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termed ARF (Gilman 1984). Using P - labelled NADP as the
ADP-ribose donor, this bacterial toxin prepared from Vibrae
cholerae catalyzes this covalent modification process. This
technique has been extensively used to identify the <A subunit
of this Gs protein. Upon cholera toxin ribosylation, the
subunit binds GTP and remains in a persistantly active state .
In this state , the <x subunit remains undissociated from the
p holomeric complex.
Under hormonally activated conditions, G proteins bind
GTP and subsequent activation of the (X subunit occurs. The
holomeric complex dissociates to liberate the free oi and p ^
subunits (Northup et_ al_ 1983; Katada et_ al 1984) and the free <*.
subunit is then able to interact with its effector system. It has
2+
been shown that Gs requires Mg for activation ( Iyengar 1981;
2+
Iyengar & Birnbaumer 1981). The Km for Mg is 5-10 mM (Iyengar
2+
1981), but the physiological concentration of intracellular Mg
is estimated to be about 0.5mM ( Birnbaumer et al 1985). A role
for hormonal / catecholamine stimulation of receptors has been
postulated whereby receptor stimulation results in an increased
24-
affinity of the G protein for Mg . Subsequent activation is 
then proposed to occur ( see sectiom 1.4.2 ” Dual Control of 
Adenylate Cyclase Activity By Hormonal Activation of Gs and Gin.)
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The oC subunit of Gs has been demomstrated to bind GDP, 
GTP and their analogues. The rate of Gs activation by non- 
hydrolysable analogues ( such as GPP(NH)P and GTP S ) is slower 
than the rate of activtion by GTP itself ( Schramm & Rodbell 
1975) . Indeed, a distinctive "lag" period is observable prior to 
activation . This is believed to reflect a distinct activation 
process which occurs after nucleotide binding ( Birnbaumer et al 
1980 ; Iyengar et al_ 1980). Once activation of the<?csubunit by 
non-hydrolysable guanine nucleotides occurs , the activation 
state is persistent ( Londos et al 1974).
The Km of Gs <X for GTP and its analogues is about 
1yM. Intracellular concentrations of GTP are about 0.1mM. 
Hence, under physiological conditions there is always 
saturating GTP levels present ( Birnbaumer et al 1985 ). Under
"basal" , that is , non-hormonally stimulating conditions , or 
when detergent solubilised Gs is used, GTP is unable to stimulate 
the activation and dissociation of the Gs complex. In order for 
GTP to activate Gs, reconstitution of the protein in the presence 
of stimulatory receptors is required ( Brandt et al_ 1983; 
Cerione et al_ 1984).
Also, Gs oc can be activated by NaF in the presence of 
2+ 3+
Mg and Al . Indeed, these conditions were used in the earlier 
procedures for Gs isolation and purification ( Sternweis & 
Gilman 1982). The precise mechanism by which'NaF activates Gs is 
unknown, but the compound appears to promote persistent subunit 
dissociation.
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Without doubt, one of the most useful tools which has 
been used to study G protein modulation of adenylate cyclase 
activity is the S 49 mouse lymphoma cell mutant which has been 
named "CYC ". This cell mutant is deficient in Gs activity
(Bourne et_ slL 1975; Sternweis et_ al_ 1981). Originally, this cell 
mutant was believed to be devoid of adenylate cyclase activity
because stimulatory ligands such as p- adrenergic agonists and 
guanine nucleotides were unable to stimulate this enzymes 
activity ( Abramson'et al 1985).
However, Ross & Gilman (1977) reconstituted Gs activity 
into CYC cells . Under these conditions they demonstrated the 
presence of a functional adenylate cyclase catalytic unit
which could be stimulated by NaF , guanine nucleotides and p
adrenergic agents.
Structural and Functional Characteristics of Gi
Gi, is the guanine nucleotide regulatory protein which 
has the ability to inhibit adenylate cyclase activity . It 
has been purified extensively from bovine brain ( Neer et al 
1984) and rat liver (Bokoch ^t £l 1984). This protein is a 
heterotrimeric protein ot p 'Y subunit composition . Theocsubunit 
has a molecular weight of 41 K Da and has been shown to have 75*
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sequence homology with another related G protein Go. Gi <x has 
been cloned by Michel et_ al_ (1986) and this group in addition 
have identified another G protein which they have called <X h. 
This c< h species has an apparent molecular weight of 39 K Da 
and also exhibits 75% sequence homology with Gi .The function 
of both Gh and Go have yet to be determined.
Gi, Go and Gh are ribosylated by a component isolated 
from the bacterium Bordetella pertussis. This component, known as 
pertussis toxin or islet activating protein (IAP) catalyzes the 
ADP- ribosylation of a C-terminal region of the oC subunits of 
these G proteins using NAD as the ADP -ribose donor. This 
pertussis toxin ribosylation technique has been extensively 
utilized to identify the 41 K Da Gi <X. subunit ( Katada & Ui 1982; 
Bokoch et_ al_ 1984; Codina et_ al 1984). It is however now apparent 
that the use of this technique to identify this 41 K Da protein 
is not as specific a tool for recognition as had previously been 
assumed.
Pertussis toxin ribosylates Gic< when it is in its 
holomeric J3y complex and resultantly prevents further 
activation of theoc subunit by guanine nucleotides. Aktories et_ 
al (1983) demonstrated that when Gi was preactivated with GTP7S, 
deactivation by pertussis toxin treatment does not occur .
Gi ot , like Gs oi , binds GTP and its analogues upon
2+
hormonal stimulation in the presence of Mg . TheoC subunit 
becomes activated and dissociates from the holomeric complex
68
form. Gi has a higher affinity for binding non-hydrolyzable GTP
analogues than does Gs o<- , but both show the same potency order
for these analogues of GTP 'TfS > GPP(NH)P > GPPCH P. Half maximal
2
activation of Gi si is achieved at a GTP^S concentration of 3nM, 
but half maximal activation of Gs occurs at a GTP -'TS
concentration of 30nM ( Jakobs et al 1985).
In the presence of GTP analogues, Gi oC requires a lower
2+
Mg concentration for activation than does Gs (Ross & Gilman
1980; Birnbaumer & Iyengar 1982; Hildebrandt & Birnbaumer 1983;
2+
Jakobs et_ al_ 1983; Jakobs & Aktories 1983). The Km for Mg is in
the pM range ( Hildebrandt et^  al_ 1983) and so under normal
2+
physiological conditions, Mg is not a limiting factor for 
activation.
Gi can be selectively inactivated by treatment of 
intact cells or broken membranes with the sulphydryl reagent 
N- ethylmaleimide (NEM). It is believed that NEM affects 
receptor - G protein interactions specifically at low 
concentrations ( Limbird & Speck 1983). Pretreatment of 
membranes with NEM also blocks the ADP-ribosylation of Gi by 
pertussis toxin , but the cholera toxin catalyzed ribosylation of 
Gs is minimally affected ( Jakobs et_ ad 1982; Brandt et al 1983; 
Aktories et_ al_ 1984).
2+
Finally, Ca and phorbol ester activated protein 
kinase C has been demonstrated to have the ability to 
phosphorylate Gi and thereby attenuate its activity in human
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platelet membranes and CYC cells ( Katada et_ al 1985; Watanbe e_t 
al 1985). Recently, purified Go and Gi were demonstrated to be 
phosphorylated in_ vitro by the insulin receptor tyrosyl kinase 
activity ( O ’Brien et_ ad 1987). It has yet to be established 
whether these G proteins ( and perhaps others) are phosphorylated 
by this kinase activity in_ vivo.
The Putative (5 Protein ’’Gins”
In the early nineteen eighties , Heyworth et al (1983) 
demonstrated that insulin had the ability to activate two 
distinct hepatic phosphodiesterase activities . These 
activities were resolved using a gentle homogenization and 
percoll gradient fractionation procedure. One of these 
phosphodiesterase activities termed the ’’plasma membrane enzyme’’ 
was shown to be activated 2 fold by insulin and 1.5 fold by 
cholera toxin treatment. The intriguing observation by this 
group was that although this enzyme was activated by cholera 
toxin treatment, it was not activated by glucagon or dibutyryl 
cAMP . Obviously, the cholera toxin activation was not a result 
of Gs activation by the toxin and subsequent cAMP elevation. 
Also of interest was the observation that glucagon pretreatment 
of hepatocytes blocked the activation of this enzyme by insulin.
Closely following this report was another publication 
suggesting that insulin could inhibit glucagon and GTP stimulated
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adenylate cyclase activity in broken hepatocyte membranes. This 
action was guanine nucleotide dependent ( Heyworth & Houslay
1983). This action of insulin was also dependent upon the 
concentrations of insulin and glucagon used. As the glucagon 
concentration was raised above 1nM , the ability of insulin to 
inhibit the glucagon stimulated adenylate cyclase activity was 
reduced. Intact isolated hepatocytes pretreated with glucagon 
in the presence of cAMP - phosphodiesterase inhibitors also 
demonstrated insulin’s ability to reduce glucagon stimulated 
intracellular cAMP accumulation.
As discussed previously, the bacterial toxins; cholera 
toxin and pertussis toxin have been widely used to identify Gs oc 
and Gioc respectively. Heyworth et al_ (1985) demonstrated that 
cholera toxin also catalyzed the ribosylation of a plasma 
membrane protein with a molecular weight of about 25 K Da in
isolated hepatocytes. This protein was identified as a GTP
binding protein by the use of the photo-affinity GTP analogue 
azido-GTP. When insulin was present in the incubation medium, 
cholera toxin ribosylatin of this protein was reduced. This was
therefore identified as a G protein which insulin (via its plasma
membrane receptor) had the ability to interact with.
Together with the evidence that insulin and cholera 
toxin could activate a specific plasma membrane phosphodiesterase 
species , it was suggested that this process could involve this 
GTP binding protein. In addition, the activation of this enzyme
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by insulin was unaffected by pertussis toxin pretreatment 
(Heyworth et_ al 1986). Similarly, this 25 K Da GTP binding 
protein was also apparently unaltered by pertussis toxin 
pretreatment. Also, the ability of insulin to inhibit adenylate 
cyclase activity in the presence of GTP suggested the requirement 
of a guanine nucleotide regulatory component in this action of 
insulin. As insulin only appeared to inhibit the cholera toxin 
catalyzed ribosylation of one G protein, it is probable 
that this protein is specifically coupled to the insulin 
receptor. Therefore, it is conceivable that this G protein could 
be involved in other short-term effects of insulin action.
There is evidence of the involvement of a G protein in 
insulin’s ability to stimulate a cAMP-independent protein kinase 
in sarcolemma membranes from skeletal muscle( Walaas et^  al_ 1977; 
Walaas et_ al_ 1979 ). This protein kinase activity also appears to 
be sensitive to cholera toxin pretreatment (Walaas et_ al_ 1981). 
It has also been tentatively suggested that this G protein 
(termed "Gins”) may be involved in glucose transport activation ( 
Houslay & Wakelam 1987).
Finally, Horn et al (1986) suggested that insulin and 
GTP have the ability to regulate the dephosphorylation of the p 
subunit of the insulin receptor in sarcolemma membranes. It has 
been suggested that tyrosine kinase activity could be involved in 
activation of glucose transport in insulin’s target tissues (see 
section 1.2.4) . Perhaps, Gins could be important as a link
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between these two activities. Certainly, it has recently been 
shown that the insulin receptor kinase can phosphorylated,-^in 
vitro ( O ’Brien et_ al_ 1987). Perhaps other G proteins and in 
particular, perhaps Gins, could be covalently modified by this 
kinase activity in a similar manner.
1.4 The Adenylate Cyclase Effector System And Its Regulation
1.4.1 The Enzyme Adenylate Cyclase
Using forskolin - sepharose affinity and wheat germ
lectin sepharose chromatography , the enzyme adenylate cyclase
( E.C. 4.6.1.1 ) has been purified from rabbit myocardium and
et'oi .
bovine brain cortex ( Pfeuffer et al_ 198^J Pfeuffer^1985j Smigel 
1986). The molecular weight of the catalytic unit ("C”) is 
estimated to be between 115 - 190 K Da. Higher molecular weights 
of 270 K Da have been identified in brain cortex in the presence 
of the cross-linking agent disuccinimidyl suberate ( Pfeuffer oJraji 
19856. These higher molecular weight species are believed to be 
aggregates of two or more adenylate cyclase catalytic units. 
However, these aggregates have not been observed in rabbit 
myocardial tissue ( Pfeuffer et^  al 1985q).
i' "
/ The catalytic unit of adenylate cyclase was
eP<jf
demonstrated to be a glycoprotein ( Pfeuffer^T985b; Smigel 1986).
It has therefore been suggested that the enzyme is an
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integral membrane protein with exposed regions at both the
extracellular and cytoplasmic surfaces of the plasma membrane.
This suggestion is supported by the observation that isolation
and purification of the enzyme requires significant amounts of
non - ionic detergent to extract the protein from the membrane.
Purification of the non T activated ("basal") form of
the enzyme has been achieved by the removal of forskolin from the
forskolin - affinity purified enzyme preparation . This
non - activated form of the enzyme is believed to be uncoupled
from Gs (Pfeuffer 1985) and appears to be unresponsive to
guanine nucleotide stimulation in the absence of additional Gs .
Also, this "basal" form of the enzyme is not stimulated, but is
inhibited by the addition of NaF.
Characteristically, bovine brain adenylate cyclase is
2+
proposed to exist in two forms; a Ca / calmodulin sensitive 
2+
and a Ca / calmodulin insensitive form ( Coussen et al 1985;
Yeager et el 1985). However, forskolin and lectin purified
2+
adenylate cyclase activity appears to be insensitive to Ca /
calmodulin regulation . It is not known whether only one form of
the enzyme is resolved during this purification procedure or 
2+
whether a Ca / calmodulin binding component important for 
activity regulation is lost during the procedure.
2+
There is also speculation that the Ca / calmodulin 
form of the enzyme occurs in other tissues such as pancreatic 
islets ( Valverde et_ al_ 1979) smooth muscle (Piascik et al 1983),
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cardiac muscle ( Panchenko & Tkachuk 1984 ) and human platelets
2+
(Grigorian et_ ad 1986). The mechanism by which Ca and 
calmodulin can regulate adenylate cyclase activity remains 
controversial, but recently Asano et_ al_ (1986) suggested that 
calmodulin could interact with the G proteins Gi and Go. The 
significance of this observation is not clear at the moment.
Adenylate cyclase catalyzes the formation of cAMP from
2+
Mg -ATP (see figure 11 ). The adenylate cyclase system is 
comprised of at least three distinct components ; namely , a 
receptor (or "discriminator molecule") of the type Rs or Ri (see 
section 1.4.2 for explanation) a stimulatory or inhibitory 
guanine nucleotide binding component termed a "G protein" and a 
catalytic unit ("C"). The catalytic unit is the effector system 
which upon stimulation by Rs activation of Gs or by direct 
activation of Gs results in the elevation of cAMP levels 
intracellularly . The mechanisms by which adenylate cyclase 
catalytic activity is regulated by these components will be 
discussed individually.
1.4.2 Dual Control of Adenylate Cyclase Activity By Hormonal 
Activation of Gs And Gi
Polypeptide hormones and catecholamines such as 
glucagon , adrenaline and thyroid stimulating hormone (TSH) bind 
to receptors on the extracellular surface of the plasma membrane.
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Figure 11 G Protein Regulation of Adenylate Cyclase Activity
EXTRACELLULAR 
SPACE
G protein adenylate cyclase
piasma membrane
CYTOPLASM [GDP |
ligand binding alters conformation of 
signaling ligand y f  receptor exposing binding site for G protein
receptor
protein diffusion in the bilayer leads to association of 
ligand-receptor complex with G protein, thereby 
 ^  ^ exposing a GTP-binding site on the latter
I GDP
|Gwl^
the displacement of GDP by GTP alters conformation 
of G protein, causing it to dissociate from the activated 
receptor and expose a binding site for adenylate 
\J/cyclase
a
diffusion in the bilayer leads to association of G protein 
with adenylate cyclase, thereby activating the cyclase to 
produce cAMP
cAMP
hydrolysis of the GTP by the G protein returns the G 
protein to its original conformation, causing the 
adenylate cyclase to dissociate and become inactive
the activation of cyclase is repeated until the 
dissociation of ligand returns the receptor to its 
original conformation
Figure is reproduced from "Molecular Biology of The-Cell" 
Alberts et al 1983 (Garland Publishing inc. U.S.A.)
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These receptors are believed to regulate G protein interactions 
with the adenylate cyclase catalytic unit ("C"). Receptors which 
interact with Gs to stimulate adenylate cyclase activity are 
denoted "Rs" and receptors which interact with Gi to inhibit 
adenylate cyclase activity are denoted "Ri" ( Birnbaumer et^  al 
1985).
Ligands which bind to specific receptors and cause 
activation of their respective G proteins are called "agonists”. 
Agonists upon binding to Rs or Ri receptors cause changes 
in adenylate cyclase activity via this G protein activation 
process. However, some ligands have the ability to bind 
specifically to receptors , but do not have the ability to 
activate the respective G protein. These ligands are therefore 
unable to alter adenylate cyclase activity and are therefore 
known as "blockers" or "antagonists". There is also a further 
class of ligands called " partial agonists" which generally tend 
to be chemically modified analogues of agonists . These ligands 
are able to activate G proteins and cause changes in adenylate 
cyclase activity, but not to the same extent as their full 
agonist counterparts. These observations have led to suggestions 
that receptors exist in at least two or more states of 
activation ( Birnbaumer et_ al_ 1985).
Addition of guanine nucleotides to membrane 
preparations has been demonstrated to reduce the affinity of 
receptors for their agonists ( Rodbell et al 1971; Rubalcava &
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Rodbell 1973). However, this effect is not observed for
(19#
antagonists to the same receptors ( Rubalcava & Rodbel^-; Maguire
et al 1976 ). This altered receptor affinity phenomenon has
been experimentally characterised fairly extensively for
glucagon and p-adrenergic receptors ( Bird & Maguire 1978;
Labarbera etal 1980).It was using the p-adrenergic system that
the ability of guanine nucleotides to regulate receptor affinity
2+
was demonstrated to be Mg dependent. Addition of guanine
2+
nucleotides to broken membranes in the absence of Mg does not
2+
reduce receptor affinity for agonists . However, Mg in the
absence of nucleotides leads to an enhancement of receptor
2+
affinity for agonists. It appears that it is this Mg enhanced 
receptor affinity that is reduced upon addition of guanine 
nucleotides.
2+
It is believed that Mg is the necessary component for
activation of Gs and subsequent subunit dissociation . It may
be therefore that activation and dissociation of Gs causes this
receptor affinity attenuation. However, it was necessary to
2+
eliminate the possibility that Mg was directly acting upon
the receptor and thereby regulating agonist binding without
altering Gs function. Therefore, Cyc cells which are deficient
in functional Gs (Kent et al 1980) and reconstitution systems
(Shorr £t al 1981 ; Kalleher et al 1983) have been used to
2+
demonstrate that it is indeed the G protein which binds Mg and 
thereby regulates receptor affinity.
78
Interestingly, in rat liver the glucagon receptor does
2+
not increase its affinity for agonists in the presence of Mg 
However , guanine nucleotides do reduce the receptor’s affinity 
for agonists ( Rojas et_ al_ 1983). The order of potency for
guanine nucleotide transformation of glucagon and 
P-adrenergic receptors from a high to a low affinity for
agonists has been studied. It appears that GDP is more potent
than GTP ( Rodbell et_ al_ 1971; Iyengar et al 1980) at initiating 
this process. These observations have led to the proposal that 
receptors in the low affinity state are ’’uncoupled” from the G 
protein Gs . This uncoupling process prevents further Rs and Gs 
interactions and may be concomitant with the G protein
interacting with the adenylate cyclase catalytic unit .
Models to explain molecular interaction of the receptor, 
G protein and catalytic unit of the adenylate cyclase system have 
been proposed (Arad et al_ 1984) . Although the "Collision 
Coupling" model is probably one of the most favoured, other 
models cannot be entirely ruled out.
1.4.3 Models Proposed To Illustrate The Mechanism By Which 
Adenylate Cyclase ("C") j_ Gs_ And Rs Interact
Three major models have been proposed to explain the 
sequence of events occuring between the components C, Gs and Rs
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upon hormonal stimulation of the adenylate cyclase system. These 
models are :
1. The Precoupled Model
Rs.Gs(GDP). C — * HRs.Gs.f(GTP).C’ — » HRs.Gs.(GDP).C
This model proposes that all three components are associated with 
each each other at all times. Binding of agonist to the receptor 
in the presence of GTP results in the activation of the 
precoupled receptor-G protein-catalytic unit complex and 
subsequent stimulation of cAMP production by the catalytic unit. 
The activation "cycle" is terminated by hydrolysis of the GTP.
2. The Collision Coupling Model
Rs + Gs(GDP) .C — s> H. Rs .Gs1. (GTP) .C’ — » HR +'Gs(GDP).C
(Active) (Inactive)
This model proposes that the G protein and the catalytic unit are 
always associated with each other , but the receptor only 
briefly associates with the Gs.C complex upon agonist binding.
3. The Shuttle Model
Rs + Gs(GDP) — > H.Rs.Gs'(GTP) — > HRs + Gs'(GTP)
Gs(GDP) + C 
(Inactive)
Gs? (GTP) + C — » Gs’ (GTP).C’ — ?
(Active)
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This model proposes that all three components are separate 
entities which only interact in an ordered sequence. Initially, 
the agonist in the presence of GTP is proposed to associate with 
the G protein which in turn dissociates from the receptor complex 
and associates with the catalytic unit to activate the adenylate 
cyclase system. The "cycle" is once again terminated by the 
hydrolysis of GTP to yield the free (unassociated) G protein.
Detailed kinetic studies have been performed primarily 
using the p-adrenergic receptor system because major purification 
and classification advances have been made in this system. The 
precise mechanism by which hormonal stimulation of the adenylate 
cyclase activity is achieved remains controversial. In addition, 
the kinetic arguements are complex. However, evidence to support 
and / or discredit each model will be very briefly discussed 
below in order to try to demonstrate the complexity of the 
adenylate cyclase system and its control.
In general, the precoupled model has been superseded
in popularity by the other two models. This is mainly due to
the observation that p-adrenergic receptors in the presence of 
2+
Mg and GTP exhibit an altered affinity for agonist binding. 
This altered affinity has been suggested to be a result of Rs.Gs 
dissociation. Under the constraints of this model, the three 
components must remain associated at all times. Similarly, after 
challenging cells with catecholamines , a desensitized ( ie. less
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responsive ) state with respect to further hormone challenge has 
been observed. This state is concomitant with the down regulation 
of ^-adrenergic receptors from the cell surface. There is no
evidence for simultaneous movement of Gs into intracellular
fractions under these conditions ( Levitzki 1986). Thus, there
is evidence for the Rs and Gs unassociated state which is in
major disagreement with the precoupled model proposed.
However, the collision coupling model assumes only a 
transient receptor-G protein -catalytic unit complex formation. 
So Rs and Gs dissociation is within the confines of this model. 
Also, probably the most convincing evidence for the 
persistently associated Rs-C complex state is the fact that Gs 
o<. has been copurified with the catalytic unit .
Finally, the shuttle model is in agreement with the 
observation that non-hydrolyzable GTP analogues are able to
activate Gs in the absence of the catalytic unit. Under the 
constraints of the other two models, this would not be expected 
to occur because Gs and C would always be associated. Therefore 
activation of Gs would be dependent upon the presence of C. 
However, one piece of evidence which could discredit this model 
is the observation that Rs and Gs in the absence of GTP can form
a complex in the presence of agonists (levitzki 1986). This
should not occur under the constraints of the three separate 
component state of the shuttle model.
Thus , the model by which the components of the
adenylate cyclase system interact remains unclear, although
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complex kinetic analysis has been reported to favour the 
collision coupling model ( Levitzki 1986).
1.4.4 Use of Forskolin To Stimulate Adenylate Cyclase Activity
Forskolin is a diterpene isolated from the plant Coleus 
forskolii. Its structure is illustrated in figure 6 (appendix 
II). This compound has been shown to have the ability to elevate 
adenylate cyclase activity in a wide variety of tissues and 
organisms ( Seamon & Daly 1986). In rat liver, forskolin 
increases the Vmax of the enzyme without affecting the enzyme’s 
Km for Mg.ATP (Birnbaumer et al 1983). Forskolin can activate 
solubilized adenylate cyclase in the presence of both ionic and 
non-ionic detergents. This observation has led to the suggestion 
that this compound does not activate membrane associated 
adenylate cyclase by causing perturbation of either membrane 
structure or interactions between the catalytic unit and 
phospholipids (Seamon & Daly 1986).
However, the precise mechanism by which this compound 
can activate adenylate cyclase activity is still unknown. 
Indeed, its site or sites of binding are still a controversial 
issue. "Forskolin can bind directly to the catalytic unit of 
adenylate cyclase. This property has been used to purify this 
protein (Pfeuffer et_ al_ 1985; Smigel 1986). However, another 
site for forskolin binding has been suggested to involve the G
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protein Gs. Forskolin binding studies (Seamon & Daly 1986) have 
indicated that there is an increase in the number of forskolin 
binding sites under conditions which activate Gs . There appears 
to be synergistic activation of adenylate cyclase in the
presence of both forskolin and cholera toxin. Also, in the
presence of Gs and stimulatory hormones , forskolin has been 
reported to have a higher affinity for activating adenylate 
cyclase ( Clark _et_ aJ 1982; Green & Clark 1982). It is therefore 
possible that cooperativity exists between Gs and forskolin
activation of the adenylate cyclase catalytic unit.
Barber & Goka (1985) have suggested that Gs and the 
catalytic unit are at all times associated. They suggest that 
Upon forskolin binding to the catalytic unit , Gs activation is 
triggered by the dissociation of the £ subunit from the Gs 
holomeric complex. However, one important observation to be 
considered is that forskolin does have the ability to activate 
adenylate cyclase in the absence of a functional Gs ( Clark et^  al 
1982). Similarly, Florio & Rosso (1983) have demonstrated that 
forskolin can activate adenylate cyclase in the absence of Gi.
In summary then, whether forskolin activates adenylate 
cyclase by direct interaction with the catalytic unit alone or 
whether forskolin stimulates both Gs and the catalytic unit is 
still a controversial issue. However, this compound is of great 
use as a tool by which one can stimulate the activity of 
adenylate cyclase without affecting receptor-catalytic unit
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interactions. Hence, I have used this compound to elevate 
adenylate cyclase activity to allow me to study the function of 
both inhibitory and stimulatory G proteins without the 
requirement for receptor dependent processes . Receptor function 
could conceivably be altered in a diseased state such as 
diabetes and therefore cannot be assumed to be "normal” (see 
chapter 3 )•
1.5 The Aims of This Project
Initially, the aim of my project was to gain a more 
in-depth understanding of the role which G proteins play in 
insulin action. In particular, it was hoped that further 
evidence would be found to support the contention that insulin 
activates a specific G protein which has been termed "Gins". This 
G protein activation was proposed to be involved in the insulin 
mediated inhibition of adenylate cyclase activity (see section
1.3.3 ).
Work carried out previously within the group in which I 
worked demonstrated that pertussis toxin abolished this insulin 
mediated inhibition of adenylate cyclase activity (published 
Heyworth et_ al_ 1986). Therefore, there were new implications 
of a role for Gi in this inhibitory process. Thus, the main aim 
of my project became that of distinguishing between the role of 
Gi and Gins in this process.
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Also, this action of insulin is a rapid 
"short-term" effect of insulin associated with the plasma 
membrane. It is therefore possible that a relationship between 
alterations in G protein function and insulin resistance 
observed in diabetic states could occur.
Therfore, in summary, the aims of my project were to :
1. Investigate the role of Gi and Gins in the ability of insulin 
to inhibit adenylate cyclase activity.
2. Investigate the possibility of a relationship between insulin 
resistance in the diabetic state and G protein function.
3. Investigate the possibility of the involvement of Gins in 
other short-term effects of insulin action.
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2 . Materials & Methods
2.0 Materials and Methods
2.1 Chemicals
Appendix 1 lists suppliers of chemicals and enzymes used.
2.2 Animals
Male Sprague - Dawley rats were obtained from the 
University of Glasgow breeding colony and unless otherwise stated 
were aged 8-10 weeks old and weighed 220 - 250 g.
Male Zucker rats aged 8 - 1 0  weeks old were obtained from Olac
Ltd., Shaw’s Farm, Blackthorn, Bicester, Oxon. U.K. Obese 
homozygotes (fa / fa ) and both homozygote ( +/+ ) and
heterozygote ( fa / + ) lean Zucker rats were used.
2.3 Chemical Induction of Type I_ Diabetes
Diabetes Mellitus was induced in Sprague - Dawley rats 
by one intra - peritoneal injection of either streptozotocin ( 50 
mg/Kg ) in citrate buffer pH 4 as described by 
Sauerheber et al (1984) or alloxan (130 mg/Kg ) in 0.9 % saline. 
Controls received one intra- peritoneal injection of citrate or 
saline respectively.Urine glucose was monitored using ” Diabur - 
Test 5000 ” sticks and animals were, sacrificed 7 or 3 days
later in the case of streptozotocin and alloxan treated rats
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respectively. At the time of sacrifice , blood samples were
removed by intra - cardiac puncture and blood glucose 
concentration was determined using " Dextrostix n in conjunction 
with a glucometer (Ames, Slough, U.K.) Only when blood glucose 
concentrations were > 10 mM and glucosuria was detectable at
the time of sacrifice were animals assumed to be diabetic and 
used.
2.4 Reversal of The Diabetic State
10 I.U. of insulin zinc suspension was injected subcutaneously 
72 h after streptozotocin induction of the diabetic state. 
Subsequent daily injections for a period of 7 days were
repeatedly administered and the presence of glucosuria carefully 
monitored. Glucosuria was generally absent within 24 - 48 h
after initial administration of insulin.
2.5 Treatment of Sprague Dawley Rats with Metformin.
The hypoglycaemic drug Metformin (Hermann 1979 ) was
continuously administered orally in water at a carefully
controlled daily dosage of 350 mg / Kg immediately after 
injection of streptozotocin or citrate buffer until the time of 
sacrifice.
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2.6 Source of Human Blood For Platelet Preparations
Blood was obtained from the antecubital vein of normal 
(healthy) or type II diabetic volunteers. Normal (control) 
volunteers were not undergoing and had not been undergoing 
medication for at least one month before donating. Each diabetic 
patient donated only 30 - 40 ml of blood per session and gave 
their consent to its use.
2.7 Solutions
All solutions were prepared using double -distilled 
deionized water. pH values were measured using a Beckman 31 pH 
meter. Tris - HC1 buffers were cooled to the required temperature 
prior to adjustment of the pH to the required value.
2.8 Preparation of Isolated Hepatocytes.
Preparation of isolated hepatocytes was essentially 
using the technique described by Elliot et_ al (1976) which is 
a modification of the method used by Berry and Friend (1969).
Rats were anaesthetised by one intra - peritoneal 
injection of 0.4ml of a 60mg / ml solution of Sagatal (Sodium 
Pentobarbitone solution containing 4mg/ml heparin ). Upon loss of
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the flexor and corneal responses, the abdominal cavity was opened 
up with a mid line incision to just below the diaphragm. The 
inferior vena cava and hepatic portal vein were then ligated. The 
inferior vena cava was cannulated with a 16 gauge needle 
containing a solution of heparin ( 10mg/ml) and the hepatic 
portal vein was then cannulated with a 19 gauge needle and the 
ligatures tightened to secure the positioning of the cannulae.
The liver was perfused in the physiological direction 
2+
with 80 ml of Ca - free Krebs Henseleit bicarbonate buffer pH
o
7.4 containing 1mg/ml EDTA at a constant temperature of 37 C and 
a steady flow rate of 30ml/min using a Watson - Marlow 
peristaltic pump. The Krebs - Henseleit bicarbonate buffer had 
the following composition : -
25mM NaHCO , 1.2 mM MgSO , 1.2mM KH PO , 5mM KCland 120mM NaCl
3 4 2 4
and was freshly prepared for each perfusion. The pH was
maintained at 7.4 units by thorough gassing with 0 :C0 (95% :5/S
2 2
v/v). Air bubbles were prevented from entering the liver by the 
positioning of a "bubble trap" between the pump and the hepatic 
portal vein cannula.
The EDTA containing buffer was washed out with 50 ml of
2+
Ca - free Krebs Henseleit bicarbonate buffer containing 20 mM 
glucose and discarded. 60 mg of collagenase was added to 100ml 
of this buffer and circulated for 30 inin.
The thoracic cavity was opened and the blood vessel directly
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above the diaphragm was occluded by the use of a haemostat. After
30 rain the liver had a very "blotchy” appearance and the liver
capsule was disrupted. When this stage was reached , the
perfusion was terminated.and the cannulae removed. The liver was
2+
transfered to a plastic beaker containing 35ml of Ca - free
Krebs Henseleit bicarbonate buffer and dispersed using plastic
teaspoons. The subsequent cell suspension was gently filtered
through nylon mesh with a pore size of 150 pm and washed with a
further 20ml of buffer. The suspension was then centrifuged at
50g for 2.5 min at room temperature in an MSE Centaur 
av
centrifuge. The supernatant was removed and discarded and the
pellet resuspended in 40ml of Krebs Henseleit bicarbonate buffer
containing 2.5mM CaCl and centrifuged as before to remove
2
erythrocytes. The final cell pellet was resuspended in Krebs
Henseleit bicarbonate buffer containing 2.5mM CaCl to give a
2
cell dry weight of 20 - 30mg/ml.
2.9 Dry Weight Determinations
1ml portions of cell suspensions were pipetted into
preweighed glass vials and dried to constant weight in an oven at 
o
120 C for 0.5 h. The mean dry weight of three samples from each 
cell suspension was determined.
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2.10 Assessment of Cell Viability
2.10.1 Assay of Intracellular ATP Content
Intracellular ATP content was determined using the
procedure of Stanley & Williams (1969). A 0.5ml aliquot of
hepatocyte suspension (cell dry weight 5 - 6  mg/ml ) was added to
50 pi of 20 % (w/v) perchloric acid, vortex mixed and put on ice
for 10 min to allow protein precipitation. Subsequent
centrifugation in a Hawksley - Gelman microfuge at 14,000 g for
av
2 min allowed sedimentation of the precipitate and removal of the
supernatant. Neutralisation of the supernatant was achieved using
a solution of 0.5 M triethanolaraine containing 2M K0H.
10 pi of appropriately diluted supernatant containing
20 - 80 pmoles of ATP was added to 3ml of assay reagent. The
assay reagent consisted of a freshly prepared mixture (1:1:1) of
80mM MgSO , 10mM K HPO /KH PO (pH 7.4) and 100mM Na ASO . A 
4 2 4 2 4 2 4
range of standard ATP samples containing 0 - 1 5 0  pmoles of ATP
were also prepared and all samples were left in the dark for 30
min. Preparation of the Firefly lantern extract (Sigma FLE - 50)
involved homogenization of the extract with 10 ml of deionised
water in the dark and 1 h later, centrifugation for 2 min in a
Hawskley - Gelman microfuge at 14,000 g
av
Initiation of the assay was by addition of 50 ul of 
this supernatant to each sample vial and chemiluminescencewas 
immediately measured using an LKB liquid scintilation counter in 
the absence of fluorescent light . ATP determinations were
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routinely performed using 20 ml glass scintilation vials which 
had been previosly treated with 0.1M NaOH and 0.1M HC1 to
decrease non - specific photoemission. ATP content for viable 
cells was in the range of 9 - 11 nmoles / mg dry weight.
2.10.2 Trypan Blue Exclusion
100 pi of cell suspension (20 - 30 mg/ml dry weight)
was added to a solution consisting of 800 pi of Krebs Henseleit
bicarbonate buffer and 100 pi of trypan blue dye ( 0.1$ w/v ). 
The suspensiom was then inverted gently to allow mixing and
viewed on a microscope under high power using a haemocytometer 
counting chamber. Cells were counted and those not excluding dye 
were assumed to be non - viable. Only cell preparations 
exhibiting > 90 % dye exclusion were used.
2.11 Incubation and Hormone/Drug Treatment of Isolated 
Hepatocytes
Incubation of hepatocytes was performed essentially by
using the procedure described by Smith et_ a!L (1978).
1ml of isolated hepatocyte suspension (cell dry weight 20 - 30
mg / ml) was pipetted into 25 ml glass conical flasks
(pretreated with dimethyldichlorosilane to prevent cell
adhesion) containing 4ml of pregassed Krebs Henseleit bicarbonate
buffer supplemented with 2.5mM CaCl , 10mM glucose and 2.5 %
2
(w/v) bovine serum albumin. Vials were closed using nsuba-sealsn
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(Gallenkamp & Co. Ltd., Widnes, Cheshire, U.K.) and gassed for 15
o
sec with 0 : CO (95 % : 5%) prior to incubation at 37 C in a
2 2 -1 
shaking water bath preset to 120 cycles min . Cells were
routinely preincubated for 20 min prior to drug or hormone
treatment. Addition of hormones or drugs was by injection of
solutions through the "suba-seals” using a 50pl glass syringe.
Cells were gassed for 20 S every 10 min to maintain the buffer pH
at 7.4 and prevent cell anoxia. After the required period of
incubation, cell suspensions were put on ice to quench reactions
and membranes were prepared as appropriate.
2.12 Preparation of A_ Crude Membrane Pellet From Isolated 
Hepatocytes
Crude membrane pellets were prepared as outlined by
Houslay & Elliot (1979). In brief, hepatocytes were isolated as
previously described and incubated with appropriate drugs or
hormones for the required period of time and placed on ice. 1ml
samples from each flask were pipetted into 1.5ml plastic vials
and then centrifuged at 14,000 g in a "micro Rapide ”
av
temperature controlled bench centrifuge (A.R, Horwell, Hampstead,
o
London, U.K.) at 4 C for 6 min. The supernatant was discarded
and the pellet resuspended and disrupted in 150pl of 1mM KHCO pH
3
7.2 with 12 up and down actions using a 1ml syringe and a 25 G
needle. A further 150pl of 1mM KHCO solution was added and the
3
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o
sample centrifuged at 14,000 g for 6 min at 4 C. The resultant
av
washed and hypotonically lysed cell pellet was collected and 
resuspended to an appropriate volume (10 - 12 mg/ml protein 
content ).
2.13 Hepatocyte Plasma Membrane Preparation Using Percoll 
Fractionation
Rat hepatocyte plasma membranes were prepared using 
the procedure developed by Heyworth et al (1985). The method 
involved washing hepatocytes, followed by homogenization 
and finally purification of plasma membranes from these cells on 
a percoll gradient. This is described below :
2.13.1 Preparation of Hepatocytes
Isolated hepatocytes (0.9 mg dry weight / rat liver )
were resuspended to 30ml with Krebs Henseleit bicarbonate pH 7*4,
washed with 80ml of ice - cold 0.25M sucrose containing 3mM
imidazole pH 7.4 and centrifuged at 500 g for 2.5 min in an
max
MSE Centaur 2 bench centrifuge.
2.13.2 Homogenization of Hepatocytes
The cells were resuspended in 40 ml of 0.25M sucrose 
/3mM imidazole buffer pH 7.4 and placed in a 50ml Amicon 
Ultrafiltration unit and exposed to an oxygen - free , nitrogen
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2 o
atmosphere at a pressure of 151b / in for 10 min at 4 C. After
which,- the pressure was released rapidly .
The suspension was then homogenized by hand in a 50ml glass
Potter - Elvejm homogenizer with two up and down strokes of a
teflon pestle. The homogenate was centrifuged for 2.5 min at
500g , the supernatant collected and the pellet resuspended in
max
20 ml of the sucrose / imidazole buffer and subjected to the
pressurisation and homogenization procedure as before.
The two supernatant fractions were then combined and
centrifuged at 27,500 g for 15 min. The resulting pellet was
max
resuspended in 20 ml of the sucrose / imidazole buffer and placed 
on ice.
2. 13.3 Percoll Gradient Purification
A working percoll solution was prepared consisting of
20 ml of a 90 % (v/v) percoll solution containing 0.25M sucrose,
20 ml of 6mM imidazole containing 0.25M sucrose pH 7.4 and 80ml
of 3mM imidazole containing 0.25M sucrose pH 7.4 . The pH of the
solution was adjusted to 7.4 using a solution of dilute HC1 and 
o
cooled to 4 C.
30 ml of this working solution was placed in a
50ml centrifuge tube and 2ml of 3mM imidazole containing 0.25M
sucrose pH 7.4 was layered on top. 5ml of the hepatocyte
homogenate was layered onto each gradient and centrifuged at
27,500 g in an MSE 21 centrifuge using an 8 x 50 fixed angle 
max
rotor at 4 C for 15 min.
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The first 2ml from each tube was discarded and the
plasma membranes were collected in the next 5ml fraction. The
plasma membrane fractions were combined , diluted 1:2 with 3mM
imidazole containing 0.25M sucrose pH 7.4 and 30 ml fractions
were layered onto a 10 ml "cushion" of 3mM imidazole containing
55 % sucrose pH 7.4 and centrifuged at 48,000 g for 15 min at 
o max
4 C.
The membranes were collected from the bottom
interface and washed by dilution (1:1) with 3mM imidazole
containing 0.25M sucrose pH 7.4 and were again centrifuged at
o
48,000 g for 15 min at 4 C. The plasma membranes recovered 
max
were resuspended in 2ml of 3mM imidazole containing 0.25M
o
sucrose pH 7.4 and aliquoted for storage at - 80 C.
2.14 Purification of Plasma Membranes From Whole Rat Liver
Liver plasma membranes were prepared using a 
modification ( Marchmont et_ al_ ; 1981 ) of the method of Pilkis
et_ al_ (1974).
3 rats were stunned and decapitated , their livers
were removed, washed, and chopped in ice - cold 1mM KHCO pH
3
7.2. Using 3 volumes of liver : 1 volume of KHCO solution, the
3
livers were homogenized with 6 strokes of a motor driven 
homogenizer (setting 3) and a teflon pestle. The homogenate was 
strained through 2 layers of muslin, diluted to 300ml with KHCO
3
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o
buffer and centrifuged at 2,000 g for 10 min at 4 C using an
max
MSE 21 cenrifuge and an 8 x 50 ml fixed angle rotor. The 
resultant supernatant was discarded and the pellets poured onto 
72g of sucrose in a plastic beaker and the volume adjusted to
120 ml with the KHCO buffer. This suspension was stirred at 4 C
3
for 30 min and then 20 ml portions were pipetted into clear 
centrifuge tubes. On top of this homogenate was carefully 
layered 12 ml of 48.2 % sucrose in 3mM imidazole pH 7.4 ,
followed by 6.5 ml of 42.5 % sucrose in 3mM imidazole pH 7.4
The gradients were then centrifuged at 100,000 g
max
for 3 h in a Beckman ultra centrifuge] using an SW 28 rotor at
4 C. Care was taken to ensure slow acceleration and deceleration 
speeds were selected to minimise disruption of the gradient. 
The plasma membranes collected at the 4 2 . 5 - 4 8 . 2  % sucrose
interface were ,T hoovered off " using a pasteur pipette, diluted 
1:1 with ice - cold KHCO buffer and centrifuged at 25,000 g
for 15 min at 4 C, resuspended in 5ml of KHCO buffer and stored 
° 3
at - 80 C in 0.25 ml aliquots.
2.15 Preparation of Intact Human Platelets
Intact human platelets were prepared as described by
MacIntyre and Pollock (1983).
10 ml aliquots of freshly collected human blood were immediately
added to plastic centrifuge tubes containing 1ml of trisodium
citrate solution ( 3*8 % w/v) and inverted to allow mixing.
o
o
o 3 max
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The suspension was centrifuged at 800 g for 5 min at
av
room temperature in a Centaur 2 bench centrifuge, the
supernatants were removed and combined and to each 1ml of
supernatant was added 40 ul of 100mM EGTA and 10 ul of 1M citric
acid. The mixture was subsequently centrifuged at 1,000 g for
av
10 rain at room temperature and the pellet resuspended in Hepes'
buffered Tyrodes' solution consisting of 129 mM NaCl, 10.9 mM
trisodium citrate, 8.9 mM NaHCO , 0.56 mM D - glucose, 5mM
3
Hepes, 2.8 mMKCl, 0.8 mM KH PO , 0.84 mM MgCl , 2.4 mM CaCl
2 4 2 2
and 0.35 % (w/v) bovine serum albumin pH 7.4 .
1 ml of this buffer was added per 10 ml of fresh blood
o
used, and the suspension was incubated at 37 C in siliconised
glass conical flasks placed in a shaking water bath preset to 120 
-1
cycles min for 15 min prior to any drug additions. The flasks
were sealed using n suba-seal” stoppers and drug additions were
made by injection through the stoppers using glass micro
syringes. After the appropriate time of incubation with drugs
the reaction was terminated by the addition of an equal volume of
ice - cold Hepes’ buffered Tyrodes’ solution and the suspension
centrifuged at 30,000 g for 15 min using an MSE Hi - spin 21
av o
centrifuge and an 8 x 50 fixed angle rotor cooled to 4 C.
The resultant pellet was homogenized and washed using
the procedure outlined below for preparation of a crude membrane
pellet from human platelets.
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2.16 Preparation of A Crude Membrane Pellet From Human
Platelets
Membrane Pellets were prepared from platelets using the 
method outlined by Jakobs et_ sd (1982).
10 ml portions of freshly collected blood were immediately mixed
with 1ml of 3.8 % (w/v) trisodium citrate and centrifuged at
1,OOOg for 5 min in a Centaur 2 bench centrifuge at room
av
temperature. The supernatant was collected and centrifuged at
30,OOOg for 15 min using an MSE Hi-Spin 21 centrifuge and an 
av o
8 x 50 rotor cooled to 4 C .
The resulting pellet was homogenized in 15 ml of ice -
cold 10 mM Tris containing 1 mM EDTA pH 7.4 using 10 up and down
strokes with a glass Potter - Elvejm homogenizer and teflon
pestle and recentrifuged at 30,OOOg as before. The final
av
pellet ; the "crude membrane pellet" , was then resuspended in
10 mM Tris / HC1 pH 7.4 to 2 ml for every 100ml of fresh blood
o
used and stored in 50 jil aliquots at - 80 C.
2.17 Protein Estimations !
Protein determinations were routinely made using 
the procedure of Peterson (1977) which is a modification of the 
method of Lowry et al (1951) . This procedure allows the initial 
removal of solutions which could interfere with the normal Folin-
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Lowry protein estimation by solubilisation and subsequent
precipitation of protein prior to the colourimetric estimation of
protein content.
Standard solutions of bovine serum albumin were
-1
prepared containing 0 - 100 yg of protein ml and unknown
protein solutions were also made up to a 1ml volume in plastic
centrifuge tubes. 0.1 ml of 0.15% (w/v) deoxycholate was added to
each tube, mixed and incubated at room temperature for 10 min.
0.1ml of 72$ T.C.A. (w/v) was then added , mixed and left at
room temperature for 5 min. The samples were then centrifuged in
a bench Centaur 2 at 3,000g for 15 min at room temperature and-
av
the supernatants decanted and discarded.
1ml of distilled water was added to each sample and a
11 Lowry C" solution was prepared consisting of 50ml of 4$ (w/v)
Na CO containing 0.4$ (w/v) S.D.S. and 1ml of 1$ (w/v)
2 3
CuSO .5H 0 in 2% (w/v) sodium citrate.
4 2
1ml of this Lowry C solution was added to each sample for 
exactly 10 min and then 0.5 ml of Folin & Ciocalteu’s reagent 
(diluted 1:5 with water) was added and colour development was 
allowed to occur for 30 - 60 min before measuring absorbance 
at 650 nm with an LKB spectrophotometer linked up to 
an Apple 2e computer. Estimations were always performed in 
triplicate using an LKB "Wavescan" linear regression curve -
i
fit program. (LKB , Surrey, U.K.).
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2.18 Preparation of cAMP Binding Protein From Bovine Cardiac
Muscle
The procedure used was that employed by Rubin et_ al 
(1974) and involves 3 distinct stages of purification:
2.18.1 Homogenization
The pericardium and fat tissue were removed from a
fresh bovine heart and the heart was chopped into 2.5 cm cubes
and minced as finely as possible using a Moulinex electric
mincer. The minced heart was mixed with 4L of 40 mM KPO buffer
4
pH 6.1 containing 2 mM B mercaptoethanol and homogenized in -a
Waring blender for 1 min in small batches. The homogenate was
o
centrifuged at 10,OOOg for 10 min at 4 C and the supernatant
av
was filtered through Whatman No. 54 filter paper using a 
Buchner funnel and flask under vacuum. The pellet was extracted 
twice more with 1 L of the same buffer and the filtered 
supernatants were combined.
2.18.2 (NH ) SO Precipitation 
4 2 4
The combined supernatants were brought to 55%
saturation by the addition of solid (NH ) SO at a concentration
4 2 4
of 320 g / L . The pH was maintained between 7 and 8 by the
addition of concentrated (NH )0H solution. Protein precipitation
4
was allowed to occur for 2.5 - 3 h, after which , the precipitate
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o
was collected by centrifugation at 10,OOOg for 10 min at 4 C.
av
The supernatant was discarded and the precipitate dissolved in
500ml of 50 mM Tris / HC1 pH 7.6 containing 10mM NaCl and 4mM B
mercaptoethanol . This solution was dialysed overnight against
o
5 L of the Tris buffer at 4 C to remove the (NH ) SO .
4 2 4
2.18.3 DE 50_ Cellulose Purification
In the original method used by Rubin et_ al_ (1974) 
DEAE - Sephadex was used. However, this was not available when 
this binding protein was first purified by us and so DE - 50 
Cellulose was used as a substitute. This was found to be adequate 
for the preparation and so it was routinely used for each 
subsequent preparation.
2.18.4 Pretreatment of DE 50_ Cellulose Before Use
50g of DE - 50 Cellulose was stirred in 2 L of 0.5 M 
HC1 and left for 30 min . The resin was then washed with 
distilled water until the pH rose to 4 units. The DE - 50 
Cellulose was then stirred into 2 L of 0.5 M NaOH and then left 
for 30 min. The resin was then washed until the eluate was 
neutral and the whole acid / alkali cycle repeated once more. The 
resin was then equilibrated with 50 mM Tris / HC1 pH 7.6 
containing 10 mM NaCl and 4 mM B mercaptoethanol and a final
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slurry was prepared to give a wet settled volume : final volume
ratio of 2 : 1
2.18.5 Absorption of The Binding Protein By The Resin
The dialysed preparation was stirred for 1 h with 800 
ml of equilibrated DE - 50 Cellulose and under these conditions 
cAMP - dependent protein kinase activity should be absorbed. The 
resin was collected by filtration using Whatman No. 54 filter 
paper on a Buchner funnel and flask under vacuum. The resin was
washed with 3 L of Tris / HC1 pH 7.6 containing 10 mM NaCl and 
4mM B mercaptoethanol until the filtrate became colourless. The 
gel was then mixed with 200ml of 50 mM Tris /HC1 pH 7.6 
containing 0.3 mM NaCl and 4mM B mercaptoethanol for 45 min. 
Collection of the DE - 50 Cellulose was achieved by filtration 
and washing of the resin with 50 mM Tris/HCl buffer using a 
Buchner flask and funnel.
2.18.6 Isolation of The cAMP Binding Protein
The combined filtrates were brought to 35 % saturation
with 119g / L of solid (NH ) SO and the pH maintained between 7
4 2 4
and 8 units with 1NH OH solution and after 1 h the precipitate
4 o
was collected by centrifugation at 10,OOOg for 10 min at 4 C
av
and discarded. The supernatant was brought to 75 % saturation by
the addition of 258g / L of solid (NH ) SO and the precipitate
4 2 4
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formed after 1 h was collected by centrifugation at 10,OOOg as
av
before and the pellet suspended in a minimum volume of 50 mM KPO
4
buffer containing 4mM B mercaptoethanol pH 7. This suspension
o
was dialysed overnight at 4 C against 2 L of the same buffer.
0
The purified protein kinase was stored at - 80 C in 0.25 ml
aliquots. Under these conditions each preparation was found to
be stable for 6 - 9 months. Aliquots were never refrozen, but
o
could be used for up to 48 h after thawing if stored at 0 - 4 C .
2.19 Assay of Adenylate Cyclase Activity
Adenylate cyclase ( E.C. 4.6.1.1 ) was assayed as
described by Houslay et_ al (1976). An assay cocktail was
prepared containing 1.5 mM ATP, 5mM MgSO , 10mM theophylline, 1mM
4
EDTA , 7.4 mg / ml phosphocreatine , 0.2 mg /ml creatine kinase,
25 mM triethanolamine hydrochloride , 1mM dithiothreitol and 0.8 
mg / ml bovine serum albumin. The cocktail was then adjusted to 
pH 7.4 with K0H solution. Drugs, hormones and membranes were 
added as appropriate to the cocktail to give a final assay 
volume of 100yil.
o
These samples were then incubated at 30 C for 10-15
min. The reaction was terminated by placing the samples in a
o
water bath for 3 min at* a temperature > 90 C. Precipitated
protein was then pelleted by centrifugation at 14,OOOg for 5
av
min and the supernatants removed for cAMP determination.
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Adenylate cyclase activity was expressed as pmoles cAMP produced 
- 1 - 1
min mg protein. The linearity of enzyme activity with 
respect to incubation time and protein concentrations used were 
always ensured.
2.19.1 cAMP Determination
Determination of cAMP content in samples assayed for
adenylate cyclase activity was based on the saturation binding
assay of Brown et_ al_ (1972) as modified by Tovey et_ al_ (1974) and
described by Whetton et al (1983).
Essentially this assay depends upon the specific
binding of cAMP to a cAMP binding protein isolated and purified
from bovine heart as described in section 2.18. Samples are
incubated with the binding protein for a suitable period of time
to allow a state of equilibrium to occur. The bound cAMP is then
separated from unbound cAMP by the use of a charcoal / B.S.A.
suspension . The charcoal absorbs free nucleotides and therefore 
3
estimation of H-cAMP bound to the protein can be made.
Total cAMP binding to the protein is estimated by
incubation of tritiated cAMP in the absence of unlabelled cAMP . 
Non-specific cAMP binding is estimated by the incubation 
of b'ritiated cAMP in the absence of both unlabelled cAMP and 
binding protein . Using a range of solutions of known unlabelled 
cAMP concentration it is possible to sequentially reduce the
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proportion of labelled cAMP bound to the protein as the two cAMP 
species compete for a finite number of binding sites. Thus, a 
standard displacement curve can be constructed and estimation of 
cAMP content can be made.
A range of (unlabelled) cAMP standard solutions (0-320
pmoles / ml ) were prepared in assay buffer containing 50mM Tris
3
and 5mM EDTA pH 7.4. Tritiated cAMP (5,8- H-Adenosine 3f»5f
cyclic phosphate) in 5055 ethanol was diluted in the Tris / EDTA
assay buffer to give about 500,000 cpm /ml . 100pl of this
solution was added to plastic vials containing 50pl of assay
buffer. Then 50pl of standard cAMP solution or 50pl of
supernatant from samples with unknown cAMP content were added to
these vials and mixed gently. Finally 100pl of binding protein
(prepared as described in section 2.18 and diluted 1/100 with
assay buffer) was added to the samples and gently mixed. The
o
samples were incubated at 4 C for 1.5 - 3 h . Just prior to
termination of the incubation period a charcoal solution was
prepared consisting of 2% GSX-100 charcoal and 1^ bovine serum
albumin suspended in ice - cold assay buffer. The suspension was 
o
gently mixed at 4 C for about 10 min prior to use.
0.25 ml of charcoal suspension was added to samples to
terminate the incubation period and the charcoal was pelleted by
o
centrifugation for 5 min at I4,000g at a temperature of 4 C.
av
0.4 ml of the supernatant was then removed , dispersed into
108
"Ecoscint" scintillation fluid and counted in an LKB
scintillation counter.
In order to estimate cAMP content in the samples from 
adenylate cyclase assays ,it was necessary to construct a 
standard curve with known cAMP standard solutions each time an 
experiment was undertaken. The LKB scintillation counter used 
in our laboratory had an RIA curve fitting facility . Therefore, 
cAMP content in pmoles /sample was automatically calculated 
from each standard curve and printed out . Routinely the 
sensitivity of the binding assay was between 0.25 and 8,
pmoles / sample.
32
2.20 Preparation of Qf- _P ]_ GTP
32
[ P ] GTP was prepared using the technique outlined by Maxam 
& Gilbert (1980) procedure 2.
PGK
Glycerate-3-P + GTP .... — 1,3 Diphosphoglycerate + GDP
GAP-DH
1, 3 Diphosphoglycerate -^--------Glyceraldehyde-3-P + Pi
3 phosphoglycerate kinase (EC 2.7.2.3 ) catalyzes the
reversible phosphorylation of glycerate 3-phosphate to
1,3 diphosphoglycerate using the nucleotides ATP or GTP as 
phosphate donors. In the presence of glyceraldehyde 3-phosphate
109
dehydrogenase (EC 1.2.1.12), the 1,3 diphosphoglycerate is 
converted to glyceraldehyde 3-phosphate.
However, under the conditions of the reaction mixture,
32
[ P ] - labelled inorganic phosphate is also present and the
position of equilibrium of the reaction is shifted so far to the
32
left that the Pi is incorporated into the 1,3
diphosphoglycerate and subsequently into GTP at the '?f position. A
32 32
theoretical conversion of 78% of the Pi to [ P] GTP is
reported to be possible. However, 60-70 % conversion was
routinely obtained.
The procedure used is a four stage process involving
the removal of ( NH ) SO from the commercially bought enzymes,
4 2 4
incubation of the reaction mixture and PEI- cellulose thin
layer chromatography identification and quantification of
32
reactants and products. Finally, purification of the ^ [ P] GTP 
synthesized was achieved by the use of ion-exchange
chromatography.
2.20.1 Removal of (NH ) SO From Commercial Enzyme Preparations 
' 4 2 4
The purpose of this procedure is to remove residual
(NH ) SO which could inhibit the reaction and also to remove any 
4 2 4
traces of inorganic phosphate which may be present in the enzyme
preparations which would reduce the percentage conversion of the 
32 32
[ P] labelled Pi into [ P] GTP.
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12.5 pi of yeast 3-Phosphoglycerate kinase (specific
activity ca. 4.5U/pl) and 32.5 pi of rabbit muscle glyceraldehyde
-3 phosphate-dehydrogenase ( specific activity ca. 0.8 U / pi)
were combined in a 1.5ml plastic vial and sedimented by
o
centrifugation for 5 min at I4,000g at 4 C . The supernatant
av
was carefully removed and discarded.
The sediment was very gently resuspended in 50pl of a
"wash buffer" consisting of 100mM Tris-HCl (pH8) containing 10mM
+
B- mercaptoethanol , 1mM EDTA (pH8), 0.1mM NAD and 3.2M(NH ) SO
4 2 4
using a heat sealed glass capillary tube and again sedimented by 
centrifugation as before. The pellet was washed once more as 
before and recentrifuged. The walls of the vial and the top of 
the the pellet were then carefully washed with 12.5 pi of 
distilled water trying not to disturb the pellet. Finally, the
enzymes were sedimented once more by centrifugation and the
resultant pellet was very gently resuspended in 37.5pl of 
distilled water and placed on ice.
2.20.2 Incubation of The Reaction Mixture
32
500pl of [ P] labelled inorganic phosphate ( specific
activity 1mCi / 100pl) was carefully neutralised with 10pl of
500mM NaOH using a heat - sealed glass capillary tube for mixing.
To this was added 50pl of a 10 x concentrated solution containing
(final concentrations) 500mM Tris-HCl (pH8), 50mM MgCl , 20mM
2
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reduced glutathione , 10mM glycerate 3 phosphate , 1mM EDTA (pH8)
+
and 0.1mM NAD . 5\il of GTP and 2pl of the washed enzyme 
suspension were added to initiate the reaction and the mixture 
was gently mixed and incubated at room temperature for 20 min. 
After which, the reaction was terminated by placing the reaction 
vial on ice.
2.20.3 PEI-Cellulose Thin Layer Chromatography
A 20 x 40 cm sheet of PEI-cellulose was cut in half and
pre-run in water to take most of the yellow soluble material to
the top. The plates were dried and marked in pencil into 10 x
5cm rectangles with an origin line 1.5 cm from the bottom. These
o
rectangles were cut out and stored at 4 C prior to use.
1\il reaction mixture samples were spotted onto these 
plates immediately prior to initiation of the reaction and
immediately before termination of the reaction. The plates were
■ (
left to ^ dry at room temperature for 5 min and then placed in a
chromatography tank containing 10ml of 0.75M KPO buffer(pH3*5)
4
until the buffer had travelled 3/4 of the way up the plate
( within approximately 30 min). Under these conditions excellent 
separation of Pi and GTP is achieved; Pi runs near the front and
GTP has an Rf of ca. 0.15-0.20.
32
The relative amount of [ P ] -labelled Pi and GTP 
were quantified by developing an autoradiograph of the dried
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plate and cutting out the relevant areas for Cerenkov counting 
using a wide-open channel setting on an LKB scintillation 
counter.
32
As the specific activity of the P was high; exposure
of the film (Kodak XAR-5) to the PEI-cellulose plate was only
required for 1 min . From these counts the percentage conversion
32 32
of [ P ] -labelled Pi to ^ [ P ] GTP could be calculated.
32
It is also possible to ensure the [ P ] -labelled inorganic
32
phosphate has been converted to ^ [ P ] labelled GTP by the use
of Norit A charcoal slurry.
1pl samples taken at 0 and 20 min incubation times were
added to 200 pi of 50mM NaPO pH 7. 100pl of this mixture was
4
transfered to a plastic vial and to this was added 0.5ml of a 5%
slurry of Norit A charcoal in 50mM NaPO pH 7. The suspension
4
was immediately vortex-mixed and centrifuged for 5 min at 
o
l4,000g at 4 C. 0.4ml of the supernatant was removed and 3ml 
av
of "Ecoscint" scintillation fluid was added. Under these 
conditions the charcoal is saturated with unlabelled inorganic 
phosphate and the radio -labelled GTP can thus be separated from 
the radiolabelled inorganic phosphate by specific absorption to 
the charcoal.
A 0 min reaction mixture sample allows the 
determination of non-specific binding to the charcoal by Pi. 
This "blank" is subtracted from all samples. Use of this 
relatively quick method enabled continuation of the preparation
113
to the purification stage without waiting for the PEI-cellulose 
chromatography quantification to have reached completion.
32
2.20.4 Purification of The [_ P_ ]_ GTP
Purification of the radio-labelled GTP was by the use
of the anion exchange resin Dowex 1-X2 (100-200 mesh Cl form).
50g of Dowex resin was suspended in 1.5L of 1M NaOH for 30 min
and then filtered and washed with 5L of water on a large Buchner
funnel. The Dowex was then suspended in 1.5L of 1M HC1 for 30
min and the resin filtered and washed as before.
A 30 cm column of this washed Dowex resin was poured in
a glass Pasteur pipette which had been "plugged" with a small
amount of siliconised glass wool . The column was washed with 5
ml of 1M NaCl, followed by 10ml of distilled water and then the
sample applied. This was then washed with 5 ml of water,
followed by 20ml of 0.02M NH Cl / 0.02 M HC1 to elute inorganic
4
phosphate , GMP and GDP. In order to remove NH ions the
4
column was subsequently washed with a further 10ml of water and
the GTP was eluted with 15 aliquots of 0.75 ml of 0.25M HC1. The
15 eluted fractions were collected in 1.5ml plastic vials
containing 0.25 ml of 1M Tris (pH9).
These fractions were Cerenkov counted and the peak
fractions (usually tubes 2-14) were pooled , aliquoted and stored 
o
at -80 C. Using the Norit A charcoal method outlined above,
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samples of this final GTP preparation stage were found to be 95 % 
absorbable.
Specific activity of the radio-labelled GTP was 
calculated by the following equation :
32
% Conversion X mCi £ pi Used = Radioactivity / 20nmoles GTP.
2.21 Assay of GTPase Activity
GTPase activity was measured as described by Houslay et_
al (1986) which is based on the original GTPase assay developed
by Cassel & Sellinger (1976).
The assay, in a final volume of 100pl contained 0.1pM
C32P ] GTP, 5mM MgCl , 100mM NaCl, 1mM dithiothreitol, 0.5mM
2
EGTA, 1mM APP(NH)P, 0.6pM GTP, 1mM Oubain, 50mM Tris-HCl pH 7 and
drugs as appropriate. The assay cocktail was prepared on ice and
initiation of the reaction was by the addition of human platelet
membranes. The cocktail was then incubated for exactly 5 min at 
o
30 C and the reaction was terminated by the addition of 0.5ml of
a 2% ice-cold Norit A charcoal suspension in 50mM KPO buffer
4
pH 7.0 . This was immediately followed by vortex - mixing and
centrifugation at l4,000g for 5 min.
av
0.4ml of the supernatant was removed and Cerenkov
counted in an LKB scintillation counter using a wide-open channel 
setting.
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2.22 Pertussis Toxin Catalyzed Ribosylation of Human Platelet
Broken Plasma Membranes
2.22.1 Pertussis Toxin Preactivation
100pl of pertussis toxin (500pg/ml) was added to 100pl of 40mM
dithiothreitol and gently mixed. The solution was then incubated 
o
at 37 C for 45 min. The incubation was terminated by placing the 
sample on ice.
2.22.2 Ribosylation of Membranes
A ribosylation cocktail containing 2mM NAD , 2mM ATP, 1mM GTP,
30mM thymidine and 100mM KPO pH 7.4 was prepared. 0.5ral of this
4
cocktail was added to the preactivated pertussis toxin sample
300pl of platelet membranes (approximately 1.5mg of protein) were
o
then added, gently mixed and incubated at 37 C for 30 min. The
sample was then centrifuged for 15 min at l4,000g at a 
o av
temperature of 4 C to pellet the membranes. The pellet was then
washed twice with 500pl of water and finally resuspended to the
required volume in 10mM Tris / HC1 pH 7.4.
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2.23 Cholera Toxin Catalyzed Ribosylation of Human Platelet
Broken Plasma Membranes
2.23.1 Cholera Toxin Preactivation
100pl of cholera toxin (1mg /ml) was added to 100jil of 40mM
dithiothreitol and gently mixed. This solution was incubated at 
o
30 C for 20 min. The incubation was terminated by placing the 
sample on ice.
2.23*2 Cholera Toxin Ribosylation of Membranes
A ribosylation cocktail containing 2mM NAD , 1mM GTP, 30mM
thymidine and 100mM KPO pH 7.4 was prepared . 0.5ml of this
4
cocktail was added to the preactivated cholera toxin sample.
300pl of platelet membranes ( approximately 1.5mg of protein)
o
were then added , gently mixed and incubated at 30 C for 10 min.
o
The sample was then centrifuged for 15 min at I4,000g at 4 C to
av
pellet the membranes. The pellet was washed twice with 500pl of 
water and finally resuspended to the required volume in 10mM Tris 
-HC1 pH 7.4 .
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3. Characterization of G Protein Control of Hepatic Adenylate
Cyclase Activity In Control And Diabetic Rats
118
Introduction
In this chapter, I have attempted to characterize the 
guanine nucleotide regulatory components Gi and Gs of the rat 
hepatic adenylate cyclase system in the "normal" (control), type 
I and type II diabetic states. GTP (Itoh et al 1984) and 
non-hydrolyzable GTP analogues ( Hildebrandt _et_ al 1982; Katada 
et al 1984) have been demonstrated to specifically activate Gi 
and Gs. Using the non-hydrolyzable GTP analogue , 5*-guanyly- 
imidodiphosphate (GPPNHP), I have attempted to demonstrate that 
the two G proteins can be sequentially activated due to their 
differing affinities to bind the nucleotide.
_10
Hence, at low concentrations of the nucleotide (10
_8
10 M ) Gi is activated prior to Gs . At higher concentrations
J _4
of the nucleotide (10 - 10 ) Gs also becomes activated and an
overall stimulation of the adenylate cyclase catalytic unit is 
observable as Gs regulatory "input" counterbalances and overtakes 
Gi regulatory "input".
Under "basal" (resting) conditions, Gi inhibition of 
adenylate cyclase is not observable. In order to observe this 
inhibition, the adenylate cyclase activity must be elevated. 
This can be achieved either by the use of the diterpene , 
forskolin, or by the use of a stimulatory ligand such as a B- 
adrenergic agonist. As discussed earlier in the general 
introduction, forskolin has the ability primarily to increase the 
maximal velocity of adenylate cyclase without affecting the Km
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for the enzyme’s substrate ; Mg.ATP. The mechanism by which this 
compound has the ability to stimulate the catalytic unit remains 
relatively little understood. However, it is a useful tool to 
elevate the activity of the catalytic unit without the 
requirement for ligand-receptor interactions. Such interactions 
themselves of course could be altered in a diseased state such as 
diabetes.
Also, the use of this diterpene facilitates the 
characterization of the Gs component because although forskolin 
elevates the catalytic unit’s activity (as does Gs) , they do so 
synergistically with each other ( Seamon & Daly 1986). Thus, Gs 
stimulation of adenylate cyclase activity can be observed in the 
presence of forskolin.
Also in this chapter I have investigated the effect of 
metformin therapy on the activation of Gi and Gs by GPP(NH)P. 
Metformin, as briefly discussed in the general introduction, is a 
member of> the biguanide family of hypoglycaemic drugs. It has 
been used in type II diabetic therapy and has been reported to 
have ”post-receptor effects" which may attenuate insulin 
resistance (Lord et al 1983 ). As a G protein is a "post-
receptor site" it was therefore conceivable that this drug could 
alter the function of one or more G proteins . Also, if this were 
found to be true , a relationship between G protein function and 
insulin resistance in the diabetic state may well prevail.
An additional method by which to assess Gi and Gs
activity is to study glucagon’s ability to stimulate adenylate
120
cyclase activity in the absence and presence of pertussis toxin 
treatment. Glucagon activates Gs and pertussis toxin attenuates 
Gi activity by promoting the ribosylation of the Gi <** subunit. 
Resultingly, the holomeric Gi ( oi B Y ) complex formation is 
favoured and this inactive state of Gi prevails.
Finally, a general characterization of the adenylate 
cyclase system in each of the control and diabetic states is 
undertaken using compounds such as sodium fluoride,forskolin , 
GTP and glucagon.
Additional Methods
Hepatocytes were isolated using the collagenase perfusion 
technique outlined in section 2.8.
Crude membranes were prepared from hepatocytes as described in 
section 2.12.
Adenylate cyclase activity was assayed as outlined in section
_4
2.19 in the presence of forskolin (10 M ) . Activity was
o
assayed for 10 min at 30 C with a final membrane protein 
concentration of 20-40 jag/ml. Forskolin was diluted to the 
required concentration using absolute ethanol and therefore basal 
activities were assayed in the presence of absolute alcohol also. 
Pertussis toxin and TPA pretreatment of hepatocytes was 
undertaken as described in section 2.11. Pertussis toxin 
(100ng/ml) and TPA (10ng/ml) pretreatments involved incubation
121
of each compound with hepatocyte suspensions as described in 
section 2.11 for 1 h and 20 min for each respective drug. 
Animal treatments are as described in sections 2. 3 2. 5
All assays were performed in triplicate and values given are mean 
+/- SEM values .
Monocomponent porcine insulin and porcine glucagon were used 
throughout.
”nn refers to the number of j separate animals used . 1
122
3.1- Use of The Guanine Nucleotide GPP(NH)P To Regulate 
Forskolin Stimulated Adenylate Cyclase Activity
123
Figure 3.1.1 Guanine Nucleotide Regulation of Forskolin
Stimulated Adenylate Cvclase Activity In Hepatocytes 
Isolated From Control Rats
Crude membrane pellets were prepared from hepatocytes 
isolated from control Sprague Dawley rats.
Adenylate cyclase activity was assayed in the presence 
of forskolin (10“4 M ) and increasing concentrations of 
5'- guanylyl-imidodiphosphate (GPP(NH)P) . Activity is 
expressed as a percentage of forskolin stimulated 
activity in the absence of GPP(NH)P.
All activities are expressed as mean +/_ S.E.M. values 
(n=S)-
Basal and forsko lin  stim ulated adenylate cyclase 
activities were 1.30 +/_ 0.10 and 18.20 +/_ 2.00
pmoles cAMP produced min“T mg""* respectively.
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Figure 3.1.1 Guanine Nucleotide Regulation of Forskolin 
Stimulated Adenvlate Cvclase Activity In Hepatocytes 
Isolated From Control Rats
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Figure 3.1.2 Guanine Nucleotide Regulation Of Forskolin
Stimulated Adenvlate Cvclase Activity In Hepatocytes 
Isolated From Streptozotocin-lnduced Diabetic Rats
Type I diabetes (I.D.D.M.) was chemically induced in 
Sprague Dawley rats as outlined in Materials and Methods. 
Crude membrane pellets prepared from hepatocytes 
isolated from these animals were assayed for adenylate 
cyclase activity in the presence of forskolin 
(10“4 M) and increasing concentrations of 
5 ' -guanylyl -imidodiphosphate (GPP(NH)P) . Activity is 
expressed as a percentage of forskolin stimulated 
activity in the absence of GPP(NH)P. AH activities are 
expressed as mean +/_ S.E.M. values (n=5).
Basal and forsko lin  stim ulated adenylate cyclase 
activities were 0.64 +/_ 0.02 and 11.20 +/- 1.00 pmoles
cAMP produced m in ''1 mg-1 respectively.
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Figure 3.1.2 Guanine Nucleotide Regulation of Forskolin
Stimulated Adenvlate Cvclase Activity In Heoatocvtes
Isolated From Streotozotocin - Induced Diabetic Rats
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Figure 3.1.3 Guanine Nucleotide Regulation of Forskolin
Stimulated Adenylate Cvclase Activity In Hepatocytes 
Isolated From Diabetic Rats Undergoing Insulin Therapy.
Type I diabetes (I.D.D.M.) was chemically induced in 
Sprague Dawley rats and Insulin administered daily as 
outlined in Materials and Methods.
Crude membrane pellets were prepared using hepatocytes 
isolated from these animals and assayed for adenylate 
cyclase activity in the presence of forskolin 
(10“ ^ M  ) and increasing concentrations of 
5'- guanylyl-imidodipphosphate (GPP(NFl)P). Activity is 
expressed as a percentage of forskolin stimulated 
activity in the absence of GPP(NH)P. Activities are mean 
+/- S.E.M. values (n=4).
Basal and forskolin stimulated activities were 0.68 
+/_ 0.04 and 10.90 +/_ 0.90 pmoles cAMP
produced min- "! mg“ 1 respectively.
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Figure 3.1.3 Guanine Nucleotide Regulation of Forskolin
Stimulated Adenvlate Cvclase Activity In Hepatocytes 
Isolated From Diabetic Rats Undergoing Insulin Therapy
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Figure 3.1.4 Guanine Nucleotide Regulation of Forskolin 
Stimulated Adenylate Cvclase Activity In Hepatocytes 
Isolated From Lean Zucker Rats
Crude membrane pellets were prepared from hepatocytes 
isolated from lean Zucker rats.
Adenylate cyclase activity was assayed in the presence of 
forskolin (10"4 M) and increasing concentrations of 
5 '-guanylyl-im idodiphosphate (GPP(NH)P). Activ ity is 
expressed as a percentage of forskolin stimulated 
activity in the absence of GPP(NH)P . All activities are 
expressed as mean +/_ S.E.M. values (n= 3).
Basal and forsko lin  stim ulated adenylate cyclase 
activities were 1.14 +/_ 0.02 and 17.10 +/_ 2.00
pmoles cAMP produced min“ 1 mg"^ respectively.
Figure 3.1.4 Guanine Nucleotide Regulation of Forskolin
Stimulated Adenylate Cvciase Activity in Hepatocytes 
isolated From Lean Zucker Rats
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Figure 3.1.5 Guanine Nucleotide Regulation of Forskolin
Stimulated Adenylate Cvciase Activity In Heoatocvtes 
Isolated From Obese Zucker Rats
Crude membrane pellets were prepared from hepatocytes 
isolated from obese Zucker Rats.
Adenylate cyclase activity was assayed in the presence 
of forskolin (10"4 M) and increasing concentrations of 
5'-guanylyl-im idodiphosphate (GPP(NH)P). Activity is 
expressed as a percentage of forskolin stimulated 
activity in the absence of GPP(NH)P. All activities are 
expressed as mean +/_ S.E.M. values (n=3).
Basal and forsko lin  stim ulated adenylate cyclase 
activities were 1.24 +/_ 0.10 and 18.38 +/_ 1.60 
pmoles cAMP produced min"'1 mg""* respectively.
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Figure 3.1.5 Guanine Nucleotide Regulation of Forskolin
Stimulated Adenvlate Cvclase Activity in Heoatocvtes 
isolated From Obese Zucker Rats
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3.2 GPP(NH)P Dependent Inhibition of Forskolin Stimulated
Adenylate Cyclase Activity
129
Figure 3.2.1 GPPfNHIP - Dependent Inhibition of Forskolin 
Stimulated Adenylate Cvclase Activity In Hepatocvtes 
Isolated From Control Rats
Crude membrane pellets were prepared from hepatocytes 
isolated from Sprague Dawley rats.
Adenylate cyclase activity was assayed in the presence of 
forskolin (10"4 M) and increasing concentrations of 
5'- guanylyl-im idodiphospate (GPP(NH)P). Activity is 
expressed as a percentage of forskolin stimulated 
adenylate cyclase activity. All activities are expressed 
as mean +/_ S.E.M. values (n= 5).
Basal and forsko lin  stim ulated adenylate cyclase 
activities were 1.30 +/_ 0.10 and 18.20 +/_ 2.00
pmoles cAMP produced min""* mg""* respectively.
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Figure 3.2.1 GPPfNhHP - Dependent Inhibition of Forskolin
Stimulated Adenylate Cvciase Activity in Heoatocvtes 
Isolated From Control Rats
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Figure 3..2.2 Effect of Streptozotocin Induced Diabetes
On GPP(NH)P Mediated Inhibition of Adenylate Cvciase 
Activity In Isolated Hepatocvtes
Type i diabetes (I.D.D.M.) was induced in Sprague Dawley 
rats as described in Materials and methods .
Crude membrane pellets were prepared from 
hepatocytes isolated from diabetic rats.Adenylate cyclase 
activity was assayed in the presence of forskolin (10"4 
M) and  i n c r e a s i n g  c o n c e n t r a t i o n s  of  
5'-guanylyl-im idodiphoshate (GPP(NH)P ). Activity is 
expressed as a percentage of forskolin stimulated 
adenylate cyclase activity. All activities are expressed 
as mean +/_ S.E.M. values (n=5).
Basal and forskolin stimulated adenylate cyclase 
activities were 0.64 +/_ 0.02 and 11.20 +/- 1.00
cAMP produced min-1 mg'^ respectively.
Figure 3.2.2 Effect of Low Concentrations of GPP(NH)P On 
Forskolin Stimulated Adenvlate Cvclase Activity in Hepatocvtes 
Isolated From Streotozotocin- induced Diabetic Rats
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Figure 3..2.3 Effect of Alloxan Induced Diabetes On
GPPfNPHP Mediated Inhibition of Adenvlate Cvclase 
Activity In Isolated Hepatocvtes
Type I diabetes (I.D.D.M.) was induced in Sprague Dawley 
rats as described in Materials and methods .
Crude membrane pellets were prepared from 
hepatocytes isolated from these diabetic rats.
Adenylate cyclase activity was assayed in the presence of 
forskolin (10“ 4 M) and increasing concentrations of 
5'-guanylyl-im idodiphoshate (GPP(NH)P ). Activity is 
expressed as a percentage of forskolin stimulated 
adenylate cyclase activity. All activities are expressed 
as m ean+/_ S.E.M. values (n=5).
Basal and forsko lin  stim ulated adenylate cyclase 
activities were 0.87 +/_ 0.07 and 12.30 +/- 1.50
pmoles cAMP produced min""* mg""* respectively.
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Figure 3.2.3 Effect of Alloxan Induced Diabetes On
GPPfNH^P Mediated Inhibition of Adenvlate Cvclase 
Activity In Isolated Hepatocvtes
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Figure 3.2.4 Effect of TPA And Pertussis Toxin
Pretreatm ent On GPP(NH)P Mediated Inhibition of 
Adenvlate Cvclase Activity in Hepatocvtes Isolated From 
Control Rats
Crude membrane pellets were prepared from ( a ) control, 
( 0  ) TPA (10ng/ml) and ( #  )Pertussis toxin (100ng/ml) 
pretreated hepatocytes isolated from Sprague Dawley 
rats.
Adenylate cyclase activity was assayed in the presence of 
forskolin (10“4 M) and increasing concentrations of 
5'-guanylyl-im idodiphoshate (GPP(NH)P ). Activity is 
expressed as a percentage of forskolin stimulated 
adenylate cyclase activity. All activities are expressed 
as mean +/_ S.E.M. values (n=5).
Basal adenylate cyclase activities were 1.30 +/_ 0.10 ,
1.24 +/_ 0.10 and 1.35 +/_ 0.15 pmoles cAMP
produced min"1 mg"1 for control, TPA and Pertussis toxin 
treated hepatocytes respectively. Similarly, the forskolin 
stimulated activities for these preparations were 18.20 
+/_ 2.00 , 19.00 +/_ 2.04 and 19.60 +/_ 2.21
pmoles cAMP produced min"1 mg“1 respectively.
Figure 3.2.4 Effect of TPA And Pertussis Toxin
Pretreatment On GPPfNhOP Mediated Inhibition of 
Adenvlate Cvclase Activity in Hepatocytes isolated 
From Control Rats
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Figure 3..2.5 Insulin Reversal of Streptozotocin Induced
Diabetes And Its Effect On GPPfNHIP Mediated Inhibition 
of Adenvlate Cvclase Activity In Isolated Hepatocytes
Type I diabetes (I.D.D.M.) was induced in Sprague Dawley 
rats as described in Materials and methods .
Crude membrane pellets were prepared from 
hepatocytes isolated from ( m ) ■ diabetic,- ) 'nsu,in
treated diabetic and ( ^  ) control non treated rats. 
Adenylate cyclase activity was assayed in the presence of 
forskolin  (10“ 4 M) and increasing concentrations of 
5'-guanylyl-im idodiphoshate (GPP(NH)P ). Activity is 
expressed as a percentage of forskolin stimulated 
adenylate cyclase activity. All activities are expressed 
as mean +/_ S.E.M. values (n=5).
Basal adenylate cyclase activities were 0.64 +/_ 0 .02
0.68 +/_ 0.04 and 1.30 +/_ 0.10 pmoles cAMP
produced min"** mg""* for diabetic animals treated with 
saline , insulin and control non treated animals 
respective ly.
Forskolin stimulated activities were 11.20 +/_ 1.00
10.90 +/_0.90 and 18.20 +/_ 2.00 pmoles cAMP produced 
min"** mg"1 respectively.
Figure 3.2.5 Insulin Reversal of Streptozotocin- Induced 
Diabetes And Its Effect On GPPfNHIP Mediated Inhibition
Of Adenvlate Cvclase Activity In Isolated Hepatocytes
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Figure 3.2.6 GPPfNH^P - Dependent Inhibition of Forskolin
Stimulated Adenvlate Cvclase Activity In Hepatocytes 
Isolated From Lean Zucker Rats
Crude membrane pellets were prepared from hepatocytes 
isolated from Lean Zucker rats.
Adenylate cyclase activity was assayed in the presence of 
forskolin (10“4 M) and increasing concentrations of 
5'- guanylyl-im idodiphospate (GPP(NH)P). Activity is 
expressed as a percentage of forskolin stimulated 
adenylate cyclase activity. All activities are expressed 
as mean +/_ S.E.M. values (n= 5).
Basal and forsko lin  stim ulated adenylate cyclase 
activities were 1.14 +/_ 0.02 and 17.10 +/_ 2.00
pmoles cAMP produced min""* mg""* respectively.
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Figure 3.2.6 GPPfNH^P - Mediated Inhibition of Forskolin
Stimulated Adenvlate Cvclase Activity In Hepatocytes
Isolated From Lean Zucker Rats
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Figure 3.2.7 Effect of TPA And Pertussis Toxin
Pretreatm ent On GPPfNHIP Mediated Inhibition of 
Adenvlate Cvclase Activity In Hepatocytes Isolated From 
Lean Zucker Rats
Crude membrane pellets were prepared from ( a  ) control, 
( <> ) TPA (10ng/ml) and ( £ )Pertussis toxin (100ng/ml) 
pretreated hepatocytes isolated from lean Zucker rats. 
Adenylate cyclase activity was assayed in the presence of 
forskolin (10"4 M) and increasing concentrations of 
5'-guanylyl-im idodiphoshate (GPP(NH)P ). Activity is 
expressed as a percentage of forskolin stimulated 
adenylate cyclase activity. All activities are expressed 
as mean +/_ S.E.M. values (n=4).
Basal adenylate cyclase activities were 1.14 +/_ 0.02,
1.20 +/- 0.10 and 1.24 +/_ 0.15 pmoles cAMP produced
min""* mg""* for control, TPA and Pertussis toxin treated 
membranes respectively.
Similarly, forskolin stimulated activities were 17.10 
+/_ 2.00 , 18.20 +/_ 1.95 and 19.00 +/_ 2.10
pmoles cAMP produced min""* mg""* respectively.
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Figure 3.2.7 Effect of TPA And Pertussis Toxin
Pretreatment On GPPfNH^P Mediated Inhibition of 
Adenvlate Cvclase Activity in Hepatocytes isolated From 
Lean Zucker Rats
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Figure 3.2.8 GPPfNI-hP - Dependent Inhibition of Forskolin 
Stimulated Adenvlate Cvclase Activity In Hepatocytes 
Isolated From Obese Zucker Rats
Crude membrane pellets were prepared from hepatocytes 
isolated from obese Zucker rats.
Adenylate cyclase activity was assayed in the presence of 
forskolin (10"4 M) and increasing concentrations of 
5'- guanylyl-im idodiphospate (GPP(NH)P). Activity is 
expressed as a percentage of forskolin stimulated 
adenylate cyclase activity. All activities are expressed 
as mean +/_ S.E.M. values (n= 3)
Basal and forsko lin  stim ulated adenylate cyclase 
activities were 1,24 +/_ 0.10 and 18.38 +/_ 1.60
pmoles cAMP produced min"1 mg"^ respectively.
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Figure 3.2.8 GPPfNhOP-Dependent Inhibition of Forskolin
Stimulated Adenvlate Cvclase Activity In Hepatocytes 
Isolated From Obese Zucker Rats
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3.3 GPP(NH)P Dependent Stimulation of Adenylate Cyclase Activity
138
Figure 3.3.1 GPPfNf-HP-Dependent Stimulation of
Adenvlate Cvclase Activity In Hepatocytes isolated From 
Control And Streptozotocin Induced Diabetic Rats
Crude membrane pellets were prepared from hepatocytes 
isolated from ( ® ) control and ( i  ) streptozotocin treated 
Sprague Dawley rats. Adenylate cyclase activity was 
assayed in the presence of forskolin and increasing 
co n c e n t ra t io n s  of S ' - gu an y ly l - im id o d iph o s p h a te  
(GPP(NH)P). Activity is expressed as a percentage of 
forskolin stimulated activity in the absence of GPP(NH)P. 
All activ ities are expressed as mean +/_ S.E.M. 
values(n=5).
Basal adenylate cyclase activities were 1.30 +/_ 0.10
and 0.64 +/_ 0.02 pmoles cAMP produced min"1 mg"1 for 
control and diabetic preparations respectively. Similarly, 
forskolin stimulated activities were 18.20 +/_ 2.00
and 11.20 +/_ 1.00 pmoles cAMP produced min"1m g"1 
respective ly.
Figure 3.3.1 GPPfNhOP-Dependent Stimulation of 
Adenylate Cvciase Activity In Hepatocytes isolated From 
Control And Streptozotocin Induced Diabetic Rats
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Figure 3.3.2 GPPfNFOP-Dependent Stimulation of
Adenvlate Cvclase Activity In Hepatocytes Isolated From 
Lean And Obese Zucker Rats
Crude membrane pellets were prepared from hepatocytes 
isolated from ( □  ) lean and ( Q ) obese Zucker rats. 
Adenylate cyclase activity was assayed in the presence of 
fo r sko l i n  and inc rea s ing  c o n c e n t ra t io n s  of 
5 '-guanylyl-im idodiphosphate (GPP(NH)P). Activity is 
expressed as a percentage of forskolin stimulated 
activity in the absence of GPP(NH)P. All activities are 
expressed as mean +/_ S.E.M. values(n=3).
Basal adenylate cyclase activities were 1.14 +/_ 0.02 
and 1.24+/_ 0.09 pmoles cAMP produced min"1 mg^ for 
lean and obese rat preparations respectively. Similarly, 
forskolin stimulated activities were 17.10 +/_ 1.90
and 18.30 +/_ 2.01 pmoles cAMP produced m in '^m g ’ "1 
respective ly.
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Figure 3.3.2 GPPfNH^P-Dependent Stimulation of
Adenvlate Cvclase Activity In Heoatocvtes isolated From 
Lean And Obese Zucker Rats
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3.4 Effect of Biguanide Treatment On GPP(NH)P Regulation
of Forskolin Stimulated Adenylate Cyclase Activity
141
Figure 3.4.1 Regulation of Adenylate Cvclase Activity 
Using The Guanine Nucleotide GPPfNHIP In Hepatocvtes 
Isolated From Control Rats Undergoing Biouanide Therapy
Crude membrane pellets were prepared from hepatocytes 
isolated from control Sprague Dawley rats undergoing 
metformin therapy.
Adenylate cyclase activity was assayed in the presence 
of forskolin (10"4 M ) and increasing concentrations of 
5' - guanylyl-imidodiphosphate (GPP(NH)P) . Activity is 
expressed as a percentage of forskolin stimulated 
activity in the absence of GPP(NH)P.
All activities are expressed as mean +/_ S.E.M. values 
(n=6). ,
Basal and forsko lin  stim ulated adenylate cyclase 
activities were 1.02 +/_ 0.15 and 17.34 +/_ 2.00
pmoles cAMP produced min- "* mg- "* respectively.
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Figure 3.4.1 Regulation of Adenvlate Cvclase Activity Using
The Guanine Nucleotide GPPfNH)P in Hepatocvte Membranes 
isolated From Control Rats Undergoing Biguanide Therapy
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Figure 3.4.2 Regulation of Adenylate Cvclase Activity
Using The Guanine Nucleotide GPPfNHIP In Hepatocvtes 
Isolated From Streptozotocin induced diabetic Rats 
Undergoing Biouanide Therapy
Crude membrane pellets were prepared from hepatocytes 
isolated from streptozotocin induced diabetic Sprague 
Dawley rats undergoing metformin therapy.
Adenylate cyclase activity was assayed in the presence 
of forskolin (10"4 M ) and increasing concentrations of 
5’ - guanyiyl-imidodiphosphate (GPP(NH)P) . Activity is 
expressed as a percentage of forskolin stimulated 
activity in the absence of GPP(NH)P.
All activities are expressed as mean +/_ S.E.M. values 
(n=5).
Basal and forsko lin  stim ulated adenylate cyclase 
activities were 0.60 +/_ 0.07 and 10.50 +/_
0.30 pmoles cAMP produced min- "1 mg"^ respectively
Figure 3.4.2 Regulation of Adenvlate Cvclase Activity Using The
Guanine Nucleotide GPPfNhOP In Hepatocvtes 
isolated From Streptozotocin Induced Diabetic Rats 
Undergoing Biauanide Therapy
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Figure 3.4.3 Regulation of Adenylate Cvdase Activity
Using The Guanine Nucleotide GPPfNHIP In Hepatocvtes 
Isolated From Lean Zucker Rats Undergoing Biouanide 
Therapy
Crude membrane pellets were prepared from hepatocytes 
isolated from lean Zucker rats undergoing metformin 
therapy.
Adenylate cyclase activity was assayed in the presence 
of forskolin (10"4 M ) and increasing concentrations of 
5’ - guanylyl-imidodiphosphate (GPP(NH)P) . Activity is 
expressed as a percentage of forskolin stimulated 
activity in the absence of GPP(NH)P.
All activities are expressed as mean +/_ S.E.M. values 
(n=4).
Basal and fo rsko lin  stim ulated adenylate cyclase 
activities were 1.23 +/_ 0.10 and 19.68 +/_ 2.10
pmoles cAMP produced min""* mg""* respectively.
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Figure 3.4.3 Regulation of Adenylate Cvclase Activity
Using The Guanine Nucleotide GPPfNt-HP in Hepatocvtes 
Isolated From Lean Zucker Rats Undergoing Biguanide Therapy
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Figure 3.4.4 Regulation of Adenylate Cvclase Activity 
Using The Guanine Nucleotide GPPfNFOP In Hepatocvtes 
Isolated From Obese Zucker Rats Undergoing Biguanide 
Therapy
Crude membrane pellets were prepared from hepatocytes 
isolated from obese Zucker rats undergoing metformin 
therapy.
Adenylate cyclase activity was assayed in the presence 
of forskolin (10"4 M ) and increasing concentrations of 
5' - guanylyl-imidodiphosphate (GPP(NH)P) . Activity is 
expressed as a percentage of forskolin stimulated 
activity in the absence of GPP(NH)P.
All activities are expressed as mean +/_ S.E.M. values 
(n=5).
Basal and forsko lin  stim ulated adenylate cyclase 
activities were 1.00 +/_ 0.10 and 15.00 +/_ 2.01 
pmoles cAMP produced min-  ^ mg""* respectively.
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Figure 3.4.4 Regulation of Adenviate Cvclase Activity Using The
Guanine Nucleotide GPPfNH)P in Hepatocvtes Isolated 
From Obese Zucker Rats Undergoing Biguanide Therapy
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Figure 3.4.5 Effect of Biguanide Treatment On GPPfNHIP
- Dependent Inhibition of Forskolin Stimulated Adenviate 
Cvclase Activity In Hepatocvtes Isolated From Control 
Rats
Crude membrane pellets were prepared from hepatocytes 
isolated from Sprague Dawley rats which ( q )had or( a ) 
had not undergone metformin therapy.
Adenylate cyclase activity was assayed in the presence of 
forskolin (10"4 M) and increasing concentrations of 
5'- guanylyl-im idodiphospate (GPP(NH)P). Activity is 
expressed as a percentage of forskolin stimulated 
adenylate cyclase activity. All activities are expressed 
as mean +/_ S.E.M. values (n= 6).
Basal adenylate cyclase activities were 1.02 +/_ 0.15
and 1.30 +/- 0.10 pmoles cAMP produced min""* mg""* 
fo r trea ted and untreated anim als respective ly. 
Similarly, forskolin stimulated activities were 17.34 
+/_ 2.00 and 18.20 +/_ 2.00
pmoles cAMP produced min""* mg""* respectively.
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Figure 3.4.5 Effect of Biguanide Treatment on GPPfNt-nP-Dependent
Inhibition of Forskolin Stimulated Adenviate Cvclase Activity 
In Hepatocvtes Isolated From Control Rats
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Figure 3.4.6 Effect of Biguanide Treatment On GPPfNFhP
- Dependent Inhibition of Forskolin Stimulated Adenviate 
Cvclase A c tiv ity  In H epatocvtes Iso la ted From 
Streptozotocin Induced Diabetic Rats
Crude membrane pellets were prepared from hepatocytes 
isolated from Streptozotocin induced diabetic rats which 
(a )had or( □ ) had not undergone metformin therapy. 
Adenylate cyclase activity was assayed in the presence of 
forskolin (10"4 M) and increasing concentrations of
5'- guanylyi-im idodiphospate (GPP(NH)P). Activity is 
expressed as a percentage of forskolin stimulated 
adenylate cyclase activity. All activities are expressed 
as mean +/_ S.E.M. values (n= 5).
Basal adenylate cyclase activities were 0.60 +/_ 0.07 
and 0.64 +/_ 0.02 pmoles cAMP produced min""1
m g""1 for treated and untreated animals respectively. 
Sim ilarly, forskolin stimulated activities were 10.50 
+/_ 0.30 and 11.20 +/_1.00 pmoles cAMP produced
min""1 mg""1 respectively.
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Figure 3.4.6 Effect of Biguanide Treatment On GPPfNMP-Deoendent
Inhibition of Forskolin Stimulated Adenviate Cvclase Activity 
In Hepatocvtes Isolated From Streptozotocin induced Diabetic Rats
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Figure 3.4.7 Effect of Biguanide Treatment On GPPfNHIP 
- Dependent Inhibition of Forskolin Stimulated Adenviate 
Cvclase Activity In Hepatocvtes Isolated From Lean 
Zucker Rats
Crude membrane pellets were prepared from hepatocytes 
isolated from lean Zucker rats which ( a )had or( □ ) had 
not undergone metformin therapy.
Adenylate cyclase activity was assayed in the presence of 
forskolin (10-4 M) and increasing concentrations of 
5’- guanylyl-im idodiphospate (GPP(NFl)P). Activity is 
expressed as a percentage of forskolin stimulated 
adenylate cyclase activity. All activities are expressed 
as mean +/_ S.E.M. values (n= 4).
Basal adenylate cyclase activities were 1.23 +/_ 0.10
and 1.14 +/_ 0,02. pmoles cAMP produced min- "* mg--* 
fo r trea ted  and untreated anim als respective ly. 
Similarly, forskolin stimulated activities were 19.68 
+/_ 2.10 and 17.10 +/_ 1.90 pmoles cAMP produced
m in- "* mg""* respectively.
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Figure 3.4.7 Effect of Biguanide Treatment On GPPfNhOP-Dependent
Inhibition of Forskoiin Stimulated Adenviate Cvclase Activity 
In Hepatocvtes Isolated From Lean Zucker Rats
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Figure 3.4.8 Effect of Biguanide Treatment On GPPfNHIP -
Dependent Inhibition of Forskolin Stimulated Adenviate 
Cvclase Activity In Hepatocvtes Isolated From Obese 
Zucker Rats
Crude membrane pellets were prepared from hepatocytes 
isolated from obese Zucker rats which ( p)had o r(a  ) had 
not undergone metformin therapy.
Adenylate cyclase activity was assayed in the presence of 
forskolin (10"^ M) and increasing concentrations of 
5'- guanylyl-im idodiphospate (GPP(NH)P). Activ ity is 
expressed as a percentage of forskolin stimulated 
adenylate cyclase activity. All activities are expressed 
as mean +/_ S.E.M. values (n= 5).
Basal adenylate cyclase activities were 1.00 +/_ 0.10
and 1.24 +/_ 0.09 pmoles cAMP produced min"^ mg'"*
for trea ted  and untreated anim als respective ly . 
S im ilarly, forskolin stim ulated activ ities were 15.00 
+/_ 2.01 and 18.30 +/_ 2.01 pmoles cAMP produced
m in "’* mg""* respectively.
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Figure 3.4.8 Effect of Biguanide Treatment On GPPfNmP Mediated
inhibition of Adenviate Cvciase Activity in Hepatocvtes Isolated
From Obese Zucker Rats
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Figure 3.4.9 Effect of Biguanide Therapy On GPPfNHIP
Mediated Stimulation of Adenviate Cvclase Activity In 
Hepatocvtes Isolated From Control Rats
Hepatocytes were isolated from ( n ) Metformin treated 
and ( 0 )  non treated Sprague Dawiey rats.
Crude membrane pellets were prepared and adenylate 
cyclase activity assayed in the presence of forskolin 
( 1 0 " 4  M) and in c reas ing  con cen tra tion s  of 
5!-guanylyl-imdodiphosphate (GPP(NH)P).
Activity is expressed as a percentage of forskolin 
stimulated activity in the absence of GPP(NH)P. All 
activities are given as mean +/_ S.E.M. values (n= 6 ).
Basal adenylate cyclase activities for metformin treated 
and untreated animal preparations were 1.02 +/_ 0.15 
and 1.30 +/_ 0.10 pmoles cAMP produced min""' mg""' 
respectively. S im ilarly, forskolin stimulated activities 
were 17.34 +/_ 2.00 and 18.20 +/_ 2.00 pmoles
cAMP produced min""' mg'"' respectively.
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Figure 3.4.9 Effect of Biguanide Therapy On GPPfNl-HP
Mediated Stimulation of Adenviate Cvclase Activity in
Hepatocytes Isolated From Control Rats
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Figure 3.4.10 Effect of Biguanide Therapy On GPPfNhOP
Mediated Stimulation of Adenviate Cvclase Activity In 
Hepatocvtes Isolated From Streptozotocin Induced 
Diabetic Rats
Hepatocytes were isolated from ( B ) Metformin treated 
and (U) non treated diabetic rats.
Crude membrane pellets were prepared and adenylate 
cyclase activity assayed in the presence of forskolin 
( 1 0 " 4  M) and in c rea s ing  co n ce n tra tio n s  of 
5'-guanylyl-imdodiphosphate (GPP(NH)P).
Activity is expressed as a percentage of forskolin 
stimulated activity in the absence of GPP(NH)P. All 
activities are given as mean +/_ S.E.M. values (n= 5).
Basal adenylate cyclase activities for metformin treated 
and untreated animal preparations were 0.60 +/_ 0.07 
and 0.64 +/_ 0.02 pmoles cAMP produced min""  ^ mg"^
respectively. S im ilarly, forskolin stimulated activities 
were 10.50 +/_ 0.30 and 11.20 +/_ 1.00 pmoles cAMP
produced. min“ "Lmg“ !  respectively.
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Figure 3.4.10 Effect of Biguanide Therapy On GPPfNmP
Mediated Stimulation of Adenviate Cvclase Activity in 
Hepatocvtes isolated From Streptozotocin Inrinreri 
Diabetic Rats
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Figure 3.4.11 Effect of Biguanide Therapy On GPP(NH)P
Mediated Stimulation of Adenviate Cvclase Activity in 
Hepatocvtes Isolated From Lean Zucker Rats
Hepatocytes were isolated from ( U ) Metformin treated 
and (D  ) non treated lean Zucker rats.
Crude membrane pellets were prepared and adenylate 
cyclase activity assayed in the presence of forskolin 
( 1 0 ~ 4  M) and inc rea s ing  con cen tra tions  of 
5’-guanylyl-imdodiphosphate (GPP(NH)P).
Activity is expressed as a percentage of forskolin 
stimulated activity in the absence of GPP(NH)P. All 
activities are given as mean +/_ S.E.M. values (n= 4).
Basal adenylate cyclase activities for metformin treated 
and untreated animal preparations were 1.23 +/_ 0.10 
and 1.14 +/_ 0.02 pmoles cAMP produced min- "* mg- "* 
respectively. S im ilarly, forskolin stimulated activities 
were 19.68 +/_ 2.10 and 17.10 +/_ 1.90 pmoles
cAMP produced min- "* mg-"* respectively.
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Figure 3.4.11 Effect of Biguanide Therapy On GPPfNl-HP
Mediated Stimulation of Adenviate Cvciase Activity In
Hepatocvtes Isoiated From Lean Zucker Rats
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Figure 3.4.12 Effect of Biguanide Therapy On GPPfNHIP
Mediated Stimulation of Adenviate Cvclase Activity In 
Hepatocvtes Isolated From Obese Zucker Rats
Hepatocytes were isolated from ( g ) Metformin treated 
and (0  ) non treated obese Zucker rats.
Crude membrane pellets were prepared and adenylate 
cyclase activity assayed in the presence of forskolin 
( 1 0 - 4 M) and inc reas ing  co ncen tra tion s  of 
5'-guanylyl-imdodiphosphate (GPP(NH)P).
Activity is expressed as a percentage of forskolin 
stimulated activity in the absence of GPP(NH)P. All 
activities are given as mean +/_ S.E.M. values (n= 5).
Basal adenylate cyclase activities for metformin treated 
and untreated animal preparations were 1.00 +/_ 0.10 
and 1.24 +/_ 0.09 pmoles cAMP produced min- ** mg- ** 
respectively. S im ilarly, forskolin stimulated activities 
were 15.00 +/_ 2.01 and 18.30 +/_ 2.01 pmoles
cAMP produced min- ** mg-** respectively.
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Figure 3.4.12 Effect of Biguanide Therapy On GPPfNhDP 
Mediated Stimulation of Adenviate Cvclase Activity In 
Hepatocvtes Isolated From Obese Zucker Rats
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3.5 Glucagon Stimulated Adenylate Cyclase Activity In The 
Presence And Absence of Pertussis Toxin Treatment
154
Figure 3.5.1 Effect of Streptozotocin Induced Diabetes On 
Glucagon Stimulation of Adenylate Cvclase Activity In 
Isolated Hepatocvtes
Crude membrane pellets were prepared from hepatocytes 
isolated from ( p  ) control and (a ) streptozotocin induced 
diabetic Sprague Dawley rats.
Adenylate cyclase activity was assayed in the presence 
of GTP (ICT^M) and increasing concentrations of glucagon. 
Activity is expressed as fold stimulation over basal (GTP 
alone ) activity and values presented are mean +/_ S.E.M. 
values (n=5).
Basal adenylate cyclase activ ities for membranes 
prepared from control and diabetic animals were 1.82 
+/_ 0.10 and 0.90 +/_ 0.06 pmoles cAMP produced
min""l mg-1 respectively.
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Figure 3.5.1 Effect of Streptozotocin Diabetes
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Figure 3.5.2 Effect of Diabetic State On Glucaaon
Stimulation of Adenylate Cvclase Activity In Isolated 
Hepatocvtes
Crude membrane pellets were prepared from hepatocytes 
isolated from ( ej ) control and ( o ) streptozotocin induced 
diabetic and ( a )  insulin treated diabetic Sprague 
Dawley rats.
Adenylate cyclase activity was assayed in the presence 
of GTP ( lO '^ M ) and increasing concentrations of glucagon. 
Activity is expressed as fold stimulation over basal (GTP 
alone ) activity and values presented are mean +/_ S.E.M. 
values (n=5).
Basal adenylate cyclase activ ities for membranes 
prepared from control , diabetic and insulin treated 
animals were 1.82 +/_ 0.10 , 0.90 +/_ 0.06 and
0.95 +/_ 0.07 pmoles cAMP produced min'"* mg""1
respective ly.
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Figure 3.5.2 Effect of Diabetic State On Glucaaon
Stimulation of Adenylate Cvciase Activity In Isolated 
Heoatocvtes
40 r
91 0 8 6- 7Zero
Log[Glucagon] M
156
Figure 3.5.3 Effect of Pertussis Toxin On Glucaaon
S tim u la tio n  of A deny la te  C vclase A c tiv ity  In 
Hepatocvteslsolated From Control Rats
Crude membrane pellets were prepared from hepatocytes 
isolated from control Sprague Dawley rats ( *  ) with, or 
( a ) without pertussis toxin pretreatment.
Adenylate cyclase activity was assayed in the presence 
of GTP (ICT^M) and increasing concentrations of glucagon. 
Activity is expressed as fold stimulation over basal (GTP 
alone ) activity and values presented are mean +/_ S.E.M. 
values (n=5).
Basal adenylate cyclase activity for membranes prepared 
from non treated and treated hepatocytes were 1.82 
+/_ 0.10 and 1.90 +/_. 0.20 pmoles cAMP produced
m in- "* mg"** respectively.
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Figure 3.5.3 Effect of Pertussis Toxin On Glucaaon
Stimulation of Adenylate Cyclase Activity In 
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Figure 3.5.4 Effect of Pertussis Toxin On Glucaaon
Stimulation of Adenylate Cvclase Activity In Hepatocytes 
Isolated From Streptozotocin Induced Diabetic Rats
Crude membrane pellets were prepared from hepatocytes 
isolated from diabetic Sprague Dawley rats ( 0 ) with, or 
( 0 ) without pertussis toxin pretreatment.
Adenylate cyclase activity was assayed in the presence 
of GTP (ICT^M) and increasing concentrations of glucagon. 
Activity is expressed as fold stimulation over basal (GTP 
alone ) activity and values presented are mean ■+/_ S.E.M. 
values (n=5).
Basal adenylate cyclase activity for membranes prepared 
from non treated and treated hepatocytes were 0.90 
+/_ 0.06 and 0.95 +/_ 0.08 pmoles cAMP produced
min""* mg""* respectively.
fol
d 
st
im
ul
at
io
n 
Ov
er
 B
as
al
 A
ct
iv
ity
Figure 3.5.4 Effect of Pertussis Toxin On Glucaaon
Stimulation of Adenylate Cvclase Activity In Hepatocytes 
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Figure 3.5.5 Glucaaon Dose Dependent Stimulation of
Adenylate Cvclase Activity In Hepatocytes Pretreated 
with Pertussis Toxin And Isolated From Streptozotocin 
Induced Diabetic And Control Rats
Hepatocytes were isolated from ( $ )diabetic and ( q ) 
controlSprague Dawley rats and pretreated with pertussis 
toxin. Crude membrane pellets were prepared and 
adenylate cyclase activity was assayed in the presence 
of GTP (10“4 M) and increasing concentrations of glucagon. 
Activity is expressed as fold stimulation over basal (GTP 
alone ) activity and values presented are mean +/_ S.E.M. 
values (n=5).
Basal adenylate cyclase activities for pertussis toxin 
treated membranes prepared from control and diabetic 
animals were 1.90 +/__ 0.20 and 0.95 +/_ 0.08
pmoles cAMP produced min"^ mg"** respectively.
Figure 3.5.5 Glucaaon Dose Dependent Stimulation of Adenvlate 
Cvclase Activity In Hepatocytes Pretreated With 
Pertussis Toxin And Isolated From Streptozotocin Induced
Diabetic And Control Rats
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Figure 3.5.6 Effect of Pertussis Toxin Treatment On
Glucaaon Stimulation of Adenylate Cvclase Activity In 
Hepatocytes Isolated From Diabetic, Insulin Treated 
Diabetic And Control Rats
Hepatocytes were isolated from ( £1 )diabetic , ( o ) 
insulin treated diabetic and ( a ) controlSprague Dawley 
rats These hepatocytes were pretreated with pertussis 
toxin and crude membrane pellets were prepared . 
Adenylate cyclase activity was assayed in the presence 
of GTP (10"4 M) and increasing concentrations of glucagon. 
Activity is expressed as fold stimulation over basal (GTP 
alone ) activity and values presented are mean +/_ S.E.M. 
values (n=5).
Basal adenylate cyclase activities for pertussis toxin 
treated membranes prepared from control diabetic and 
insulin treated diabetic animals were 1.90 ■+/__ 0.20 ,
0 .95+/_  0.08 and 1.00+/_ 0.08 pmoles cAMP produced
min"1 mg--' respectively.
Figure 3.5.6 Effect of Pertussis Toxin Treatment On Glucaaon
Stimulation of Adenylate Cvclase Activity In Hepatocytes 
Isolated From Diabetic. Insulin Treated Diabetic
And Control Rats
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Figure 3.5.7 Glucaaon Stimulation of Adenylate Cvclase
Activity In Hepatocytes Isolated From Lean And obese 
Zucker Rats
Hepatocytes were isolated from ( 0 )lean and ( 9 ) obese 
Zucker rats Crude membrane pellets were prepared and 
adenylate cyclase activity was assayed in the presence 
of GTP (10"^M) and increasing concentrations of glucagon. 
Activity is expressed as fold stimulation over basal (GTP 
alone ) activity and values presented are mean +/_ S.E.M. 
values (n=5).
Basal adenylate cyclase activities for membranes 
prepared from lean and obese animals were 1.60 
+/_ 0.12 and 1.74 +/_ 0.20 pmoles cAMP produced min"1 
m g’ ’* respectively.
Figure 3.5.7 Glucaaon Stimulation of Adenvlate Cvclase Activity In
Hepatocytes Isolated From Lean And Obese Zucker Rats
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Figure 3.5.8 Effect of Pertussis Toxin On Glucaaon 
Stimulation of Adenylate Cvclase Activity In Hepatocytes 
Isolated From Lean Zucker Rats
Crude membrane pellets were prepared from hepatocytes 
and pretreated ( e )with or ( o ) without pertussis toxin. 
Adenylate cyclase activity was assayed in the presence 
of GTP (10“^M) and increasing concentrations of glucagon. 
Activity is expressed as fold stimulation over basal (GTP 
alone ) activity and values presented are mean +/_ S.E.M. 
values (n=5).
Basal adenylate cyclase activ ities for membranes 
prepared from pertussis toxin treated and untreated 
hepatocytes were 1.64 +/_ 0.04 and 1.60 +/_ 0.12
pmoles cAMP produced min""1 mg“1 respectively.
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Figure 3.5.8 Effect of Pertussis Toxin on Glucaaon
Stimulation of Adenvlate Cvclase Activity In Hepatocytes Isolated 
From Lean Zucker Rats
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Figure 3.5.9 Effect of Pertussis Toxin On Glucaaon 
Stimulation of Adenylate Cvclase Activity In Hepatocytes 
Isolated From Obese Zucker Rats
Crude membrane pellets were prepared from hepatocytes 
and pretreated ( a )with or ( & ) without pertussis toxin. 
Adenylate cyclase activity was assayed in the presence 
of GTP (10"4 M) and increasing concentrations of glucagon. 
Activity is expressed as fold stimulation over basal (GTP 
alone ) activity and values presented are mean +/_ S.E.M. 
values (n=5).
Basal adenylate cyclase activities for membranes 
prepared from pertussis toxin treated and untreated 
hepatocytes were 1.80 +/_ 0.12 and 1.74 +/_ 0.20
pmoles cAMP produced min'"* mg""* respectively.
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Figure 3.5.9 Effect of Pertussis Toxin On Glucaaon
Stimulation of Adenviate Cvclase Activity in Heoatocvtes 
Isolated From Obese Zucker Rats
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Figure 3.5.10 Glucaaon Stimulation of Adenylate Cvclase
Activity In Hepatocytes isolated From Zucker Rats And 
Pretreated With Pertussis Toxin
Hepatocytes were isolated from ( a  )lean and ( a ) obese 
Zucker rats . Hepatocytes were pretreated with pertussis 
toxin and crude membrane pellets were prepared . 
Adenylate cyclase activity was assayed in the presence 
of GTP (ICT^M) and increasing concentrations of glucagon. 
Activity is expressed as fold stimulation over basal (GTP 
alone ) activity and values presented are mean +/_ S.E.M. 
values (n=5).
Basal adenylate cyclase activities for membranes 
prepared from lean and obese animals after pertussis 
toxin treatment were 1.64 +/_ 0.14 and 1.80 +/_
0.12 pmoles cAMP produced min""1 mg""1 respectively.
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Figure 3.5.10 Glucaaon Stimulation of Adenvlate Cvclase 
Activity in Hepatocytes isolated From Zucker Rats And 
Pretreated With Pertussis Toxin
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3.*6 Gi Quantification In Control And Diabetic States
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Figure 3.6.1 Quantification of GioC In Type I Diabetic, 
Insulin Treated And Control Hepatocyte Membrane 
Preparations
Mr (x10~3 )
97
68
■25
D.F.
<----- oCQi
0 P A 1 7.^ „ -1 ■
1 pmoles GicC mg protei:
V-0.2 +/-0.4 +/-0.5-
Track a = Streptozotocin diabetic plasma membranes 
Track b = Insulin treated streptozotocin diabetic plasma 
membranes
Track c = control plasma membranes
166
Figure 5«&.2 Quantification of Gi In Hepatocyte Membranes 
Prepared From Lean & Obese Zucker Rats
Mr (XtO“3)
— -66
— 43
Qri oC
— 25
— “Dye Front
Track a = Lean Zucker rat preparations 
Track b = Obese Zucker rat preparations
The identity of the higher molecular weight band (' approx. 60KDa) 
is unknown , but as the antibody used to recognize GiOC was 
affinity purified prior to use, it is believed , to be a .form of 
Gi c< present in these rat preparations, but this -form.of ..Gi©( was 
hot apparaht in the Sprague Dawley fat species-
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3.7 Characterization of Gs Function
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Discussion of Results
The non-hydrolyzable analogue, GPP(NH)P, has been used 
to demonstrate specific activation of two distinct G proteins 
which characteristically regulate adenylate cyclase activity. 
These two G proteins; Gi and Gs, which inhibit and stimulate 
adenylate cyclase activity respectively, are selectively 
activated by the nucleotide as a result of their differing 
affinities to bind the nucleotide.
Characteristically by sequentially activating each G 
protein , biphasic GPP(NH)P dose response curves are obtained 
(see figures 3.1.1 - 3.1.5 ). When each G protein activation 
"phase" is separated out , it can be clearly observed that Gi 
activation is abolished in the chemically-induced type I diabetic 
model. This abolition of Gi function occurred when two different 
drugs; streptozotocin (figure 3.2.2) and alloxan ( figure 
3.2.3) were used independently to destroy B cell function. This 
suggests that the diabetic condition rather than the drugs 
themselves are causing Gi function to be lost. Indeed, when 
insulin therapy was administered to streptozotocin induced 
diabetic rats, Gi function was restored in hepatic membrane 
preparations. However, the maximum inhibition of adenylate 
cyclase activity achieved under these conditions was reduced from 
42$ ( controls) to 27$ ( insulin treated diabetic preparations).
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This may be due to the rather crude experimental procedure 
adopted to reverse the diabetic condition by insulin 
administration. Insulin was administered by daily intramuscular 
injection of 10I.U. of an insulin-zinc suspension to each 250g 
rat. This dose of insulin appeared to normalize blood glucose 
levels to those found in control animals (4.6 +/- 0.6 mM) and 
glycosuria was not observed within 24-48 h after initial insulin 
administration. However, it is possible that this dose of 
insulin could have been rather high when compared to other
workers (Chatzipanteli & Saggerson 1983). Although the same 
maximal Gi activity was not observed, the concentration of 
GPP(NH)P which elicited 1/2 maximal inhibition (ie. 1/2 maximal 
Gi activation) was comparable in the reversed diabetic state and 
controls. This 1/2 maximal Gi activation is estimated to occur 
with a GPP(NH)P concentration of O.SnM ,compared with 0.1nM for 
controls. It would appear therefore that the affinity for
GPP(NH)P binding to Gi was not significantly altered.Therefore, 
the suggestion that the reduced maximal Gi function may be
reflective of reduced levels of Gi protein itself rather than
changes in the nucleotide binding affinity may be proposed .
When the Gi function profiles for lean and obese Zucker 
rats are examined (see figures 3.2.6 - 3.2.8 ) it is clear
that the same trends are observed. In lean (control) Zucker rat 
membranes GPP(NH)P activates Gi to the same extent (40 % ) with
-j
a comparable 1/2 maximal concentration of 1nM. However, in 
the type II diabetic model (the obese Zucker rat) , Gi function
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is once again abolished. These obese Zucker rats are 
characteristically hyperinsulinaemic (see section 1. 1.4 ) . 
Therefore this Gi function abolition cannot be due to insulin 
deficiency as proposed in the type I diabetic model above.
In summary therefore, in both models of type I and type 
II diabetes the activation of hepatic Gi mediated by low 
concentrations of the guanine nucleotide GPP(NH)P is abolished. 
Insulin administration to chemically induced (type I) diabetic 
rats partially restores hepatic Gi function. Preliminary evidence 
suggested that insulin deficiency in type I diabetic animals 
reduced the levels of Gi protein in hepatic plasma membranes.
Hepatic Gi function in the type II diabetic model (the 
obese Zucker rat) was also absent. The control for this diabetic 
model ( the lean Zucker rat) exhibited a slightly higher K0.5
value fo Gi function , but a maximal activity value which is
comparable to those obtained in control Sprague rats. It is 
therefore suggested that the mechanism by which hepatic Gi 
activity is abolished in these two diabetic models may be 
different. In the type I diabetic model, insulin deficiency 
prevails. Reversal of this condition significantly reverses 
the Gi function loss. In the type II diabetic model 
hyperinsulinaemia is characteristic.
Using high concentrations of GPP(NH)P it was possible
to activate the G protein Gs. As Gs activation of adenylate
cyclase is synergistic with forskolin stimulation of adenylate 
cyclase ( Seamon & Daly 1986) it is possible to observe 
activation of this G protein in the presence of this diterpene.
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Figure 3.3.1 demonstrates that inducement of the type I 
diabetic state using the compound streptozotocin had no 
significant effect upon Gs activation by high concentrations of 
the nucleotide. Similarly using this technique there appeared to 
be no significant difference between hepatic Gs function in lean 
and obese ( type II diabetic model) Zucker rats. It is therefore 
proposed that hepatic Gs function in both models of diabetes 
remains unaltered. This observation is very encouraging because 
it suggests that alterations in G protein function in these 
diabetic models are specific and not necessarily reflective of a 
wholely dysfunctional adenylate cyclase system.
Throughout my studies with type I diabetic animal 
preparations, it was very noticeable that the basal (resting) 
adenylate cyclase activities were routinely about half the value 
of those for control animals. Similarly the forskolin stimulated 
activities were also about half the level in diabetic (type I) 
animal preparations than those in controls. The reason for this 
is unknown, but I would suggest that this could be a reflection 
of a reduction in the absolute amount of the catalytic unit in 
the insulin deficient state. For this reason all data in this 
chapter is expressed as a percentage of the basal or forskolin 
stimulated states. The fold stimulation of adenylate cyclase 
activity over the basal activity for control and type I diabetic 
states show no significant differences in the presence of 
forskolin ( see table 2). Therefore as Gs activation and the
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forskolin fold stimulation of adenylate cyclase activities are 
comparable in each system, it is suggested that activities of Gs 
and C (the catalytic unit) remain unaltered.
The type II diabetic preparations did not show reduced 
adenylate cyclase activities when compared with controls (the 
lean Zucker rat).However, once again only a Gi dysfunction is 
proposed.
As an "internal" control, the effect of TPA and 
pertussis toxin upon Gi function was investigated. Both these-
compounds have been shown to attenuate Gi function (Katada et_ al_ 
1985; Watanbe et_ al_ 1985; Aktories et al 1983). Thus in both the 
Sprague and Zucker rat preparations ( figures 3.2.4 and 3.2.7 )
these agents were observed to abolish this GPP(NH)P mediated 
inhibition of adenylate cyclase activity . Hence, it is believed 
that this apparent GPP(NH)P mediated inhibition is indeed due to 
the activation of Gi alone.
The effect of the hypoglycaemic drug metformin was 
investigated with respect to its effect upon GPP(NH)P mediated 
inhibition and stimulation of adenylate cyclase activity. 
Metformin therapy appeared to reduce the maximal inhibition of 
adenylate cyclase activity from 42$ in control animal 
preparations to 20$ in metformin treated animal preparations. 
The estimated concentration at which 1/2 maximal inhibition was 
attained was not significantly altered (0.1 & 0.3 nM for control 
and metformin treated respectively). The streptozotocin induced 
type I diabetic preparations (figure 3.4.6) still showed no Gi
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function irrespective of metformin treatment. The type II 
diabetic preparations (figures 3.4.7 and 3.4.8) showed similar 
trends to the Sprague rat preparations. That is, the maximal 
inhibition observed in the metformin treated animal preparations 
was reduced from 45 % (in non-treated treated lean Zucker rats) 
to 20 % ( in metformin treated lean Zucker rat
preparations). However, this time the concentration of GPP(NH)P 
eliciting 1/2 maximal inhibition was reduced from 1nM (control 
preparations) to 0.1nM (metformin treated preparations). 
Metformin treatment did not restore Gi function in the obese 
Zucker (type II diabetic model) rat preparations.
Metformin therapy was also found to have no significant 
effect upon stimulation of adenylate cyclase activity using high 
concentrations of GPP(NH)P in control or diabetic type I 
preparations . However, this drug did reduce the maximal
activation of Gs in the obese Zucker (type II diabetic model) 
rat preparations. The reason for this is unknown.
From this section of work it was therefore concluded
that metformin did not restore hepatic Gi function in the 
diabetic state preparations. Indeed, in controls it reduce the 
maximal inhibition of adenylate cyclase activity elicited by Gi. 
Also, this drug did not alter Gs function in controls or type I 
diabetic preparations. However, the .type II diabetic model 
preparations exhibited a reduced maximal Gs stimulation of 
adenylate cyclase activity.
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In order to confirm the proposal of altered hepatic Gi 
function in the type I and II diabetic models used ,the effect of 
pertussis toxin pretreatraent of hepatocytes was investigated. The 
rationale being that if hepatic Gi function is not present in 
these diabetic model states, then pertu ssis toxin ( which 
attenuates Gi function) should have no appreciable effect upon 
the adenylate cyclase system in these preparations. As adenylate 
cyclase is under the dual control of Gi and Gs in ’’normal” 
systems, if Gi ’’input” is removed by pertussis toxin treatment, 
then Gs stimulation of the system should be enhanced.
Figure 3.5.1 demonstrates that maximal glucagon 
stimulation of adenylate cyclase activity in control Sprague 
Dawley rat preparations was 20 fold over basal with an estimated 
K q j. of 10nM. However, the chemically induced diabetic animal 
preparations exhibited a maximal glucagon stimulation of 30 fold 
over basal with a Kg ^ of 9nM (figure 3*5.2).
Pertussis toxin pretreatment of control hepatocytes 
resulted in an enhanced maximal glucagon stimulation of adenylate 
cyclase activity of 25 fold over basal with an estimated K q ^ of 
10nM (figure 3.5.3). However, pertussis toxin had no effect upon 
glucagon stimulation in the chemically induced diabetic rat 
hepatocyte preparations ( figure 3.5.4).
Also, when pertussis toxin pretreated hepatocyte preparations 
from both control and type I diabetic rats are compared the 
glucagon dose response curves areAsuperimposable (figure 3*5.5). 
The insulin treated diabetic rat hepatocyte preparations
1 77
displayed a slightly elevated maximal glucagon stimulation of 
adenylate cyclase activity when compared with controls, but less 
so than that observed in the type I untreated diabetic
state (figure 3.5.2).
Thus, it would appear that the proposal that hepatic Gi 
function is abolished in the type I model of diabetes is in 
agreement with the pertussis toxin studies undertaken.
Hepatic glucagon stimulation of adenylate cyclase 
activity in both lean and obese zucker rat preparations exhibited 
similar characteristics to those observed in the Sprague Dawley 
rat control preparations. That is, maximal glucagon stimulation 
was 17 and 20 fold over basal for lean and obese zucker rat 
preparations respectively (figure 3.5.7). Pertussis toxin 
pretreatment of hepatocytes from lean Zucker rats exhibited an 
enhanced maximal glucagon stimulation of adenylate cyclase 
activity. The elevated stimulation was 24 fold over basal and 
the estimated was unaltered at 10nM (figure 3.5.8).
However, pertussis toxin pretreatment of hepatocytes isolated 
from obese Zucker rats (the typell diabetic model) did not result 
in an elevated maximal glucagon stimulation of adenylate cyclase 
activity (figure 3.5.9). In fact, the two curves displaying 
glucagon dose dependent stimulation of adenylate cyclase activity 
for non-treated and pertussis toxin treated hepatocytes 
from these animals were superimposable.
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In summary therefore, it appears that pertussis toxin 
pretreatment of hepatocytes isolated from the type II diabetic 
model , the obese Zucker rat, has no ability to enhance hepatic 
glucagon stimulation of adenylate cyclase activity because Gi 
function is already abolished. However, as no enhanced glucagon 
responsive state was apparent in the non-pertussis toxin treated 
hepatocytes from these animals, it would appear that the 
mechanism by which Gi function is abolished may be different from 
that observed in the type I diabetic model state.
In order to distinguish whether Gi function was lost in 
these diabetic animals as a result of reduced synthesis of the 
protein or else due to a covalent modification of this protein , 
collaboration with Dr. G. Milligan ( also in the Biochemistry 
department at Glasgow university) was undertaken. Dr. Milligan
had an antibody raised against a ten amino acid peptide sequence 
found in the oL subunits of Gi and transducin. As transducin has 
only been isolated from rod outer segments, this antibody only 
recognised Gi in liver . Plasma membranes were purified from 
isolated hepatocytes as described in section 2. 13 and Dr. 
Milligan quantified G i ^  in membranes prepared from all control 
and diabetic animal types using a Western blotting technique. 
This technique involved the separation of membrane proteins using 
SDS polyacrylamide gel electrophoresis , followed by transference 
of proteins to nitrocellulose and specific recognition of the Gi 
subunit protein using the antibody and appropriate stain.
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The results obtained are illustrated in figures 3*6.1 
and 3*6.2 . Figure 3.6.1 shows the relative amounts of Gict
found in streptozotocin diabetic, insulin treated streptozotocin 
diabetic and control preparations. It can be clearly seen that 
there is no appreciable Gi oi protein in the plasma membranes 
isolated from diabetic animals. Insulin reversal of the diabetic 
state brought back Gi<X. protein in hepatocyte membranes by about 
50 % when compared to control levels of the protein. This is in 
good agreement with the Gi functional studies which demonstrated 
a return of Gi function after insulin treatment by approximately 
60 %.
Figure 3.6.2 demonstrates that the levels of Gi 
protein in plasma membranes prepared from lean and obese Zucker 
rats were not significantly different. Therefore it appears that 
although Gi function is lost in obese Zucker rat preparations , 
Gi 0( protein is not reduced in plasma membranes from these 
preparations.
I would therefore suggest that hepatic Gi function in 
the type I diabetic animal model is abolished because Gi 
synthesis is prevented. However, hepatic Gi function in obese 
Zucker rat preparations is abolished , but Gi levels in these 
hepatocyte plasma membranes are "normal". Therefore I suggest 
that Gi function is absent in these membranes because there may 
be a modification of the protein which results in attenuated 
activity . The antibody used to recognize Gi also recognizes the 
protein when it is ribosylated or phosphorylated.
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It would be tempting to speculate that in the 
hyperinsulinaemic obese Zucker rat , the constantly high levels 
of insulin in the blood stream could have triggered the 
phosphorylation of the G protein Gi. Certainly, in vitro studies 
have demonstrated that the insulin receptor kinase has the 
ability to phosphorylate Gi . However, more studies would be 
required to determine more convincingly the kind of covalent 
modification occurring in these membranes.
Finally, as these obese zucker rat preparations do not 
exhibit an enhanced glucagon stimulated adenylate cyclase 
activity in the presence or absence of pertussis toxin 
pretreatment, I would suggest that this proposed Gic( subunit 
modification prevents the reassociation of B subunits to form 
the holomeric Gi protein complex and thereby does not allow Gi 
to act as a "sink" for these B ^  subunits. Therefore, by mass 
action, once the Gs subunits are released they may reassociate 
with the free B ^ Y which would "normally" be complexed with Gi 
subunits as a result of the pertussis toxin pretreatment. 
Therefore no enhancement of glucagon stimulated adenylate cyclase 
activity would be observed. To test this hypothesis of course, 
an antibody directed against B 'Y subunits would be required to 
quantify free B "Y levels in each control and diabetic state. As 
there is a constantly elevated glucagon stimulated state in the 
chemically induced diabetic model, I would suggest that B /Y 
levels in these preparations are reduced. I am therefore 
proposing that insulin has the ability (mechanism unknown) to
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regulate both the expression of Gi and B^X subunits in rat 
hepatocyte plasma membranes.
Finally, Tables 2 and 3 demonstrate that although the 
basal adenylate cyclase activity in hepatocyte plasma membranes
derived from type I diabetic animals was half that found in
control animals, the fold stimulation elicited by forskolin 
(0.1mM), GTP (0.1mM), and NaF (15mM) in the presence or absence 
of metformin treatment was not significantly altered. Therefore, 
it is suggested that the only component in the hepatic adenylate 
cyclase system which is altered in the diabetic state is Gi . Gs
and C appear to be functionally "normal". The reason for the
reduced adenylate cyclase activity in the chemically induced 
diabetic animals is unknown. However, this may reflect reduced 
amounts of the catalytic unit or a general change in enzyme 
activities within the plasma membrane as a result of altered 
physical properties of the membrane structure itself .
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4. Insulin Mediated Inhibition of Hepatic Adenylate Cyclase
Activity In Control And Diabetic States
133
Introduction
Insulin was first shown to have the ability to inhibit 
glucagon and GTP stimulated adenylate cyclase activity by 
Heyworth et al (1983). This action of insulin was demonstrated 
to be dependent upon the insulin and glucagon concentrations 
used. When a glucagon concentration greater than 1nM is used, 
insulin’s ability to inhibit adenylate cyclase activity is 
significantly reduced.
As this action of insulin was dependent upon guanine 
nucleotide concentration, this process is proposed to involve a G 
protein. I have attempted to investigate this action of insulin 
in control and diabetic states. This process could be considered 
as providing an index by which to assess insulin sensitivity in 
hepatocytes with respect to one insulin action. Therefore the 
effect of the hypoglycaemic drug , metformin, was investigated.
As pertussis toxin and the phorbol ester TPA have been 
shown to attenuate Gi activity, these compounds were used to try 
to establish whether this insulin mediated process involes this G 
protein.
Additional Methods
All studies, with the exception of experiments using 
TPA and pertussis toxin , were carried out using sucrose gradient 
purified liver plasma membranes (see section 2.14). TPA and 
pertussis toxin experiments were carried out using isolated 
hepatocyte crude membrane pellets (see section 2.8 - 2.12).
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Animal treatments are described in section 2.3 - 2.6.
Monocomponent porcine insulin and porcine glucagon were used
o
throughout. Adenylate cyclase activity was assayed at 30 C for 12 
min using a final membrane protein concentration of 50 - 60
pg/ml.
Pertussis toxin was incubated with hepatocyte
suspensions for 1 h using the procedure outlined in section 2.12
at a final concentration of 100ng / ml. TPA was incubated with
hepatocyte suspensions for 0 - 15 min at a final concentration of
o.1ng / ml. At each time point, a 1ml sample of the suspension
o
was removed and centrifuged at I4,000g for 6 min at 4 C. The
av
hepatocyte pellet was then washed twice with ice - cold KHCO pH
3
7 and the final lysed cellular pellet was resuspended to an
appropriate volume and assayed for Gi and insulin mediated
inhibition of adenylate cyclase activity. Only the
-8
concentrations of insulin (10 M) and glucagon ( 0.5nM) eliciting 
maximal response in these two processes were used in these 
studies.
Finally , the effect of metformin incubation with 
hepatocytes isolated from Sprague Dawley control rats was 
investigated. A series of metformin concentrations were 
incubated with a suspension of hepatocytes for 5 min. Samples 
were then extracted ,washed and the cells lysed.A crude membrane 
pellet was prepared and basal adenylate cyclase activity was 
assessed.
"n^ refers to the number1 of independent membrane
preparations used unless otherwise stated.
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Figure 4.1 Insulin Mediated Inhibition of Adenylate
Cvclase Activity In Liver Membranes Prepared From 
Control Rats
Liver plasma membranes were prepared from control 
Sprague Dawley rats as outlined in Materials & Methods. 
Adenylate Cyclase Activity was assayed for 12 min at 
30°C in the presence of GTP (10"^M) , glucagon 
(5 x 10"10 M) and increasing concentrations of insulin. 
Inhibition is shown as a percentage of adenylate cyclase 
activity in the presence of GTP and glucagon , but in the 
absence of insulin .
Basal (GTP alone) specific activity was10.47 +/- 0.36 
and glucagon stimulated activity in the presence of GTP 
was 15.71 +/- 1.21 pmoles cAMP produced /min/mg. 
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Figure 4.1 Insulin Mediated Inhibition of Adenvlate
Cvclase Activity In Liver Membranes Prepared 
From Control Rats
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Figure 4.2 Effect of Streptozotocin Induced Diabetes On
Insulin's Ability To Inhibit Adenviate Cvciase Activity In 
Liver Membranes
Liver plasma membranes were prepared from ( n  )control 
and (m )Streptozotocin - induced diabetic Sprague Dawley 
rats as outlined in Materials & Methods.
Adenylate Cyclase Activity was assayed for 12 min at 
30°C in the presence of GTP (10"^M) , glucagon 
(5 x 10“ 10 M) and increasing concentrations of insulin. 
Inhibition is shown as a percentage of adenylate cyclase 
activity in the presence of GTP and glucagon , but in the 
absence of insulin .
Basal (GTP alone) specific activities were 10.47 +/-
0.36 and 5.24 +/- 0.19 pmoles cAMP produced /min/mg
for control and diabetic preparations respectively.
Similarly, glucagon stimulated activities in the presence
of GTP were 15.71 +/- 1.21 and 7.65 +/- 0.51 pmoles
cAMP produced /min/mg respectively.
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Figure 4.3 Effect of Alloxan Induced Diabetes On Insulin's
Ability To Inhibit Adenylate Cvclase Activity in Liver 
Membranes
Liver plasma membranes were prepared from ( a  )control 
and (m )Alloxan - induced diabetic Sprague Dawiey rats as 
outlined in Materials & Methods.
Adenylate Cyclase Activity was assayed for 12 min at 
30°C in the presence of GTP (10“^M) , glucagon 
(5 x 10-10 M) and increasing concentrations of insulin. 
Inhibition is shown as a percentage of adenylate cyclase 
activity in the presence of GTP and glucagon , but in the 
absence of insulin .
Basal (GTP alone) specific activities were 10.47 +/- 
0.36 and 4.82 +/- 0.21 pmoles cAMP produced /min/mg 
for control and diabetic preparations respectively. 
Similarly, glucagon stimulated activities in the presence 
of GTP were 15.71..+/- 1.21 and 6.90 +/- 0.70 pmoles 
cAMP produced /min/mg.
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Figure 4.4 Effect of Diabetic State On Insulin's Ability To
Inhibit Adenylate Cvclase Activity In Liver Membranes
Liver plasma membranes were prepared from (ry )con tro l 
(@) Streptozotocin - induced diabetic and (fig) 
Streptozotocin and insulin treated Sprague Dawley rats 
as outlined in Materials & Methods.
Adenylate Cyclase Activity was assayed for 12 min at 
3;0°C in the presence of GTP (10“^M) , glucagon 
(5 x 10-10 M) and increasing concentrations of insulin. 
Inhibition is shown as a percentage of adenylate cyclase 
activity in the presence of GTP and glucagon , but in the 
absence of insulin .
Basal (GTP alone) specific activities were 10.47 +/- 
0.36 , 5.24 +/-0.19 and 6.60 +/- 0.48 pmoles cAMP
produced /min/mg for control / diabetic and insulin 
treated preparations respectively. Similarly, glucagon 
stimulated activities in the presence of GTP were 15.71 
+/- 1.21 ,7.65 +/- 0.51 and 9.77 +/- 0.41 pmoles cAMP 
produced /min/mg.
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Figure 4.4 Effect of Diabetic State On Insulin's
Ability To Inhibit Adenylate Cvclase Activity 
In Liver Membranes
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Figure 4.5 Insulin Mediated Inhibition of Adenvlate
Cvclase Activity In Liver Membranes Isolated From Lean 
Zucker Rats
Liver plasma membranes were prepared from lean Zucker 
rats as outlined in Materials & Methods.
Adenylate Cyclase Activity was assayed for 12 min at 
30°C in the presence of GTP (10'^M) , glucagon 
(5 x 10-10 M) and increasing concentrations of insulin. 
Inhibition is shown as a percentage of adenylate cyclase 
activity in the presence of GTP and glucagon , but in the 
absence of insulin .
Basal (GTP alone) and glucagon stimulated specific 
activities in the presence of GTP were 10.11 +/- 1.12 
and 15.37 + /-/*ao pmoles cAMP produced /min/mg 
respectively.
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Figure 4.5 Insulin Mediated Inhibition of Adenviate
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Figure 4.6 Insulin Mediated Inhibition of Adenylate
Cvclase Activity In Liver Membranes Prepared From Lean 
And Obese Zucker Rats
Liver plasma membranes were prepared from ( m ) lean 
and ( m ) obese Zucker rats as outlined in Materials & 
Methods.
Adenylate Cyclase Activity was assayed for 12 min at 
30°C in the presence of GTP (1CT4M) , glucagon 
(5 x 1 0 " ^  M) and increasing concentrations of insulin.
Inhibition is shown as a percentage of adenylate cyclase 
activity in the presence of GTP and glucagon , but in the 
absence of insulin .
Basal (GTP alone) specific activities were 10.11 +/- 
1.12 and 10.32 +/- 0.81 pmoles cAMP produced /min/mg 
for lean and obese animal preparations respectively. 
Similarly, glucagon stimulated activities in the presence 
of GTP were 15.37 +/- 1.20 and 16.10 +/- 0.99 pmoles 
cAMP produced /min/mg.
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Figure 4.6 Insulin Mediated Inhibition of Adenylate
Cvclase Activity In Liver Membranes Prepared
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Figure 4.7 Effect of Biauanide Treatment On Insulin's
Ability To Inhibit Adenylate Cvclase Activity In Control 
Liver Membranes
Liver plasma membranes were prepared from control 
Sprague Dawley rats which ( & ) had or ( Q ) had not 
undergone oral metformin therapy prior to sacrifice.
Adenylate Cyclase Activity was assayed for 12 min at 
30°C in the presence of GTP (10"^M) , glucagon 
(5 x 10-10 M) and increasing concentrations of insulin.
Inhibition is shown as a percentage of adenylate cyclase 
activity in the presence of GTP and glucagon , but in the 
absence of insulin .
Basal (GTP alone) specific activities were 9.46 +/- 
1.01 and 10.47 +/- 0.36 pmoles cAMP produced /min/mg 
for for metformin treated and non - treated animal 
preparations respectively. Similarly, glucagon stimulated 
activities in the presence of GTP were 13.99 +/- 1.70 
and 15.71 +/- 1.21 pmoles cAMP produced/min/mg.
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Figure 4.7 Effect of Biauanide Treatment On
Insulin's Ability To Inhibit Adenviate Cvclase
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Figure 4.8 Effect of Biauanide Treatment On Insulin’s
Abilitv To Inhibit Adenvlate Cvclase Activitv In Liver
Membranes Prepared From Streptozotocin Induced
Diabetic Rats
L iver plasm a m em branes were prepared from 
Streptozotocin induced diabetic Sprague Dawley rats 
which ( 6 ) had or ( o ) had not undergone oral metformin 
therapy prior to sacrifice.
Adenylate Cyclase Activity was assayed for 12 min at 
30°C in the presence of GTP (10“^M) , glucagon 
(5 x 10-10 M) and increasing concentrations of insulin. 
Inhibition is shown as a percentage of adenylate cyclase 
activity in the presence of GTP and glucagon , but in the 
absence of insulin .
Basal (GTP alone) specific activities were 3.43 +/- 0.29
and 5.24 +/= 0.19 pmoles cAMP produced /min/mg for for
metformin treated and non - treated animal preparations
respectively. Similarly, glucagon stimulated activities
in the presence of GTP were 5.09 +/- 0.32 and . 7.65 +/-
0.51 pmoles cAMP produced /min/mg.
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Figure 4.8 Effect of Biauanide Treatment On Insulin's 
Ability To inhibit Adenviate Cvciase Activity 
in Liver Membranes Prepared From 
Streptozotocin Induced Diabetic Rats
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Figure 4.9 Effect of Biauanide Treatment On Insulin’s
Ability To Inhibit Adenylate Cvclase Activity In Liver 
Membranes Prepared From Control And Diabetic Rats
Liver plasma membranes were prepared from ( 4 )control 
and ( a ) Streptozotocin induced diabetic Sprague Dawley 
rats which had undergone oral metformin therapy prior 
to sacrifice.
Adenylate Cyclase Activity was assayed for 12 min at 
30°C in the presence of GTP (10"^M) , glucagon 
(5 x 10"10 M) and increasing concentrations of insulin. 
Inhibition is shown as a percentage of adenylate cyclase 
activity in the presence of GTP and glucagon , but in the 
absence of insulin .
Basal (GTP alone) specific activities were 9.46 +/- 1.01 
and 3.43 +/- 0.29 pmoles cAMP produced /min/mg for 
for control and diabetic animal preparations respectively. 
Similarly, glucagon stimulated activities in the presence 
of GTP were 13.99 +/- 1.70 and 5.09 +/- 0.32 pmoles 
cAMP produced /min/mg.
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Figure 4.9 Effect of BiauanideTreatment On Insulin's
Ability To Inhibit Adenylate Cvclase Activity 
In Liver Membranes Prepared From Control 
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Figure 4.10 Effect of Biauanide Treatment On lnsulin*s 
Ability To Inhibit Adenylate Cvclase Activity In Liver 
Membranes Prepared From Lean Zucker Rats
Liver plasma membranes were prepared from lean Zucker 
rats which (@ ) had or ( 0 ) had not undergone oral 
metformin therapy prior to sacrifice.
Adenylate Cyclase Activity was assayed for 12 min at 
30°C in the presence of GTP (10'4M) , glucagon 
(5 x 10-^0 M) and increasing concentrations of insulin. 
Inhibition is shown as a percentage of adenylate cyclase 
activity in the presence of GTP and glucagon , but in the 
absence of insulin .
Basal (GTP alone) specific activities were 9 .00 '+ /-'1 .05 
and 10.11 +/- 1.12 pmoles cAMP produced /min/mg for 
fo r trea ted and non-treated animal preparations 
respectively. Similarly, glucagon stimulated activities 
in the presence of GTP were 13.62 +/- 0.86 and 15.37 +/- 
1.20 pmoles cAMP produced /min/mg.
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Figure 4.10 Effect of Biauanide Treatment On Insulin’s
Ability To Inhibit Adenylate Cvclase Activity In Liver
Membranes Prepared From Lean Zucker Rats
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Figure 4.11 Effect of Biauanide Treatment On Insulin's
Ability To Inhibit Adenylate Cvclase Activity in Liver
Membranes Prepared From Obese Zucker Rats
Liver plasma membranes were prepared from obese Zucker 
rats which ( & ) had or (a ) had not undergone oral
metformin therapy prior to sacrifice.
Adenylate Cyclase Activity was assayed for 12 min at
30°C in the presence of GTP (10"4M) , glucagon 
(5 x 10""10 M) and increasing concentrations of insulin. 
Inhibition is shown as a percentage of adenylate cyclase 
activity in the presence of GTP and glucagon , but in the 
absence of insulin .
Basal (GTP alone) specific activities were 9.55 +/- 1.20 
and 10.32 +/- 0.81 pmoles cAMP produced /min/mg for
treated and non-treated animal preparations respectively. 
Similarly, glucagon stimulated activities in the presence 
of GTP were 14.72 +/- 1.66 and 16.10 +/- 0.99 pmoles 
cAMP produced /min/mg.
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Figure 4.11 Effect of Biquanide Treatment On Insulin's
Ability To Inhibit Adenylate Cvclase Activity In 
Liver Membranes Prepared From Obese Zucker Rats
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Figure 4.12 Insulin Mediated Inhibition of Adenylate 
Cvclase Activity In Liver Membranes Prepared From 
Zucker Rats Undergoing Biauanide Therapy
Liver plasma membranes were prepared from ( a  )lean and 
(& ) obese Zucker rats which had undergone metformin 
therapy prior to sacrifice.
Adenylate Cyclase Activity was assayed for 12 min at 
30°C in the presence of GTP (ICH’M) , glucagon 
(5 x 10"10 M) and increasing concentrations of insulin. 
Inhibition is shown as a percentage of adenylate cyclase 
activity in the presence of GTP and glucagon , but in the 
absence of insulin .
Basal (GTP alone) specific activities were 9.00 +/- 1.05 
and 9.55 +/- 1.20 pmoles cAMP produced /min/mg for 
lean and obese animal preparations respectively. 
Similarly, glucagon stimulated activities in the presence 
of GTP were 13.62 +/- 0.86 and 14.72 +/- 1.66 pmoles 
cAMP produced /min/mg.
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Figure 4.12 insulin Mediated Inhibition of Adenvlate
Cvclase Activity In Liver membranes Prepared 
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Table 4 Incubation of Hepatocytes With Metformin: Effect
Upon Adenylate Cyclase Activity
Metformin Concentration 
(mM)
Adenylate Cyclase Activity 
pmoles min  ^mg ^
1.20 +/- 0.10 
0.20 +/- 0.05 
0.00 -  
0.00 -  
0.00
n=3 experiments. Values given are mean +/- SEM values.
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Figure 4.13 Effect of Pertussis Toxin Treatment
Crude membranes were prepared from (3 ) control and (§) 
pertussis pretreated hepatocytes isolated from Sprague 
Dawley rats as outlined in Materials & Methods.
Adenylate Cyclase Activity was assayed for 12 min at 
30°C in the presence of GTP (10“4M) , glucagon 
(5 x 10-10 M) and increasing concentrations of insulin. 
Inhibition is shown as a percentage of adenylate cyclase 
activity in the presence of GTP and glucagon , but in the 
absence of insulin .
Basal (GTP alone) specific activities were 1.32 +/- 0.08 
and 1.26 +/- 0.60 pmoles cAMP produced /min/mg for 
control and pertussis toxin treated preparations 
respectively. Similarly, glucagon stimulated activities 
in the presence of GTP were 2.02 +/- 0.15 and 1.85 +/- 
0.12 pmoles cAMP produced /min/mg respectively.
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Figure 4.14 Effect of TPA Treatment Upon The Inhibition
of Adenylate Cyclase Activity Mediated By Insulin And 
GPP(NH)P
Hepatocytes were incubated with TPA (O.lng/ml) for
0-16 minutes at 37^0 in a shaking water bath.
Hepatocyte suspension samples were removed at the
appropriate time point and crude membrane pellets
were rapidly prepared. Gi function was assessed
—4( □ ) for each sample using forskolin (10 M)
O
and GPP(NH)P (10 M) as described in chapter3.
Insulin mediated inhibition was assessed (ffl)
— 8 — 4for each sample using insulin (10 M), GTP (10 M)
-10
and glucagon (5x10 M)as described in chapter 4.
The inhibition of adenylate cyclase mediated by 
each process is expressed as a percentage of the 
inhibitory function of each process.
Values shown are mean +/- SEM values for n=4 
experiments (4 animals).
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Discussion of Results
Insulin has the ability to inhibit glucagon (0.1nM) 
stimulated adenylate cyclase activity in the presence of 
GTP (0.1mM) (see figure 4.1). The estimated concentration of 
insulin which elicits 1/2 maximal inhibition of glucagon 
stimulated adenylate cyclase activity is 0.1nM. Maximal 
inhibition (20 +/- 3 %) occurs at 10nM insulin. This insulin
mediated inhibition of adenylate cyclase activity is abolished in 
the chemically induced diabetic state ( figures 4.2 & 4.3 ).
This diabetic state was induced using two different chemicals; 
streptozotocin and alloxan. It was therefore assumed that the 
effects observed were not due to toxic effects upon the adenylate 
cyclase system ,or upon the liver itself. Instead ,these effects 
were assumed to be due to the chemical induction of an insulin 
deficient condition in these animals.
Evidence to confirm this assumption is that insulin 
treatment of these diabetic animals reverse the physical 
characteristics associated with type I diabetes displayed in 
these animals. This included the reversal of such charateristics 
as elevated plasma glucose levels and the presence of glycosuria. 
In addition, the ability of insulin to inhibit glucagon 
stimulated adenylate cyclase activity in the presence of GTP 
returns (figure 4.4). Not only do these insulin reversed 
diabetic preparations display an enhanced maximal inhibition (30
201
+/- 2 %), but also the K.q ^( the concentration of insulin which
elicits 1/2 maximal inhibition) was reduced from 0.1nM (in 
controls) to 0.04nM (in insulin treated preparations).
When this action of insulin is examined in liver 
membranes prepared from Zucker rats, membranes from the lean 
(control) animals displayed an insulin mediated inhibtion of 
adenylate cyclase activity with a maximal inhibitory response of 
2*1'+/- 3%), and a K>| ^estimated value for the process of 0.1nM 
(see figure 4.5). However, the type II diabetic model, the obese 
Zucker rat, displayed a reduced maximal inhibition of 17 +/- *\% 
and an estimated K n j-of 0.1nM. It was also noticable that the 
maximal response for the process occurred at an insulin 
concentration of 5nM which is slightly lower than that observed 
in the control animals.
Insulin resistance is well documented in this type II 
diabetic state , but it is clearly evident ( figure 4.6 ) that 
insulin action on the adenylate cyclase system in this state does 
not display an increased ^for the process. However, a reduced 
maximal response in this state is observed.
Administration of the hypoglycaemic drug metformin was 
once again examined. Metformin was found to enhance the maximal 
inhibition mediated by insulin by 35 % when compared to controls. 
Also, the K o f ° r the process in the presence of metformin 
treatment was increased from 0.1nM to 0.5nM.
When the effect of metformin therapy in streptozotocin 
induced diabetic animal preparations was investigated , the
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results obtained were very surprising ( figure 4.8 ). Drug
therapy appears to return this previously abolished inhibitory 
action of insulin. The maximal response is 20 +/- 2 % which is 
very similar to that observed in controls and the K0.5 estimated 
value for the process in these preparations is 0.5nM.
When metformin treated control and diabetic states are 
compared (figure 4.9) there appears to be an elevated maximal 
response , but apart from this , the two curves are 
superimposable. Metformin therapy administered to lean Zucker 
rats resulted in similar effects to those observed in Sprague 
Dawley rat preparations. Metformin treatment enhanced the 
maximal inhibition by approximately 29 % to 31 +/- 5 % and the 
K0.5 estimated for the process was increased from 0.1nM to 0.9nM.
Similarly, membrane preparations obtained from 
metformin treated obese Zucker rats were more responsive to 
insulin . The maximal inhibition mediated by the hormone in these 
preparations was increased from 17 +/- 1 to 30 +/- 2 % when
compared to controls. Also, when the insulin response in 
metformin treated lean and obese Zucker rat preparations were 
compared , superimposable curves were obtained.
In summary therefore, it appears that insulin 
inhibition of glucagon stimulated adenylate cyclase activity is 
abolished completely in the type I diabetic model, but this 
action of insulin returns upon metformin therapy with responses 
comparable to control non-diabetic animal preparations. Insulin
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therapy also restored this inhibitory action of insulin, but 
resulted in a more pronounced response and a slightly lower Kv 0.5 
value.
Similarly, Metformin treatment of lean and obese Zucker 
rats resulted in a heightened response to insulin with a slightly 
increased Kq.5 value . Again, the non-treated diabetic model 
(type II) was less responsive than the control ,but this action 
was not totally absent as in the case of the type I diabetic 
model. In every case of metformin administration, the maximal 
response to insulin was enhanced and the Kq.5 values were also 
increased. However, considering the limits of accuracy in 
estimating these values, it is not possible to comment on the 
significance of these E. 0^ .5 changes.
Pertussis toxim pretreatment of control Sprague Dawley 
rat hepatocytes abolished insulin’s ability to inhibit adenylate 
cyclase activity (figure 4.13). This confirms the findings of 
Heyworth et al (1986).
Using the phorbol ester , TPA, at a final concentration 
of 0.1ng /ml, Gi function and insulin’s ability to inhibit 
adenylate cyclase activity was investigated. Following an 
incubation time-course with this compound (figure 4.14), it is 
clearly observable that Gi function is abolished within 10 min. 
However, at this time point only 30 % of insulin’s ability to 
inhibit adenylate cyclase activity is removed. It is therefore 
suggested that insulin inhibits adenylate cyclase activity by a 
process which is independent of the inhibitory G protein Gi.
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Finally, the effect of metformin incubation with 
hepatocytes isolated from control Sprague Dawley rats was 
investigated (table 4). It was found that metformin at a 
concentration greater than 2mM obliterated adenylate cyclase 
activity all together. When the equivalent oral metformin dose 
is 8mM. However, in. vitro studies with this drug are generally in 
the 1pM-10pM range. It therefore seems unlikely that the effects 
observed in preparations from animals which have undergone 
metformin therapy are direct membrane effects. It is also 
probable that metformin is metabolized in the gut of these 
animals prior to reaching the blood stream.
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5. High Affinity GTPase Activity Within Human Platelet Broken 
Plasma Membranes
206
Introduction
Guanine nucleotide regulatory proteins undergo a cycle
of activation and deactivation under agonist stimulated
conditions. The activation process is described in detail in the
2+
general introduction and involves Mg , receptors (Rs or Ri) and 
the binding of GTP. The deactivation process is known as the 
GTPase activity of the protein. This activation-deactivation 
cycle is summarized schematically as follows :
ligand
(G Protein.GTP
(G Protein.GTP)
I ACTIVE
(Rapid)
(G.Protein)
CG.Protein.GDP)
GDP INACTIVE
Cholera Toxin
Pertussis Toxin
GTPase activity is an intrinsic activity within the G protein and 
in the presence of specific agonists this GTPase activity can be 
stimulated.
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This phenomenon was first demonstrated by Cassel & Selinger 
(1976) and has since been demonstrated by others in a variety of
\c\£k
Essentially, the cell type chosen must have a low 
endogenous GTPase activity as most cellular GTPase activity is a 
result of low affinity GTP hydrolysis. This low affinity GTPase 
activity is regarded as "non-specific” or "background" activity 
and must be accounted for and subtracted from the total cellular 
GTPase activity in order to "observe " GTPase activity associated 
with G proteins. .
Also, utilization of GTP as a phosphate donor must be
reduced in order to "observe" this high affinity GTPase activity.
Thus, the inclusion of the non-hydrolyzable ATP analogue,
+ +
APP(NH)P adenylyl -imidodiphosphate, and the Na /K ATPase 
inhibitor, oiybain is often made to GTPase assay systems.
In this chapter, I have attempted to demonstrate that
in human platelet membranes , insulin has the ability to
stimulate the GTPase activity of a G protein distinct from that 
associated with Gs, Gi and the G protein involved in
phospholipase C activation, Gp ( Blackmore et_ al 1985; Bradford & 
Rubin 1986.).
cell types using a variety of receptor ligands ( Grandt et al 
Fain et"aX^lS85; Houslay et al 1986).
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Additional Methods
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[ P] GTP was prepared as outlined in section 2.20 .
GTPase activity was assayed as described in section 2.21. Toxin 
pretreatment of membranes were undertaken as described in 
sections 2.22 and 2.23. Unless otherwise stated, the ligand 
concentrations were as follows :
Isoproterenol 1jiM, PGE1 20pM, Adrenaline lOOpM, Propranolol 1uM, 
Insulin 10nM and vasopressin 10nM.
Unless otherwise indicated , the final GTP concentration was 
0.6pM. Values given are mean +/- SEM values and n = number of 
experiments performed. All assays were performed in triplicate 
and linearity of GTPase activity was ensured for incubation times 
and membrane protein concentrations used.
GTPase activity shown is the high affinity GTPase 
activity associated with G protein function. Non - specific 
GTPase activity has been eliminated by the inclusion of a high 
concentration (0.1mM) of non-radiolabelled GTP during each 
experiment. Under these conditions (Cassel & Selinger 1976; 
Houslay et al 1986) only high affinity GTPase activity is 
observable.
The additivity ratio shown in table 6 was calculated as
follows :
S tim u la tio n  Observed For Drug Corrib in  ration
r] Tr^ t ,*v * ^ "t ^ ■ —  ■— ■ ■ — . . . . .  . ,. - — .... i. , i . . , . —
(Stimulation By Drugl + Stimulation By Drug 2)
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Therefore for ligands which stimulate one GTPase activity, the 
additivity ratio equals 0.5 . For ligands which stimulate
distinct GTPase activities, the additivity ratio equals 1.0.
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5.1 Dose-Dependent Ligand Stimulation Of Specific
GTPase Activity
211
Figure 5.1.1 Dose Response Curve For Stimulation of
GTPase Activity Bv Adrenaline
Specific GTPase activity was assayed in the presence of 
0.6 pM GTP , IpM  propranolol and increasing
concentrations of adrenaline. Activity is expressed as a 
percentage stimulation of the basal specific GTPase 
activity. Basal specific activity was 27.59 +/- 1.89
pmoles GTP hydrolysed min""* mg- "1.
Values shown are mean +/- SEM values for n=5 
experiments ( 3 independent blood donors).
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Figure 5.1.2 Dose response curve for GTPase stimulation 
Bv PGE1
Specific GTPase activity was assayed in the presence of 
0.6 pM GTP and increasing concentrations of PGE1. 
Activity is expressed as a percentage stimulation of the 
basal specific GTPase activity. Basal specific activity 
was 27.59 +/- 1.89 pmoles GTP hydrolysed min""1 mg""1. 
Values shown are mean +/- SEM values for n=5 
experiments ( 3 independent blood donors).
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Figure 5.1.3 Dose Response Curve For Stimulation of
GTPase Activity Bv Insulin
Specific GTPase activity was assayed in the presence of 
0.6 pM GTP and increasing concentrations of insulin. 
Activity is expressed as a percentage stimulation of the 
basal specific GTPase activity. Basal specific GTPase 
activity was 27.59 +/- 1.89 pmoles GTP hydrolysed
min'"* mg""* ■
Values shown are mean +/- SEM values for n=5 
experiments ( 3 independent blood donors).
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5.2 Effect of GTP Concentration On Ligand Stimulation 
of Specific GTPase Activity
Figure 5.2.1 Effect of GTP concentration On Adrenaline
Stimulation of GTPase Activity
Specific GTPase activity was assayed in the presence of 
0.1 mM adrenaline, 1pM propranolol and increasing 
concentrations of GTP. Activity is expressed as a 
percentage stimulation of the basal specific GTPase 
activity at each corresponding GTP concentration.
Values shown are mean +/- SEM values for n=5 
experiments ( 3 independent blood donors).
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F ig u re  5.2.2 Effect of GTP concentration On PGE1
Stimulation Of GTPase Activity
Specific GTPase activity was assayed in the presence of 
20 (jM PGE1 and increasing concentrations of GTP. 
Activity is expressed as a percentage stimulation of the 
basal specific GTPase activity at each corresponding GTP 
concentration.
Values shown are mean +/- SEM values for n=5 
experiments ( 3 independent blood donors).
Figure 5.2.2 Effect of GTP Concentration On
PGE1 Stimulation of GTPase Activity
120 r
100
0.60.4 0.8 1.00.0 0.2 1 . 2
[GTP] fiM
Figure 5.2.3 Effect of GTP concentration On Insulin
Stimulation of GTPase Activity
Specific GTPase activity was assayed in the presence of 
10nM Insulin and increasing concentrations of GTP. 
Activity is expressed as a percentage stimulation of the 
basal specific GTPase activity at each corresponding GTP 
concentration.
Values shown are mean +/- SEM values for n=5 
experiments ( 3 independent blood donors).
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5,3 Kinetic Analysis of Ligand Stimulated Specific
GTPase Activity
219
Figure 5.3.1 Lineweaver - Burke Plot For Control Samples
Specific GTPase activity was assayed as described in 
"Additional Methods " section in the presence of 
increasing concentrations of GTP, but in the absence of 
receptor ligands.
Estimated Km and Vmax values are given in table 5.
Values shown are mean +/- SEM values for n=6
experiments (3 individual blood donors).
Figure 5.3.1 Lineweaver - Burke Plot For Control Samples
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Figure 5.3.2 Lineweaver - Burke Plot For Adrenaline
Treated Samples
Specific GTPase activity was assayed as described in 
"Additional Methods " section in the presence of 100 uM 
adrena line  , 1 |jM proprano lo l and increasing
concentrations of GTP .
Estimated Km and Vmax values are given in table 5.
Values shown are mean +/- SEM values for n=6
experiments (3 individual blood donors).
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Figure 5.3.2 Lineweaver- Burke Plot For Adrenaline Treated Samples
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Figure 5.3.3 Lineweaver - Burke Plot For PGE1 Treated
Samples
Specific GTPase activity was assayed as described in 
"Additional Methods " section in the presence of 20 pM 
PGE1 and increasing concentrations of GTP.
Estimated Km and Vmax values are given in table 5.
Values shown are mean +/- SEM values for n=6
experiments (3 individual blood donors).
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Figure 5.3.4 Lineweaver - Burke Plot for Insulin Treated
Samples
Specific GTPase activity was assayed as described in 
"Additional Methods " section in the presence of 10 nM 
insulin and increasing concentrations of GTP.
Estimated Km and Vmax values are given in table 5.
Values shown are mean +/- SEM values for n=6
experiments (3 individual blood donors).
1/V
 
[1
/(p
m
ol
es
/m
in
/m
g)
]
Figure 5.3.4 Lineweaver-Burke Plot For Insulin Treated Samples
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Table 5 Kinetic Analysis of High Affinity GTPase Activity 
In Human Platelet Membranes
Treatment Lineweaver-Burke Eadie-Hofstee
Km Vmax Km Vmax
Control 0.6 53 0.6 52
Adrenaline/
Propranolol 0.4 66 0.5 82
PGE.
0.4 66 0.6 85
Insulin 0.3 59 0.4 66
—  1 —1Km units are pM and Vmax units are pmoles min mg .
Drug concentrations are as outlined in "additional methods"
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5.4 Evidence For Insulin Activation of A Novel G Protein
Table 6 Stimulation of GTPase Activity Using Drug Combinations
Drug combination Observed Expected Additivity Ratio
Stimulation Stimulation
Isoproterenol 18 +/- 3%
Adrenaline/
Propranalol 135 +/- 10%
Insulin 58 +/- 7%
PGE1 94 +/- 6 %
Iso.+Adren/prop. 137 +/- 10% 153 % 0.9
Iso. + Insulin 70 +/- 5 % 76 % 0.9
Iso. + PGE ,
1 .52- +/- -3 % 112 % 0.5
Adren./Prop. +
Insulin 200 +/- 15 % 193% 1.0
Adren./Prop.+
PGE, ,
1 250 +/- 10% 229% 1.1
Insulin+PGE,
1 135 +/- 16% 152% 0.9
Insulin + PGE^
+ Adren./Prop. 245 +/- 18% 287% 0.8
Abbreviations used above:
Iso. (isoproterenol) ; Adren. ( adrenaline)
Drug concentrations are as detailed in "Additional Methods"
(n=6 experiments, 3 blood donors )
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Discussion of Results
High affinity GTPase activity was observed in human 
platelet membranes. This activity was stimulated by the drugs 
isoproterenol, adrenaline, PGE1, vasopressin and insulin 
Isolproterenol and PGE1 are agonists of Rs type receptors which 
activate Gs ( Lester et^  al 1982; Aktories et al_ 1982).
Adrenaline has the ability to bind to both and p- adrenergic
receptors. 0^^ receptors are able to activate Gi ( Jakobs et al
1985) and j3~ adrenergic receptors activate Gs Brandt (et al 
1983) . Hence, in order to stimulate only Gi activity with this 
ligand, it is necessary to use the ^ "blocker" or antagonist
propranolol.
Dose - response curves were constructed for adrenaline, 
PGE1 and insulin stimulated GTPase activity (figures £. 1.1 -
5.1.3). This allowed estimation of the saturating concentration 
(that is the concentration of ligand required to fully activate 
their specific G protein) for each ligand. These ligand 
concentrations were then used to estimate the affinity of each 
stimulated GTPase activity for the substrate GTP. Two reciprocal 
plots ; the Lineweaver-Burke and Eadie - Hofstee plots were 
derived and Km and Vmax values were estimated in the presence and 
absence of receptor agonists (figures 5.3.1 - 5.3-4 , also table 
5).
It can be concluded that adrenaline, PGE1 and insulin 
all increase the Vmax value when compared to the control ( no 
agonist) state by about 40%, 40% and 20% respectively. Although,
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the estimated Km values were all of comparable magnitude (0.4- 
0.6pM ). These estimated values are also of comparable magnitude 
to those estimated for Gi and Gs by other workers using platelet 
membranes ( Lester et_ al_ 1982; Avdonin et_ al_ 1985).
Also, when the effect of combinations of ligands upon 
GTPase activity was examined (table 6) , it is clearly
observable that when insulin was present in combination with
adrenaline/propranolol, or PGE1 or vasopressin, this hormone 
stimulated a GTPase activity distinct from those stimulated by 
each of the other drugs. Only the combination of isoproterenol 
and PGE1 exhibited an additivity ratio equal to 0.5 and this is 
of course because both ligands stimulate the same G protein Gs.
Finally, when the effect of pertussis toxin and cholera 
toxin pretreatment was investigated, it was found (table 7) that 
pertussis toxin reduced only adrenaline / propranolol stimulated 
GTPase activity to any significant extent (56 %). However,
cholera toxin reduced both PGE1 and insulin stimulated GTPase
activity by 73 % and 90 % respectively.
In summary therefore, it is proposed that insulin has 
the ability to stimulate a high affinity GTPase activity in human 
platelet membranes which has an estimated Km for GTP of 0.4 pM. 
The insulin stimulated GTPase activity is both insulin and GTP 
concentration dependent ; maximal stimulation of GTPase activity 
occurs at an insulin concentration of 10nM. The insulin 
concentration which elicits 1/2 maximal stimulation of this 
GTPase activity (at a GTP concentration of 0.6pM) is estimated to
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be 5nM. The GTPase activity stimulated by insulin appears to be 
distinct from that stimulated by ligands which activate Gi, Gs 
and the putative Gp . It is proposed therefore that insulin 
stimulates a distinct G protein whose activity is unaltered by
pertussis toxin pretreatment, but is significantly reduced by
cholera toxin pretreatment.lt is therefore suggested that this G
protein has the characteristics which were observed for the
putative Gins G protein (Heyworth et_ aT 1985). There is no 
evidence for insulin stimulated GTPase activity associated with 
the G protein Gi.
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6. Conclusions Drawn
Animal models of diabetes have been used to try to gain 
an insight into possible G protein alterations occurring in the 
diabetic state. In order to assess G protein function, the 
adenylate cyclase effector system has been studied. This 
effector system not only allowed the characterization of Gs and 
Gi, but also presented an opportunity to study a rapid, short 
term effect of insulin.
Insulin’s ability to inhibit adenylate cyclase activity 
is a guanine nucleotide dependent process and therefore may well 
involve one or more G proteins. An important aim of the project 
was to attempt to elucidate the mechanism by which insulin has 
the ability to mediate this action . G protein function in normal 
and diabetic states was characterized on the basis of G protein 
interactions with the adenylate cyclase effector system.
As detailed discussion sections have been included at
the end of each results chapter, only a brief summary of
conclusions drawn from the data will now be presented :
The results obtained suggest that Gi function in both
type I and type II diabetic animal models is abolished.
Quantification of Gi in hepatocyte membranes prepared from each 
animal type suggested that hepatic GiO( subunits were not present 
to any appreciable extent in type I diabetic animals.However, Gi 
c< was present at levels comparable to control animals in the 
type II diabetic preparations. It is therefore proposed that
loss of hepatic Gi function in type I diabetic animals reflects
2.3P
the lack of Gi odexpression in these cells. However, loss of 
hepatic Gi function in type II diabetic preparations reflects 
the occurrance of a covalent modification of Gi which leads to 
attenuation of this G proteins acivity. It is suggested that 
hepatic Gi o< expression in type I diabetic animals is controlled 
either directly or indirectly by circulating plasma insulin 
concentration. It is also possible that loss of Gi function in 
the type II diabetic animals may be a result of elevated plasma 
insulin levels.
Use of the hypoglycaemic drug , Metformin, indicated 
that Gi function was not involved in insulin mediated inhibition 
of adenylate cyclase activity. Indeed, oral administration of 
this drug to control animals resulted in the attenuation of Gi 
function, but enhanced insulin’s ability to inhibit adenylate 
cyclase activity. This action of insulin was abolished in type I 
diabetic preparations and reduced in preparations from type II 
diabetic animals, although Gi function in both these animal types 
was abolished. Metformin restored this action of insulin in the 
type I diabetic state and enhanced this action in the type II 
diabetic condition. The mechanism by which metformin restores or 
enhances this action is unknown , but it is unlikely that this 
drug mediates these effects by directly interacting with the 
membrane or the adenylate cyclase system as the effects observed 
are selective. Tables 2 and 3 demonstrate that this drug has no 
significant effect upon the function of Gs or C. Also, incubation 
of hepatocytes in the presence of this drug at concentrations
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comparable to those orally administered to animals resulted in 
the abolition of basal adenylate cyclase activity. When the 
structure of this compound is considered, this non-specific 
effect upon the adenylate cyclase system may well reflect the 
intercalation of the drug into the plasma membrane. It is 
therefore suggested that this drug may be metabolized in the gut 
of these animals and it may be a modified form of this drug which 
elicits these effects. However,lower concentrations of the drug 
have been used by other workers in cell culture studies and post­
receptor effects have been suggested. It is therefore possible 
that the drug may have the ability to enter the cells and induce 
its effects intracellularly. However, it does appear that this 
drug displays some aspects of selectivity with respect to the 
adenylate cyclase system and perhaps these are important in 
diabetic therapy. In addition, this drug provided evidence that 
Gi function and insulin’s ability to inhibit adenylate cyclase 
aotivity are unrelated.
Further evidence to support this theory was obtained 
using the phorbol ester TPA. This compound abolished Gi function 
prior to the abolition of this insulin action. However, using the 
bacterial toxin ,pertussis toxin, both Gi function and insulin 
mediated inhibition of adenylate cyclase activity was removed. It 
is proposed that pertussis toxin ribosylates Gioc subunits and 
thereby promotes the Gi (ocB*^) holoraeric state. Hence, if 
insulin binding to its receptor activated a G protein it could 
stimulate the liberation of B*^ subunits from an ( pi B
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holomeric complex. If these B"y subunits associated with Gs 
o< subunits , then the glucagon (Gs) stimulated adenylate 
cyclase activity would be "turned off" as the inactive (<X.B f^) 
complex prevails. Thus, if insulin inhibited glucagon stimulated 
adenylate cyclase activity by a B Y  reassociation process, then 
pertussis toxin pretreatment would promote B Y  subunit 
association with GiO(, prior to Gs subunit reassociation.
Evidence to support this theory comes from studying 
glucagon’s ability to stimulate adenylate cyclase activity in 
each of the control and diabetic states. It appears that enhanced 
maximal glucagon stimulation occurs in type I, but not type II 
diabetic animals. This enhanced glucagon stimulated condition is 
induced if control hepatocytes are preincubated with pertussis 
toxin. Therefore it is proposed that under these conditions, 
pertussis toxin promotes B reassociation with free Gi 
oc. subunits. Resultantly this would remove inhibitory input into 
the adnylate cyclase system and Gs activation would be enhanced. 
This enhanced stimulatory response may only be apparent at high 
stimulatory ligand concentrations, after all, Gi inhibitory input 
is only observable when the catalytic unit’s activity is 
elevated (for example, by the use of forskolin).
It is also suggested that a modified form of Gi at could 
be unable to associate with B Y  subunits. This would explain the 
inability of pertussis toxin to induce an enhanced glucagon 
stimulated state observed in controls. Therefore, it is suggested 
that insulin mediates the inhibition of glucagon stimulated
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adenylate cyclase activity by the release of subunits from a 
G protein distinct from Gi.
Finally, in chapter 5 , I have presented evidence for 
insulin having the ability to promote stimulation of a high 
affinity GTPase activity distinct from Gs, Gi and the putative 
Gp in human platelet plasma membranes. This stimulation of GTPae 
is abolished by cholera toxin preteatment, but remains unaltered 
by pertussis toxin pretreatment. It is therefore suggested that 
this GTPase activity could be associated with the putative G 
protein Gins because this GTP binding protein is cholera toxin, 
but not pertussis toxin ribosylated.
It was unfortunate that this GTPase work could not be 
undertaken using the rat platelet system. When membranes prepared 
from rat platelets were prepared and incubated with ligands 
which are known to stimulate GTPase activity associated with Gs 
or Gi, no high affinity GTPase stimulation in this system was 
observable. The reason for this is not known, but perhaps
different receptor populations (or numbers) exist in the rat 
platelet system.
Therefore, in summary, it is proposed that insulin
inhibits adenylate cyclase activity by activating a G protein 
distinct from Gi, Gs and Gp. Upon activation of this G protein, 
B 'Y subunits are released and attenuation of Gs stimulation of 
the catalytic unit is achieved. In the diabetic state, Gi
function is absent. In the type I diabetic model, insulin is
unable to inhibit adenylate cyclase activity. In the type II
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diabetic model this action of insulin is present , but reduced. 
Gs function remains unaltered in both diabetic states.
It is proposed that alterations in G protein function 
may reflect post-receptor defects in the diabetic state. In 
particular, a G protein, distinct from Gs, Gi and Gp, may be 
important in insulin action. This G protein’s activity also 
appears to be reduced in the diabetic state. The attenuation of 
this G protein’s activity may be reversed upon biguanide therapy.
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Appendix I
Chemical & Enzyme Suppliers
258
All reagents used were of analytical grade.
Supplier
Sigma Chemical Co., 
Poole,
Dorset.
Boenringer (U.K.) Ltd., 
Lewes,
East Sussex.
Chemical / Enzyme
Alloxan
BSA
Cholera Toxin
DE-50 Cellulose
Dowex 1-X2 resin
Firefly Lantern Extract (FLE-50)
Glutathione
Norit A Charcoal
Oubain
Streptozotocin
Theophylline
TPA
Trypan Blue
ATP
Collagenase
Creatine Kinase
Diabur Test 5,000
Dithiothreitol
Glyceraldehyde 3 phosphate
"dehydrogenase
259
Supplier Chemical / Enzyme
Glycerate 3-phosphate
NAD
Phosphocreatine 
Phosphoglycerate Kinase 
Triethanolamine-HCL 
Tris
May & Baker Ltd.,
Dagenham,
Essex. Hydrochloric Acid
Sagatal
Trisoium Citrate
Ames,
Slough.
Dextrstix
Calbiochem,
Cambridge. Forskolin
National Diagnostics "Ecoscint" Scintillation fluid
Aylesbury,
Buckinghamshire.
Pharmacia,
Milton Keynes.
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Percoll
Prof. Freer,
Dept. Microbiology,
University of Glasgow. Pertussis Toxin
The following reagents were generously donated as gifts :
Insulin and glucagon were donated by Dr. W.W. Brommer,
Eli Lilly & Co., I.N. (USA).
Metformin was donated by Dr. Michel Noel, Aron-S.A., 
Suresnes, France.
All other reagents were obtained from B.D.H. Ltd., Poole, 
Dorset.
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Appendix II
Structural Formulae
262
Figure A1 Structure of Alloxan
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Finure A2 Structural Formula of Streptozotocin
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Figure A4 Structural Formula of cAMP
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Figure A5 Structural Formula of Metformin
H C NH
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Figure A6 Structural Formula of Forskolin
Finure A7 Structural Formula of Phorbol Esters
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